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SUMMARY 
 
Proteins are essential components of all living organisms and participate in virtually 
every cellular process. Many proteins are enzymes, which catalyze very specific 
biochemical reactions. Protein function and enzymatic activity are often regulated by 
so-called post-translational modifications. An important covalent protein modification 
is poly(ADP-ribosyl)ation (PARylation). PARylation is carried out by certain 
members of the protein family of poly(ADP-ribose) polymerases (PARPs), whose 
founding member is PARP1. 
The aim of this thesis was to investigate the molecular mechanism of 
PARylation and to study the function of PARP1 for pro-inflammatory gene 
expression. 
 In order to study the molecular mechanism of poly(ADP-ribose) (PAR) 
formation, the enzymatic activities of the closely related PARP family members 
PARP1, PARP2 and PARP3 were characterized in vitro. By use of purified 
recombinant proteins and protein chimera, we found that the different protein 
domains of the three enzymes cooperate in a tight and very specific manner. While 
PARP1 and PARP2 catalyzed the formation of PAR, PARP3 only showed mono-
ADP-ribosylation activity. We defined the enzymatic parameters Km and Vmax for the 
DNA dependent activation of PARP1 and found that lysine residues within an auto-
modification loop of PARP1 are target sites for auto-ADP-ribosylation. Moreover, 
lysine residues in the amino-terminal basic tails of core histone molecules were 
identified as targets for trans-ADP-ribosylation by PARP1. Together, these results 
provide detailed insights into the enzymatic mechanism of PAR synthesis and 
challenge the traditional assumption, that PAR is attached onto glutamic acid 
residues. 
 To study the contribution of PARP1 for pro-inflammatory gene expression 
under the control of the transcription factor NF-κB, an in vivo model system for 
Salmonella induced colitis was employed. In this model, PARP1 was required for 
efficient expression of a subset of pro-inflammatory genes and loss of PARP1 caused 
a delayed inflammatory host response to Salmonella infection. Thus, PARP1 was 
identified as a novel host factor, which, due to its transcriptional co-activator function 
for pro-inflammatory gene expression, accelerates Salmonella induced colitis. 
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ZUSAMMENFASSUNG 
 
Proteine sind als essentielle Bestandteile aller Lebewesen an praktisch jedem 
zellulären Prozess beteiligt. Viele Proteine sind Enzyme, die sehr spezifische 
biochemische Reaktionen katalysieren. Die Funktion von Proteinen und ihre 
enzymatische Aktivität werden häufig durch so genannte post-translationelle 
Modifikationen reguliert. Eine wichtige kovalente Proteinmodifikation ist die 
Poly(ADP-Ribosyl)ierung (PARylierung). Die PARylierung wird durch bestimmte 
Mitglieder der Proteinfamilie der Poly(ADP-Ribose) Polymerasen (PARPs) 
ausgeführt, deren Gründungsmitglied PARP1 ist. 
 Ziel dieser Arbeit war es, den molekularen Mechanismus der PARylierung 
sowie die Funktion von PARP1 bei der pro-inflammatorischen Genexpression zu 
untersuchen. 
 Um den molekularen Mechanismus der Synthese von Poly(ADP-Ribose) 
(PAR) genauer zu untersuchen, wurde die enzymatische Aktivität der eng verwandten 
PARP Familienmitglieder PARP1, PARP2 und PARP3 in vitro charakterisiert. Mit 
Hilfe von gereinigten, rekombinanten Proteinen und Proteinchimären ergab sich, dass 
die verschiedenen Proteindomänen der drei Enzyme sehr eng und spezifisch 
miteinander kooperieren. Während PARP1 und PARP2 die Synthese von PAR 
katalysierten, zeigte PARP3 lediglich Mono-ADP-Ribosylierungsaktivität. Wir 
bestimmten die enzymatischen Parameter Km und Vmax für die DNA-abhängige 
Aktivierung von PARP1 und erkannten, dass Lysinreste in einer 
Automodifikationsschleife von PARP1 als Ziel für die Auto-ADP-Ribosylierung 
fungieren. Darüber hinaus identifizierten wir Lysinreste in den amino-terminalen, 
basischen Histonausläufern als Zielaminosäuren von Trans-ADP-Ribosylierung durch 
PARP1. Zusammengenommen bieten diese Resultate einen detailierten Einblick in 
den enzymatischen Mechanismus der PAR-Synthese und hinterfragen die traditionelle 
Annahme, dass PAR an Glutamate angeheftet wird. 
 Um die Beteiligung von PARP1 bei der pro-inflammatorischen Genexpression 
unter der Kontrolle des Transkriptionsfaktors NF-κB zu untersuchen, wurde von 
einem in vivo Modellsystem für Salmonellen-induzierte Kolitis Gebrauch gemacht. In 
diesem Modell war PARP1 notwendig für die effiziente Expression von einer 
Untergruppe pro-inflammatorischer Gene und der Verlust von PARP1 führte zu einer 
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verzögerten Entzündungsreaktion nach Salmonelleninfektion. PARP1 wurde folglich 
als neuer Wirtsfaktor identifiziert, der wegen seiner transkriptionellen Ko-
Aktivatorfunktion für pro-inflammatorische Genexpression beschleunigend wirkt auf 
eine Salmonellen-induzierte Kolitis. 
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1 INTRODUCTION 
 
The blueprint of life is stored in our genetic material, the DNA. DNA comprises 
protein-encoding regions, the genes, which are transcribed into a messenger called 
mRNA. mRNA in turn is translated into proteins, the executers of all main cellular 
functions and components of many cellular structures. Protein function is tightly 
controlled at several levels, one important being the level of post-translational 
modification. Post-translational modifications regulate enzyme activities, cellular 
localization, protein interactions and protein stability. Frequent protein modifications 
include phosphorylation, acetylation, methylation, ubiquitylation and sumoylation [1]. 
A fascinating post-translational modification in higher eukaryotes is poly(ADP-
ribosyl)ation (PARylation), whereby short or large negatively charged chains of 
poly(ADP-ribose) (PAR) are generated from nicotinamide adenine dinucleotide 
(NAD+) as a substrate and attached to target proteins [2]. This process is carried out 
by an enzyme family, which has been named PAR polymerases (PARPs). PARylation 
has been implicated in a multitude of cellular processes including the sensing and 
signaling of damaged DNA, the regulation of gene expression and the execution of 
different cell death programs [3]. Consequently, PARPs and PARylation play 
important and often diverse roles in carcinogenesis and tumor formation as well as in 
many inflammatory diseases [3-5]. 
 
1.1 Poly(ADP-ribosyl)ation 
1.1.1 Discovery 
PARylation was first discovered already more than 45 years ago by Pierre Chambon 
in Paul Mandel`s group [6]. In 1979, PARP1 was isolated and characterized as the 
protein mainly responsible for catalyzing the formation of PAR [7]. It was later found 
that PARP1 itself is the main acceptor protein for the attachment of PAR [8], although 
several other nuclear proteins including histones are also targeted by PARylation [9, 
10].  
 
1.1.2 Mechanism 
During PARylation, NAD+ is cleaved into ADP-ribose and nicotinamide. Multiple 
ADP-ribose moieties are connected via glycosidic ribose-ribose bonds to generate 
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linear and multiple branched chains of PAR of different length and complexity 
(Figure 1) [9, 11]. The PARylation reaction can be subdivided into three distinct 
steps: the initiation reaction, i.e. the attachment of the first ADP-ribosyl residue to an 
acceptor protein after NAD+ cleavage; the elongation reaction, i.e. the addition of 
further ADP-ribose moieties onto already transferred ADP-ribose units; and the 
branching reaction, i.e. the branching off of ADP-ribose residues from a linear portion 
of the polymer to create a branching point (Figure 1) [9, 11, 12]. PAR chain length is 
heterogenous and was described to reach up to 200 ADP-ribose units in vitro [13]. 
Long homo-polymers of ADP-ribose are often irregularly branched with an average 
branching frequency of one branching point per 20 to 50 units of ADP-ribose [13].  
Most PAR is generated in vivo within seconds to minutes after induction of 
oxidative stress and is subsequently quickly degraded by the different isoforms of 
PAR glycohydrolase (PARG) and/or by the ADP-ribose protein hydrolase 3 (ARH3) 
[14-17]. An ADP-ribosyl protein lyase has also been identified and implicated in the 
degradation of PAR [18]. The short half-life and rapid turnover of PAR suggest that 
PAR formation is a transient cellular response and that PAR levels are tightly 
controlled under physiological stress conditions.  
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Figure 1: Metabolism of PAR formation. (1) In the initiation reaction, PARP1 cleaves the glycosidic 
bond between nicotinamide and ribose in NAD+ to covalently modify acceptor proteins with an ADP-
ribosyl unit. (2) PARP1 also catalyses the elongation and branching reaction, giving rise to polymers 
with chain lengths of up to 200 units and several branching points. (3) PARG catalyses the degradation 
of PAR to free ADP-ribose. Modified from [19]. 
 
1.1.3 Responsible enzymes 
For many years, PARP1 was thought to be the only enzyme capable of catalyzing 
PAR formation. It was only when residual PAR levels were observed in PARP1 
knockout mice in the mid nineties that additional PARP family members were 
subsequently discovered [20, 21]. In 1999, PARP2 was identified as an active PARP 
with high sequence homology to the catalytic domain of PARP1 [22, 23]. Up to now 
eighteen putative PARP family members have been proposed to exist in humans 
based on homology searches and in silico characterization [24, 25]. In mouse, rat and 
pufferfish, genes for 16 putative PARP members exist, while there are 12 PARP 
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orthologues in chicken, two in Drosophila and three in C. elegans. Also amoebae, 
slime molds and plants contain several PARPs [25]. No PARP orthologue has been 
identified in yeast, however. Many of the identified putative PARP family members 
in higher eukaryotes may not be active PAR polymerases, but instead either function 
as mono-ADP-ribosyl transferases or represent completely inactive proteins.  
 
1.2 PARP family members 
1.2.1 PARP1 
Human PARP1 (EC 2.4.2.30) contains 1014 amino acids and has an apparent 
molecular weight of 113kDa. It is an abundant nuclear chromatin associated protein 
with approximately one million molecules per cell. PARP1 accounts for about 90 % 
of total PAR formation in human cells [21]. The enzyme has only low basal activity 
but is activated by double strand break mimicking DNA in vitro or by induction of 
DNA damage in vivo [26]. PARP1 and PAR formation were described to be involved 
in a variety of nuclear functions including DNA damage signaling or repair, 
modulation of chromatin structure and regulation of transcription [3]. 
PARP1 contains three functionally distinct domains: an amino-terminal DNA 
binding domain (DBD), a central auto-modification domain (AD), and a carboxyl-
terminal PARP homology domain that includes the catalytic domain responsible for 
PAR formation (Figure 2) [27]. The DBD extends from the initiator methionine to 
threonine 373 in human PARP1. It contains two structurally and functionally unique 
zinc fingers (FI: aa 11-89; FII: aa 115-199) [28]. Recently, a third so far unrecognized 
zinc binding motif was discovered (FIII: aa 233-373) [29, 30]. This motif alone does 
not bind DNA but is essential for the catalytic activity of PARP1 [29]. The DBD also 
contains a bipartite nuclear localization signal (NLS) of the sequence KRK-X(11)-
KKKSKK (aa 207-226) that targets PARP1 to the nucleus [31]. The PARP1 zinc 
fingers FI and FII are thought to recognize altered structures in DNA rather than 
particular sequences and have also been reported to be involved in protein–protein 
interactions [32]. PARP1 strongly associates with DNA single and double strand 
breaks generated either directly by DNA damage or indirectly by the enzymatic 
excision of damaged bases during DNA repair processes [28]. Several studies indicate 
that the first zinc finger is required for PARP1 activation by both DNA single and 
double strand breaks, whereas the second zinc finger may exclusively act as a DNA 
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single strand break sensor [28]. More recently, PARP1 was shown to bind to and 
become activated by intramolecular DNA quadruplexes [33]. 
The auto-modification domain of PARP1 is located in the central region of the 
enzyme, between residues 373 and 525 of human PARP1 [34, 35]. It was identified as 
the domain containing acceptor amino acids for the covalent attachment of PAR [36].  
Multiple acceptor sites for PAR were suggested to exist within PARP1 but no 
individual site has yet been identified by site-directed mutagenesis or mass 
spectrometry. The AD of PARP1 comprises a breast cancer 1 protein (BRCA1) C-
terminus (BRCT) domain (from aa 386 to 464 in human PARP1) as well as an 
unstructured loop that connects the AD with the PARP homology domain. Besides 
auto-modification, PARP1 is subject to a number of additional post-translational 
modifications: lysine residues within the AD of PARP1 can be acetylated by the 
histone acetyltransferase (HAT) p300/CBP [37]. In proteomic approaches PARP1 
was also found to be a target for covalent lysine sumoylation and phosphorylation 
[38-41].  
PARP1 contains an 80-90 amino acid long WGR domain carboxyl-terminal of 
the AD. The WGR domain is named after the most conserved central motif of 
tryptophane (W), glycine (G), arginine (R) residues and may represent a nucleic acid 
binding domain [28]. This region of PARP1 has not been extensively characterized 
and its function is still unknown.  
The catalytic domain has been suggested to catalyze at least three different 
enzymatic reactions: the attachment of the first ADP-ribose moiety onto an acceptor 
amino acid (initiation reaction), the addition of further ADP-ribose units onto already 
existing ones (elongation reaction), and the generation of branching points (branching 
reaction) [27]. The active site is formed by a phylogenetically well-conserved 
sequence of approximately 50 residues (aa 859–908 of hPARP1). This 'PARP 
signature' contains the NAD+ acceptor sites and critical residues involved in the 
initiation, elongation and branching of PAR. The catalytic glutamate at position 988 
in human PARP1 seems to be of special importance, since this residue is essential for 
PAR chain elongation but not for the NADase activity, i.e. the hydrolysis of NAD+ to 
ADP-ribose and nicotinamide [3]. 
Despite intensive research over the last decades, the molecular mechanism of 
PAR formation has not been comprehensively understood. In particular, unresolved 
issues are how DNA binding in the amino-terminal DBD triggers enzyme activation 
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in the carboxyl-terminal catalytic domain and which amino acids are targeted by the 
auto-modification reaction. 
 
1.2.2 PARP2 
The 65kDa protein PARP2 is the PARP family member that most closely resembles 
PARP1 with 60% amino acid identity between these two proteins in the PARP 
homology domain [42]. PARP2 is less active than PARP1 but is believed to be 
responsible for most of the residual PAR formation activity in PARP1 deficient cells 
[21, 22]. In response to DNA damage, PARP2 was estimated to contribute 5% to 10% 
of the total PAR synthesis in PARP1/PARP2 proficient cells [35]. Just like PARP1, 
PARP2 is found exclusively in the cell nucleus. It has been postulated previously that 
a non-conventional bipartite NLS of the sequence (KK20-X15-KKMRTCQRK44) in the 
amino-terminal region of the protein is responsible for nuclear import [22, 43]. This 
bipartite NLS was identified based on amino acid sequence analysis but was not 
experimentally investigated in the context of full-length PARP2. Moreover, the 
mechanism of PARP2 nuclear translocation has not been elucidated [43].  
PARP2 contains a WGR domain but lacks most motifs present in the amino-
terminal half of PARP1 (Figure 2). Neither a zinc binding motif nor a BRCT domain 
has been described for PARP2. In contrast to PARP1, PARP2 contains an amino-
terminal basic SAP/SAF motif, a eukaryotic module proposed to be involved in 
sequence- or structure-specific DNA and RNA binding [44]. In line with the fact that 
PARP1 and PARP2 contain different DNA binding modules, the two proteins seem to 
have different binding specificities for certain DNA structures. Consequently their 
functions may be complementary but not completely overlapping. Functional 
redundancy (at least during early embryonic development) is, however, suggested by 
the finding that PARP1/PARP2 double knockout mice die at the onset of gastrulation, 
whereas both single knockouts are viable [45]. Unique functions of PARP2 on the 
other hand include spermatogenesis, adipogenesis and T cell development [44]. 
 
1.2.3 PARP3 
PARP3 is the smallest PARP identified so far with two splice variants containing 540 
and 533 amino acids, respectively [46]. The protein domain structure of PARP3 is 
very similar to that of PARP2, featuring a small putative DBD consisting of only 54 
residues and apparently containing an amino-terminal targeting motif that is sufficient 
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to localize the long splice variant to the centrosome [46, 47]. PARP3 expression was 
recently described to be tightly regulated and restricted to only specific cell types and 
tissues [48]. The enzymatic properties of PARP3 are only poorly investigated and it is 
currently still a matter of debate whether PARP3 possesses PARylation activity or 
merely catalyzes mono-ADP-ribosylation. 
 
 
 
Figure 2: Domain organization of human PARP1, PARP2 and PARP3. Letters A-F indicate domain 
nomenclature of PARP1, numbers indicate amino acid positions. AD, auto-modification domain; 
BRCT, breast cancer 1 protein (BRCA1) C-terminus domain; CAT, catalytic domain; DBD, DNA 
binding domain; FI, zinc finger I; FII, zinc finger II; FIII, zinc binding motif III; NLS, nuclear 
localization signal; WGR, tryptophane, glycine, arginine rich domain. 
 
 
1.2.4 PARP structures 
Attempts to obtain structural information on the full-length proteins PARP1, PARP2 
and PARP3 by x-ray crystallography or NMR have not been successful up to now. 
The three-dimensional structures of single domains, however, have been solved and 
allow structure-based comparisons of different PARP family members (Figure 3) [27, 
49] (PDB: 1A26, 1GS0, and 2PA9). Although the amino acid identity between 
PARP1 and PARP2 or PARP3 is only moderate, the overall structure of the catalytic 
domains of these three proteins is nearly identical. This conservation suggests, in 
general, similar capabilities to generate PAR. Both PARP1 and PARP2 have been 
shown to synthesize very complex branched polymers at least in vitro [28].  
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Figure 3: Overlay of the crystal structures available for the catalytic domains of chicken PARP1 
(PDB: 1A26), mouse PARP2 (PDB: 1GS0) and human PARP3 (PDB: 2PA9). PDB files were obtained 
from RCSB PDB (www.rcsb.org/pdb/home/home.do), the alignment was performed using the Magic 
Fit function of the Swiss-PDBViewer with the catalytic domain of chicken PARP1 as template. 
Yellow: PARP1, blue: PARP2, green: PARP3. 
 
1.2.5 Other PARP family members 
Other PARP family members include cytoplasmic vault PARP (PARP4, vPARP) [50] 
and the telomeric tankyrases 1 and 2 (PARP5a and PARP5b) [42, 51] as well as 
several proteins with homology to PARP1 but without described PARylation activity. 
Accordingly, these proteins were proposed to not be considered true PARP family 
members but instead be renamed PARP-like mono-ADP-ribosyl-transferases (Pl-
MARTs) [28]. 
 
1.3 Role of PARP1 in chromatin remodeling 
Chromatin refers to the protein bound state of DNA within the cell nucleus. The 
nucleosome is the simplest unit of chromatin and is composed of an octamer of the 
four core histones H2A, H2B, H3 and H4 around which 147 base pairs of DNA are 
wrapped [52]. The histone octamer is predominantly globular except for the amino-
terminal unstructured histone tails. Especially the tails possess a large number of 
modified residues with distinct types of modifications such as acetylation, 
14
methylation, phosphorylation, ubiquitylation, sumoylation, proline isomerization and 
deimination [52]. Many of these modifications influence chromatin structure and 
therefore DNA dependent processes such as DNA replication, repair and 
transcription. 
A relationship between PARP1, PARylation (potentially DNA damage 
independent) and chromatin organization has been proposed and studied in vitro 
already more than 30 years ago [53-55]. PARylation of all histones was early 
demonstrated [53, 56, 57] and decompaction of chromatin structure by histone 
PARylation was observed soon later [58, 59]. Besides covalent modification of 
histones with PAR, histones and many chromatin associated non-histone proteins also 
interact non-covalently with PAR in vitro [60-63]. Whereas PARP1 was suggested to 
displace H1 from chromatin at least in the MCF-7 breast cancer cell line [64], ISWI 
was shown to promote the association of H1 with chromatin [65]. 
PARP1 may exert its functions on chromatin structure modulation also by 
additional ways. For instance, the activity of the ATP-dependent chromatin remodeler 
ISWI was shown to be regulated by PARP1 in vitro and in vivo [66]. PARylation of 
ISWI inhibited its ATPase activity by reducing the affinity of ISWI for nucleosomes. 
PARP1 and ISWI may act antagonistically in the regulation of chromatin structure by 
antagonistically regulating the association of linker histone H1 with chromatin. The 
macrodomain containing oncogene ALC1, a member of the SNF2 ATPase 
superfamiliy, was recently shown to interact with PAR by two independent research 
groups [67, 68]. ALC1 is recruited to sites of PAR formation in cells and its ATP-
dependent chromatin remodeling activity is stimulated by PARylated PARP1. 
Another interesting target for PARylation by PARP1 is the histone exchange factor 
FACT (facilitates chromatin transcription) [69]. ADP-ribosylation of FACT induces 
its dissociation from the nucleosome and thereby inhibits FACT mediated exchange 
of histone variant H2AX. Heterochromatin formation may also be regulated by 
PARylation, because the heterochromatin protein 1 α (HP1α) was shown to be 
modified by both PARP1 and PARP2 with PARylation affecting HP1α binding to 
chromatin [70]. 
PAR is recognized and bound by macrodomain containing histone variants, 
which may regulate chromatin structure and function [71]. Very recently, 
macroH2A1.1 was shown to specifically recruit to sites of PARP1 activation and PAR 
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formation after laser-induced DNA damage and to transiently compact chromatin in a 
PAR-dependent manner [72]. Following this report, macrodomains have been 
extensively discussed as novel PAR binding modules in vivo with roles in chromatin 
structure modulation, DNA damage detection and repair [73, 74]. 
Moreover, PARP1 has been shown to regulate the function of the insulator 
protein CTCF [75]. Insulators are DNA elements, which help to organize the genome 
into regulatory units by preventing the spread of heterochromatin and limiting the 
effects of enhancers [76]. Guastafierro et al. reported that CTCF stimulates DNA 
damage independent PAR formation in vitro and is PARylated in vivo, which in turn 
affects its insulator function [77].  
Auto-modified PARP1 was recently shown to localize to the DNMT1 
promotor and protect it from methylation [78]. Furthermore, PARP inhibition induced 
global DNA hypermethylation, suggesting that PAR formation counteracts DNA 
methylation [79]. 
In summary, research that has started already in the 1970s together with more 
recent findings of the last decade strongly support the notion of PARylation being an 
essential chromatin mark with important functions in many aspects of chromatin 
structure regulation. 
 
1.4 PARP1 and DNA damage 
Because PARP1 binds to and is activated by damaged DNA, a role in DNA damage 
sensing, signaling and repair has been proposed [80-86]. PARP1 is efficiently 
activated by genotoxic stress induced by a variety of stimuli, such as reactive oxygen 
species (e.g. H2O2 treatment), irradiation-induced DNA strand breaks, or alkylating 
agents [84]. Furthermore, PARP1 was shown to interact with a number of proteins 
involved in DNA damage repair pathways, including XRCC1 [87, 88], DNA ligase 
IIIα [89], DNA polymerase β [90], Ku70/80 [91], TopBP1 [92] and PCNA [93]. 
Many of these proteins also bind to PAR at least in vitro [62, 63] and were discussed 
to be direct targets for covalent PARylation [9, 24, 94].  
Using laser microirradiation in single living cells, Haince et al. showed that 
PARP1 very rapidly recruits to DNA strand breaks and that the fast accumulation of 
the repair proteins MRE11 and NBS1 at damage sites depends on PARP1 [95]. Of 
note, PARP1 accumulation after laser microirradiation was observed even before γ-
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H2AX foci appeared or ATM and 53BP1 were recruited [95]. Another similar study 
established that PARP1 is recruited to sites of laser microirradiation within seconds 
but then begins to dissociate from the damage sites after only approximately 1 minute 
and that this dissociation depends on the enzymatic activity of PARP1 [96].  
Together, a plethora of data generated during the last decades suggests a role 
for PARP1 and PARylation in different DNA repair pathways. How important these 
roles are, however, is difficult to estimate. First, there is conflicting literature 
regarding the role of PARP1 in DNA repair pathways and several studies have failed 
to show differences in DNA repair between wild type and PARP1 deficient cells [97-
99]. Second, PARP1 deficient mice are viable, fertile, have a normal lifespan and do 
not develop spontaneous tumors [100]. Thus, PARP1 may not be an essential DNA 
repair enzyme in the stricted sense, but may aid the cellular DNA repair machinery 
under certain stress conditions [101]. 
 
1.5 PARP1 and transcription 
Chromatin immunoprecipitation coupled to hybridization to genome microarrays 
(ChIP-chip) has shown that PARP1 binding is enriched at the promoters of many 
RNA polymerase II transcribed genes [64]. In gene expression microarray analysis 
performed with embryonic stem cells and livers from PARP1 knockout and wild type 
control mice, about 3.5% of the transcriptome under non-stimulated conditions was 
regulated by PARP1 with about 60-70% of the PARP1 dependent genes being 
positively regulated [102].  
The mechanism best investigated today by which PARP1 is regulating gene 
expression is the promoter specific co-regulator function (either as co-activator or co-
repressor) for a number of transcription factors. One of the first transcription factor 
families, which was described to be regulated by PARP1, is a family of inducible 
transcription factors called nuclear factor-kappaB (NF-κB), which induces the 
expression of many pro-inflammatory genes, such as cytokines, chemokines, adhesion 
molecules and inflammatory mediators [103]. The NF-kB family consists of five 
members, p50, p52, p65 (RelA), c-Rel and RelB [104]. All five proteins share an 
amino-terminal Rel homology domain (RHD) responsible for DNA binding and 
homo- and heterodimerization. NF-κΒ dimers bind to κΒ sites in the 
promoter/enhancer regions of target genes to regulate their transcription. Co-
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activators and co-repressors are commonly recruited together with NF-κΒ to regulate 
target gene expression [104]. The strongest indication for a direct role of PARP1 in 
NF-κB-dependent transcription is the impaired expression of NF-κB-dependent pro-
inflammatory mediators in PARP1 knockout mice [100, 105-107]. Mechanistic 
studies revealed that PARP1 is not required for the nuclear translocation of NF-κΒ, 
but that PARP1 directly interacts with both subunits of NF-κΒ (p65 and p50) and 
functions as a co-activator for NF-κΒ driven gene expression, a function independent 
of the DNA binding function of PARP1 and independent of PARylation activity [108, 
109]. A role of PARP1 in transcriptional regulation of NF-κΒ dependent gene 
expression is now widely accepted. There is currently no consensus in the literature, 
however, concerning the role of PARylation for NF-κΒ regulated gene expression. 
Whereas initial studies, which included overexpressed catalytically inactive PARP1 
mutants, showed that the physical presence of the protein but not its enzymatic 
activity was required for NF-κΒ driven reporter gene expression [108], other studies 
including PARP inhibitors suggested later that PARylation does have an impact on 
NF-κΒ mediated gene expression [110]. As PARP inhibitors may also target cellular 
proteins other than PARP1, these studies should be interpreted cautiously. Taking this 
into account, the precise role of PARP1 activity for NF-κΒ target gene expression 
remains still to be defined and may well depend on cell type, cell cycle stage, the 
stimulus used and the gene locus investigated.  
More recently, PARP1 was also described to regulate the nuclear factor of 
activated T cells (NFAT) family of transcription factors [111, 112]. How PARP1 
exactly influences NFAT function and whether the enzymatic activity of PARP1 is 
required for the regulation of NFAT remains unclear in these two partly contradictory 
reports. In 2009, the forkhead box O transcription factor FOXO1 was described to be 
negatively regulated by PARP1 [113]. Notably, the co-repressor function of PARP1 at 
FOXO1 regulated genes like p27Kip1 was independent of PARylation activity, despite 
the fact that FOXO1 was modified by PARP1 and the functional significance of 
FOXO1 PARylation remains unaddressed. PARP1 also interacts with and functions as 
transcriptional co-regulator for nuclear respiratory factor 1 (NRF-1) independent of 
PARP1 enzymatic activity [114]. Moreover, while the transcription factors activator 
protein-1 (AP-1), AP-2, octamer-binding transcription factor-1 (Oct-1), yin-yang-1 
(YY-1), transcription enhancer factor-1 (TEF-1), B-MYB, and TCF-4/β-catenin have 
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all been shown to only bind PARP1, p53 and fos were reported to bind PARP1 and to 
become PARylated [115-122]. PARP1 is furthermore required for the expression of 
the transcription factors Sp1 and NFI [123]. Sp1 was shown to be PARylated in 
response to H2O2 treatment and Sp1 PARylation correlated with a reduction of Sp1 
DNA binding. 
W.L. Kraus and his group recently published that PARP1 and the linker 
histone H1 reciprocally bind to RNA polymerase II transcribed promoters with 
PARP1 being enriched and H1 levels being reduced at actively transcribed genes [64]. 
PARP1 bound around the transcription start site (TSS) and PARP1 knockdown let to 
H1 binding to normally PARP1 occupied promoters and gene repression. The authors 
concluded that PARP1 functions to displace H1 from regions around the TSS to 
enhance transcription. In a follow-up publication, Kraus and colleagues reported that 
many PARP1 dependent genes are also regulated by PARG [124]. PARP1 and PARG 
were present at the promotor regions of the same genes and seemed to act in concert. 
Interestingly, the enzymatic activity of both proteins was often not required for target 
gene expression. Of note, Kraus` group analyzed transcript levels under basal non-
stimulated conditions only. How PARP1 and PARG regulate gene expression of 
inducible genes upon stimulation was not analyzed and remains unresolved. 
Together, PARP1 exerts its functions on gene expression via different 
mechanisms including transcriptional co-regulator function, regulation of insulator 
function, regulation of DNA methylation, displacement of histones and various 
effects on global or locus specific chromatin structure [125]. 
 
1.6 PARP1 and cell death 
In the 1980s it was first proposed that over-activation of PARP1 in response to strong 
DNA damage can lead to cell death associated with depleted cellular energy pools 
[126, 127]. It was noted earlier, that strong PARP1 activity results in the rapid 
consumption of NAD+ and consequently in the almost complete depletion of cellular 
NAD+ pools [128, 129]. It was suggested that NAD+ depletion in turn would lead to 
subsequent ATP depletion in an attempt of the cell to re-synthesize NAD+ at the cost 
of ATP. Eventually, this energy crisis would cause necrotic cell death according to the 
“PARP suicide” model [127]. 
A second mechanism for PARP1 dependent cell death relates to the finding 
that PARP1 activation correlates with and may be required for the release of apoptosis 
19
inducing factor (AIF) from the mitochondria [130]. Upon release from the 
mitochondrial inter-membrane space, AIF translocates to the cell nucleus and induces 
caspase-dependent or -independent apoptosis [131]. How exactly PARP1 activation 
and PAR formation inside the nucleus trigger AIF release from the mitochondria is, 
however, not clear at the moment and only the elucidation of the involved signaling 
mechanisms will provide formal proof to directly link PAR synthesis to AIF release. 
PARP1, PAR and AIF may function together as a sensory system to integrate 
information from the nucleus and the mitochondria on the genomic and metabolic 
state of a cell to mediate death/survival pathways [28].  
In summary, two mechanisms of PARP1 and PAR dependent cell death have 
thus been defined, one leading to necrosis and involving NAD+ and ATP depletion, 
another leading to apoptosis via AIF release [132]. 
 
1.7 PARP1 and inflammation 
Inflammation occurs as a defensive response to a pathogenic insult in an attempt to 
remove the insult while limiting tissue damage [133]. Inflammation can, however, be 
very harmful and in fact is an important cause of morbidity and mortality in humans. 
Inflammation is associated with immediate infiltration of immune cells, secretion of 
cytokines and release of nitric oxide and reactive oxygen species to combat a 
pathogen. PARP1 is activated by intracellular oxidative stress, can mediate necrotic 
and apoptotic cell death and is involved in pro-inflammatory gene expression. Mice 
lacking PARP1 are viable and are protected from tissue injury in various oxidative 
stress-related disease models ranging from stroke, (MPTP)-induced parkinsonism, 
myocardial infarction, streptozotocin-induced diabetes, lipopolysaccharide-induced 
septic shock, arthritis, to colitis and zymosan-induced multiple organ failure [20, 28, 
100]. These findings suggest an important role of PARP1 during inflammation. The 
protective effects observed in PARP1 knockout animals correlate well with the 
reduced expression of pro-inflammatory cytokines under the control of NF-
κΒ, indicating that the role of PARP1 as co-activator for NF-κΒ target gene 
expression may be the most important underlying mechanism [3, 100, 105-107].  
 
1.8 PARP1 and aging - at the crossroad of metabolism and inflammation 
Aging is a multi-factorial process defined as time-dependent general decline in 
physiological function, which is associated with a progressively increasing risk of 
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morbidity and mortality [134, 135]. Age-associated diseases have complex etiology 
and underlying pathogenic mechanisms. Intensive efforts have been made over the 
last decades to identify single key players at the molecular level, which are involved 
in age-related diseases. PARP1 functions as molecular stress sensor and as such is 
involved in the cellular response to a variety of age-associated stress signals. The 
enzymatic activity of PARP1 is activated by reactive oxygen species (ROS), the 
levels of which are believed to increase with age and also drive the aging process. 
PARylation requires NAD+ consumption and thus is directly linked to energy 
metabolism. Moreover, PARP1 shares its substrate molecule NAD+ with other 
enzymes involved in aging, the most prominent being the family of NAD+-dependent 
class III histone deacetylases (SIRTs). As transcriptional coactivator for NF-κB-
dependent gene expression, PARP1 is connected to the immune response, which is 
implicated in almost all age-related diseases. Furthermore, numerous experimental 
studies have demonstrated the beneficial effects of PARP inhibition for several age-
associated diseases. Together, this led us propose PARP1 to be a central key player 
during aging as an integrator at the crossroad of metabolic stress and inflammation 
[136]. 
 
1.9 PARP inhibition and inflammatory diseases 
The first non-selective broad-range inhibitor of PARP activity, 3-aminobenzamide, 
was discovered more than 25 years ago and during the last two decades over 50 
potential PARP inhibitors have been developed [101]. The involvement of PARP1 in 
cell death and the capacity of PARP1 to promote the transcription of pro-
inflammatory genes are particularly important for the development of drugs, which 
target pathophysiological situations of detrimental inflammation. On the basis of 
structural information available for the catalytic domains of PARP1 and PARP2 co-
crystallized with NAD+ or certain PARP inhibitors, it became clear that the majority 
of PARP inhibitors mimic the nicotinamide moiety of NAD+ and bind to the donor 
site within the catalytic domain [27, 49, 137]. Although the physiological functions of 
PARPs and PARylation is still under debate, numerous experimental studies during 
the last years have clearly demonstrated the beneficial effects of PARP inhibition 
from cell culture systems to pre-clinical animal models of acute and chronic 
inflammation [101, 138]. In general, the severity of many inflammatory diseases is 
suppressed by PARP inhibitors and the production of multiple pro-inflammatory 
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mediators is downregulated [139]. The reduced expression of pro-inflammatory genes 
by PARP inhibition is in contradiction to the finding that the enzymatic activity of 
PARP1 is not required for NF-κΒ dependent gene expression [108]. However, this 
discrepancy might be explained in three ways: First, it should be noted that the 
currently available PARP inhibitors do not discriminate well between PARP1 and 
other PARP family members or even other NAD+-metabolizing enzymes, which are 
described to also play a role in inflammatory response pathways [140, 141]. Second, 
based on recent reports, one cannot exclude the possibility that PARP inhibitors might 
even affect non-NAD+-consuming targets such as AKT/PKB or MMPs [142]. Third, 
the enzymatic activity of PARP1 might be required for the transcriptional activity of 
transcription factors involved in inflammatory processes other than NF-κB. Several 
groups have shown that co-operative activities between transcription factors such as 
AP-1, STAT-1 or IRF-1 in the enhanceosomes of NF-κB dependent genes are 
required for full synergistic activation of target genes [143, 144]. Considering these 
constraints of all currently available PARP inhibitors, the specific contribution of 
PARP1 enzymatic activity for inflammatory diseases, in which PARP inhibition has 
beneficial effects, needs to be evaluated very carefully.  
 
1.10 PARP inhibition in cancer treatment 
Many of the agents used in cancer treatment exert their cytotoxic effects by causing 
DNA damage. Conventional cytotoxic therapies, such as ionizing radiation or 
chemotherapy, are clinically beneficial because tumors deal less efficiently with DNA 
damage than normal tissue [145]. This is especially true for tumors with defects in the 
cellular repair systems responsible for faithful repair of damaged DNA. 
Consequently, the rational for the use of DNA repair inhibitors in cancer therapy 
relies on the assumption that inhibition of defined repair pathways will increase the 
likelihood that DNA damage will cause cell death specifically in tumor cells [145]. 
The breast cancer susceptibility proteins BRCA1 and BRCA2 function in the 
homologous recombination DNA repair pathway and loss of function of either protein 
is associated with an increased risk of developing cancer [145]. In fact, mutations in 
BRCA1 or BRCA2 account for 80-90% of all hereditary breast cancers [146]. In these 
cells, which are impaired in homologous recombination DNA repair, backup repair 
pathways may operate and deal with damage normally repaired via BRCA1/2 
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dependent pathways. Deficiency in one DNA damage repair component would thus 
render tumor cells highly sensitive to inhibition of a backup pathway, a concept called 
“synthetic lethality” [145]. Thus, inhibition of DNA damage signaling or repair might 
enhance the cytotoxicity of DNA damaging agents in a tumor specific manner. Since 
PARP1 and also PARP2 activity have been implicated in the sensing, signaling and 
repair of DNA damage, PARP inhibition has become an interesting option to treat 
cancers with defects in certain DNA repair pathways, especially in homologous 
recombination. Interestingly, cells defective for BRCA1 and BRCA2 are profoundly 
sensitive to PARP inhibition [147, 148] and chemical PARP inhibitors have been used 
in clinical trials with minimal toxicity to treat BRCA1- and BRCA2 deficient ovarian 
cancers [145]. In agreement with the concept of synthetic lethality, PARP inhibitors 
enhance the cytotoxic effects of a variety of agents commonly used in cancer 
treatment, such as alkylating agents (e.g. temozolomide), topoisomerase I inhibitors 
(e.g. irinotecan), and ionizing radiation. Recently, Mendes-Pereira et al. showed that 
also cells with mutations in the tumor suppressor gene phosphatase and tensin 
homolog (PTEN) are sensitive to PARP inhibition [149]. PTEN is involved in 
homologous recombination and is one of the most commonly mutated genes in human 
cancers. Thus, the data by Mendes-Pereira and colleagues suggest that the clinical 
assessment of PARP inhibitors should not be restricted to patients with BRCA1/2 
mutations but be extended to a larger group of patients with mutations in PTEN. 
Although PARP inhibition at the moment seems very promising for cancer 
treatment in combination with other cytotoxic anti-cancer drugs, the molecular 
mechanisms underlying the observed beneficial effects in patients in clinical trials are 
far from being understood. In particular, it remains to be experimentally established 
whether PARP inhibition in fact increases cytotoxicity exclusively because DNA 
damage repair is impaired or whether other, as yet undefined mechanisms are 
responsible for PARP inhibition dependent cell death. Moreover, as all PARP 
inhibitors used today belong to a class of NAD+ analoga and target the NAD+ binding 
pocket within the catalytic domain of PARPs, inhibition of other NAD+-binding 
proteins has to be expected and should be carefully investigated. Finally, as promising 
as the clinical trials with PARP inhibitors are, the long-term effects of PARP 
inhibition in humans have not been studied and it remains to be shown that long-term 
inhibition of a protein postulated to be involved in DNA repair has no or neglectable 
adverse effects. 
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1.11 Aim of this thesis 
The nuclear protein PARP1 plays important roles in DNA damage signaling, 
chromatin organization, regulation of gene expression and cell death. These functions 
may depend on or may be independent of the enzymatic activity of PARP1, i.e. the 
generation of PAR. The aim of this thesis was to investigate the molecular mechanism 
of PAR formation and the role of PARP1 for inflammation-induced gene expression. 
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2 RESULTS 
 
2.1 Published review articles in peer reviewed journals 
 
2.1.1 Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and 
inflammation in aging  
 
Authors: Matthias Altmeyer and Michael O. Hottiger 
Journal:  Aging. 2009 May;1(5):458-469.  
Contribution: Literature research; preparation of the model; drafting of the 
manuscript. 
 
 
2.2 Published research articles in peer reviewed journals 
 
2.2.1 Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and 
identification of lysine residues as ADP-ribose acceptor sites 
 
Authors: Matthias Altmeyer, Simon Messner, Paul O. Hassa, Monika Fey and 
Michael O. Hottiger 
Journal:  Nucleic Acids Res. 2009 Jun;37(11):3723-38. 
Contribution: Planning and designing the study; planning, performing and evaluating 
all experiments shown in Figures 1-6 and Supplementary Figures 1-6; 
in particular cloning, expression and purification of wild-type proteins, 
protein chimera and mutant proteins; in vitro mono- and poly(ADP-
ribosyl)ation assays; time-course experiments; evaluation of enzyme 
kinetics; interaction studies; structural modeling and sequence 
alignments; preparation of all figures and drafting of the manuscript. 
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2.2.2 Identification of lysines 36 and 37 of PARP-2 as targets for acetylation 
and auto-ADP-ribosylation 
 
Authors: Sandra S. Haenni*, Paul O. Hassa*, Matthias Altmeyer*, Monika Fey,  
 Ralph Imhof and Michael O. Hottiger 
  * equal contribution 
Journal: Int J Biochem Cell Biol. 2008;40(10):2274-83. 
Contribution: Planning, performing and evaluating experiments; in particular 
interactions studies between PARP2 and the histone acetlytransferase 
(HAT) GCN5 (Figure 1E); in vitro acetylation assays (Figure 2D, 
Suppl. Figure 1); PARP2 expression analyses (Suppl. Figure 3); 
determination of PARP2 and HAT localization by 
immunofluorescence (Suppl. Figure 5); preparation of figures and 
revision of the manuscript. 
 
 
2.2.3 Importin alpha binding and nuclear localization of PARP-2 is dependent 
on lysine 36, which is located within a predicted classical NLS  
 
Authors: Sandra S. Haenni*, Matthias Altmeyer*, Paul O. Hassa*, Taras 
Valovka, Monika Fey and Michael O. Hottiger 
  * equal contribution 
Journal:  BMC Cell Biol. 2008 Jul 21;9:39. 
Contribution: Planning, performing and evaluating experiments; in particular PARP2 
localization studies with single amino acid mutants (Figure 4); 
interaction analysis (Figure 5D); sequence alignments (Figure 1A); 
preparation of figures and revision of the manuscript. 
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2.2.4 Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation 
and restrains transcriptional coactivator function  
 
Authors: Simon Messner, David Schuermann, Matthias Altmeyer, Ingrid 
Kassner, Darja Schmidt, Primo Schär, Stefan Müller and Michael O. 
Hottiger 
Journal: FASEB J. 2009 Jul 31.  
Contribution: Analysis of purified poly(ADP-ribose) generated by sumoylated or 
desumoylated PARP1 using DNA sequencing gel electrophoresis and 
silver staining (Figure 3C). 
 
Only the title page of this article is presented in the following section of this thesis. 
The complete article can be obtained from the journal homepage. 
 
 
2.2.5 A macrodomain-containing histone rearranges chromatin upon sensing 
PARP1 activation 
 
Authors:  Gyula Timinszky*, Susanne Till*, Paul O. Hassa*, Michael Hothorn, 
Georg Kustatscher, Bianca Nijmeijer, Julien Colombelli, Matthias 
Altmeyer, Ernst H. K. Stelzer, Klaus Scheffzek, Michael O. Hottiger 
and Andreas G. Ladurner 
   * equal contribution 
Journal:  Nat Struct Mol Biol. 2009 Sep;16(9):923-9. 
Contribution: Cloning, expression and purification of recombinant human PARP1 
and PARP2; preparation of AGS shMock and shPARP1 cells; analysis 
of PARP1 knock-down efficiency. 
 
Only the title page of this article is presented in the following section of this thesis. 
The complete article can be obtained from the journal homepage. 
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2.3 Submitted research articles to peer reviewed journals 
 
2.3.1 PARP1 accelerates Salmonella induced gut inflammation 
 
Authors: Matthias Altmeyer, Manja Barthel, Matthias Eberhard, Hubert 
Rehrauer, Wolf-Dietrich Hardt and Michael O. Hottiger 
Journal:  Submitted to Gastroenterology 
Contribution: Performing and evaluating experiments; in particular analysis of whole 
genome expression arrays (Figures 1C, 4A, 4B, 4C, 4D), qRT-PCR 
(Figures 1D, 2A, 3F, 5A, 5B, 5C, Suppl. Figures 1A, 2), Western blot 
(Figure 2B), immuofluorescence in tissue sections and cultured cells 
(Figure 2C, Suppl. Figures 1B, 1C); statistical analyses; preparation of 
the figures and tables; writing of the manuscript. 
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INTRODUCTION 
 
Aging is a multi-factorial process defined as time-
dependent general decline in physiological function, 
which is associated with a progressively increasing risk 
of frailty, morbidity and mortality [1, 2]. The effect of 
aging is mainly observed in modern human societies 
and in animals under laboratory conditions [3]. The 
dramatic increase in mean human life span and life 
expectancy, coupled to a significant reduction in early 
mortality caused by the reduced occurrence of 
infections during the past two centuries, has led to an 
enormous increase in the number of elderly people in 
modern societies [4, 5]. This demographic phenomenon 
has been paralleled by an epidemic of chronic diseases 
associated with advanced age, most of which have 
complex etiology and underlying pathogenic mecha-
nisms [6]. Intensive efforts have been made over the last 
 
 
 
www.impactaging.com      AGING, May 2009, Vol. 1. No 5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Poly(ADP"ribose)!polymerase!1!at!the!crossroad!of!metabolic!stress!
and!inflammation!in!aging!
Matthias!Altmeyer1,2!and!Michael!O.!Hottiger1!
!
1!Institute!of!Veterinary!Biochemistry!and!Molecular!Biology,!University!of!Zurich,!Zurich,!Switzerland!
2!Life!Science!Zurich!Graduate!School,!Molecular!Life!Science!Program,!Zurich,!Switzerland!
!
Running!title:!PARP1!and!aging!
Key!words:!PARP"1,!NAD+,!ROS,!NF"!B,!inflammation,!aging!
Correspondence:!Michael!O.!Hottiger,!DVM,!PhD,!Institute!of!Veterinary!Biochemistry!and!Molecular!Biology,!University!of!
Zurich,!Winterthurerstrasse!190,!8057!Zurich,!Switzerland!
Received:!04/20/09;!accepted:!05/19/09;!published!on!line:!05/20/09!
E"mail:!!hottiger@vetbio.uzh.ch!
!
Abstract:!Poly(ADP"ribose)!polymerase!1!(PARP1)!is!a!chromatin"associated!nuclear!protein,!which!functions!as!molecular
stress!sensor.!Reactive!oxygen!species,!responsible!for!the!most!plausible!and!currently!acceptable!global!mechanism!to
explain!the!aging!process,!strongly!activate!the!enzymatic!activity!of!PARP1!and!the!formation!of!poly(ADP"ribose)!(PAR)
from!NAD+.!Consumption!of!NAD+!links!PARP1!to!energy!metabolism!and!to!a!large!number!of!NAD+"dependent!enzymes,
such! as! the! sirtuins.!As! transcriptional! cofactor! for!NF"!B"dependent! gene! expression,! PARP1! is! also! connected! to! the
immune! response,! which! is! implicated! in! almost! all! age"related! or! associated! diseases.! Accordingly,! numerous
experimental! studies!have!demonstrated! the!beneficial!effects!of!PARP! inhibition! for! several!age"related!diseases.!This
review!summarizes!recent!findings!on!PARP1!and!puts!them!in!the!context!of!metabolic!stress!and!inflammation!in!aging.!
 
 
 
 
decades to identify single key players involved in age-
related diseases. Poly(ADP-ribose) polymerase 1 
(PARP1) is a chromatin-associated nuclear protein which 
functions as stress sensor and as such is involved in the 
cellular responses to a variety of age-related stress 
signals.  
 
Poly(ADP-ribose) polymerase 1 as molecular stress 
sensor 
 
PARP1 is an abundant nuclear chromatin-associated 
multifunctional enzyme found in most eukaryotes apart 
from yeast [7]. PARP1 has been initially thought to be 
the only existing enzyme with poly(ADP-ribosyl)ation 
activity in mammalian cells. However, five additional 
Parp-like genes encoding “bona fide” PARP enzymes 
have been identified in recent years, indicating that 
PARP1 belongs to a family of “bona fide” PARP 
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enzymes [8]. The basal enzymatic activity of PARP1 is 
very low, but is stimulated dramatically under conditions 
of cellular stress [9, 10]. Activation of PARP1 results in 
the synthesis of poly(ADP-ribose) (PAR) from 
nicotinamide adenine dinucleotide (NAD+) and in the 
release of nicotinamide as reaction by-product [7, 8]. 
Following PARP1 activation, intracellular PAR levels 
can rise 10–500-fold [11-13]. Despite intensive research 
on the cellular functions of PARP1, the molecular 
mechanism of PAR formation has not been comprehen-
sively understood. Up to now, two different modes of 
PARP1 activation have been described, one dependent on 
DNA damage and one dependent on post-translational 
protein modifications (see below).  
 
PAR is a heterogeneous linear or branched homo-
polymer of repeating ADP-ribose units linked by 
glycosidic ribose-ribose bonds [7, 9, 14]. Most free or 
protein-associated PAR molecules are rapidly degraded 
in vivo [15]. This rapid turnover strongly suggests that 
PAR levels are tightly regulated under physiological 
stress conditions and that degradation of the polymer 
starts immediately upon initiation of PAR synthesis. To 
date two enzymes, poly(ADP-ribose) glycohydrolase 
(PARG) and ADP-ribosyl protein lyase, have been 
described to be involved in PAR catabolism [16, 17]. 
While PARG possesses both exo- and endoglycosidic 
activities, the lyase has been described to cleave the 
bond between proteins and mono(ADP-ribose). The 
attachment of negatively charged PAR onto proteins is 
transient but can be very extensive in vivo, as polymer 
chains can reach more than 400 units on protein 
acceptors [7]. PAR formation has been implicated in a 
variety of cellular processes, such as maintenance of 
genomic stability, transcriptional regulation, energy 
metabolism and cell death [7]. The physiological 
consequences of this post-translational modification on 
the molecular level, however, are not yet completely 
understood. It has been proposed that PAR may have a 
dual role in modulating cell survival and cell death [9, 
18, 19]. Low to moderate levels of PAR may be 
beneficial for important cellular functions, whereas 
extensive PAR formation can be detrimental and lead to 
various forms of cell death. More than a decade ago, 
PARP1 activity was linked to the aging process, as 
poly(ADP-ribosyl)ation capacity was shown to correlate 
with species-specific longevity [20, 21].  
 
Most proteins associated with PAR are nuclear DNA-
binding proteins, including PARP family members and 
histones [7, 22, 23]. PARP1 is the main acceptor for 
poly(ADP-ribosyl)ation in vivo and auto-modification 
of PARP1 abolishes its affinity for NAD+ and DNA [24, 
25]. A similar effect has been postulated for 
histones/nucleosomes. PAR polymers could function to 
alter chromatin conformation through covalent or non-
covalent interactions with histone tails and via 
displacement of histones from DNA, thus regulating the 
accessibility of the genetic material. It was suggested 
that PAR might either directly participate in chromatin 
remodelling processes or indirectly coordinate them 
through recruitment and regulation of specific 
chromatin remodelling proteins [7, 22]. Moreover, PAR 
is recognized and bound by macrodomain containing 
histone variants [26].  
 
Over 20 years ago, Nathan Berger was the first to 
suggest that cellular stress (e.g. oxidative damage) 
causes over-activation of PARP1 and subsequent NAD+ 
depletion [27, 28]. In an attempt to restore the NAD+ 
pools, NAD+ is resynthesized with a consumption of 2-4 
molecules of ATP per molecule of NAD+. As a 
consequence, cellular ATP levels become depleted, 
leading to subsequent energy failure, which results in 
cellular dysfunction and eventually in necrotic cell 
death [27, 28]. Pharmacological inhibition of the 
enzymatic activity of PARP or the complete absence of 
PARP1 was shown to significantly improve cellular 
energetic status and cell viability after exposure to 
necrosis-inducing agents [29-31]. The contribution of 
poly(ADP-ribosyl)ation reactions to necrotic cell death 
seems to be dependent on the cell type and the cellular 
metabolic status [7, 32, 33].  
 
Interestingly, genetic studies using Parp1 knockout 
mice provided preliminary evidence that energy 
depletion alone might not be sufficient to mediate 
poly(ADP-ribosyl)ation-dependent cell death [34]. A 
second model has been proposed to explain how PARP1 
regulates cell death. This model suggests that over-
activation of PARP1 induces translocation of apoptosis-
inducing factor (AIF) from the mitochondria to the 
nucleus, causing DNA condensation and fragmentation, 
and subsequent cell death [35]. 
 
Together, PARP1 can be regarded as molecular stress 
sensor with many physiological cellular functions. 
Over-activation of PARP1 results in the generation of 
large amounts of PAR. Subsequently, cellular NAD+ 
pools are depleted and AIF is released from the 
mitochondria to trigger cell death. Importantly, these 
PARP1-dependent cellular suicide mechanisms have 
been implicated in the pathomechanisms of neuro-
degenerative disorders, cardiovascular dysfunction and 
various other forms of inflammation [36]. 
  
Activation of PARP1 by reactive oxygen species (ROS)  
 
A unified theory explaining the pathogenesis of diverse 
degenerative conditions in different organs (including 
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Alzheimer’s, Parkinson’s and other neurodegenerative 
disorders, rheumatoid arthritis, atherosclerosis and other 
cardiovascular diseases, diabetes) has been proposed to 
explain how the single physiological process of aging 
may lead to diverse pathological states [37]. This 
oxidative stress theory of aging (or free radical theory 
of aging), initially proposed by Harman in 1956, 
provides the most plausible and currently acceptable 
global mechanism to explain the aging process [38]. 
The theory postulates that aging is, in the absence of 
other risk factors (e.g. infections, smoking, 
hypercholesterolemia), the net consequence of free 
radical-induced damage and the inability to counter-
balance these changes by anti-oxidative defenses. An 
increase in intracellular ROS levels through hydrogen 
peroxide treatment of cells or through the inhibition of 
ROS scavenging enzymes, such as superoxide 
dismutase (SOD1), causes premature senescence and 
can shorten cellular life span [39-45]. Mitochondria are 
the main producers of cellular ROS under normal 
conditions, as approximately 1-2% of the oxygen 
molecules consumed during respiration are converted 
into highly reactive superoxide anions [46]. Besides 
aerobic metabolism in mitochondria, "-oxidation in 
peroxisomes and certain enzymes can produce ROS. 
Intracellular ROS can damage cellular components 
through oxidation of macromolecules such as nucleic 
acids, proteins and lipids [47]. Moreover, an 
overproduction of ROS leads to rapid generation of 
peroxinitrite from nitric oxide and superoxide, causing 
an imbalance in nitric oxide signaling [48].  
 
Since the oxidative stress theory was first proposed, a 
considerable body of evidence has been published 
corroborating the idea that increased production of ROS 
underlies cellular dysfunction in various organ systems 
of aged humans and laboratory animals [49]. 
Interestingly, the enzymatic activity of PARP1 can be 
strongly activated by treatment of cells with ROS such 
as hydrogen peroxide [8]. Earlier studies described that 
PARP1 binds to oxidative damage-induced strand 
breaks within the DNA via two zinc finger motifs and 
thereby becomes activated [9]. More recently, several 
studies suggested that PARP1 activity is also regulated 
in a DNA-independent manner. A proteomic investiga-
tion uncovered many ERK1/2-induced phosphorylation 
sites in PARP1, which are located within important 
functional domains, consistent with regulatory roles in 
vivo [50, 51]. Furthermore, DNA-independent PARP1 
activation can be triggered by the direct interaction of 
PARP1 with phosphorylated ERK-2 without PARP1 
being phosphorylated itself [52].  In addition, PARP1 
can be activated by elevated levels of extracellular 
glucose, Ca2+ and angiotensin II, and allosteric 
regulation of auto-poly(ADP-ribosyl)ation by Mg2+, 
Ca2+, polyamines, ATP and the histones H1 and H3 has 
been reported [53]. Whether ROS-mediated activation 
of PARP1 is due to ROS-generated DNA damage or 
also based on other ROS-induced cellular (signaling) 
mechanisms awaits further investigations. 
 
PARP1 is linked to energy metabolism through 
NAD+  
 
NAD+ biosynthesis has become of considerable interest 
due to the important signaling functions of pyridine 
nucleotides. In mammals, niacin (collectively 
designating nicotinamide and nicotinic acid) and the 
essential amino acid tryptophan are precursors of NAD+ 
biosynthesis [12, 54]. The formation of dinucleotides 
from ATP and the mononucleotide of niacin constitute 
the most critical step in NAD+ generation, which is 
catalyzed by NMN/NaMN adenylyltransferases 
(NMNATs) [13, 55]. Since PARP1 uses NAD+ as 
substrate to synthesize PAR, PARP1 decisively depends 
on the amount of NAD+ available and may act as energy 
sensor in the nucleus. Both constitutive and activated 
levels of PAR have been suggested to be strictly 
dependent on the concentration of NAD+ in cells [15, 
56, 57]. Importantly, the nuclear concentration of NAD+ 
can be modulated by NMNAT-1 and a recent study 
revealed that NMNAT-1 is able to interact with and 
stimulate PARP1 [58]. It is thus tempting to speculate 
that PARP1 activation is supported by the localized 
action of NMNAT-1. Depending on the level of PARP1 
activity, the cellular NAD+ concentration is 
concomitantly reduced. Therefore, PARP1 not only is a 
sensor of NAD+, but in turn also influences cellular 
energy levels. 
 
Dietary restriction, also called calorie restriction, is 
defined as a life-long moderate (20-40%) reduction in 
caloric intake and has repeatedly been shown to extend 
the longevity of both invertebrates and vertebrates [59, 
60]. Reducing the caloric intake starting even at an old 
age has also been shown to increase the life span of flies 
and mice and is sufficient to reverse gene expression 
changes associated with aging [61-63]. Furthermore, 
dietary restriction in rodents delays the onset and 
reduces the severity of many age-related diseases, such 
as cardiovascular disease, diabetes, osteoporosis, 
cataracts, neurodegenerative disease and cancers [60]. 
Although it was initially expected that dietary 
restriction would reduce overall cellular energy levels 
by slowing down glycolysis and the tricarboxylic acid 
(TCA) cycle [59], this assumption has been challenged, 
since dietary restriction was shown to cause an increase 
in NAD+/NADH ratios in yeast cultures [64]. Whether 
this is also the case in mammalian cells remains to be 
determined. Along the same lines, the impact of dietary 
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restriction on enzymes that depend on NAD+ (e.g. 
PARP1) is currently being investigated in multiple 
laboratories. Whether and how PARP1 activation 
differs in species with different maximal life span (and 
possibly also with different cellular NAD+ pools), 
however, remains an open question. 
 
Crosstalk between PARP1 and other NAD+-
consuming enzymes 
 
NAD+ is an essential cofactor regulating numerous 
cellular pathways and has recently been recognized as a 
substrate for a growing number of NAD+-dependent 
enzymes [11, 13]. NAD+-dependent post-translational 
protein modifications are catalyzed by several enzyme 
families, including PARPs and the sirtuin family of 
NAD+-dependent class III histone deacetylases (SIRTs) 
[8, 65, 66]. SIRTs and the yeast homolog and founding 
member of the sirtuins, Sir2, are induced by dietary 
restriction and have been implicated in senescence and 
aging, although the exact mechanisms are not yet 
known [59, 67]. Intriguingly, ADP-ribosylation by 
PARP1 could modulate the NAD+-dependent 
deacetylation of proteins by SIRTs via the 
NAD+/nicotinamide connection. The decline of NAD+ 
levels and the rise of nicotinamide upon PARP1 
activation have immediate effects on other NAD+-
consuming enzymes [57, 68, 69]. SIRTs require NAD+ 
as substrate and are inhibited by low levels of 
nicotinamide [70]. Consequently, under conditions of 
cellular stress and PARP1 activation, the activity of 
SIRTs is downregulated. 
 
PARPs and sirtuins may not only compete for the same 
substrate, but might also regulate each other more 
directly. For instance, PARP1 and SIRT1 interact at the 
protein level and SIRT1 might be regulated by PARP1-
dependent trans-ADP-ribosylation [7]. Another link 
between PAR generation and acetylation/deacetylation 
reactions comes from the very recent identification of 
three lysine residues in the auto-modification domain of 
PARP1 as acceptor sites for auto-ADP-ribosylation 
[71]. The same lysines were previously identified as 
targets for acetylation by p300 and PCAF [72]. 
Remarkably, simple addition of PCAF reduced 
poly(ADP-ribosyl)ation of PARP1 (own unpublished 
observation), suggesting that the interaction domain of 
PARP1 with PCAF is overlapping with the ADP-ribose 
acceptor sites. We recently also published that 
acetylation of lysine residues interferes with ADP-
ribosylation [73]. This finding points at an interesting 
crosstalk between acetylation of and ADP-ribosylation 
by PARP family members. It will certainly be 
interesting to further investigate the crosstalk between 
PARP1-dependent  ADP-ribosylation  and acetylation/ 
deacetylation reactions. NAD+ levels can be expected to 
play an important role for the interplay between these 
two NAD+-dependent post-translational protein 
modifications. Whether the balance between and the 
tight regulation of poly(ADP-ribosyl)ation and NAD+-
dependent deacetylation is altered during aging remains 
to be investigated. Furthermore, it will be important to 
identify additional NAD+-dependent enzymes involved 
in the aging process.  
 
Emerging pathological evidence indicates that major 
chronic age-related diseases, such as atherosclerosis, 
arthritis, dementia, osteoporosis and cardiovascular 
disease, are inflammation-related [74]. A link between 
NAD+ metabolism and the regulation of an 
inflammatory response is suggested by the finding that 
nicotinamide phosphoribosyltransferase (NAMPT), one 
of the enzymes involved in NAD+ biosynthesis from 
nicotinamide, increases cellular NAD+ levels in 
response to stress [75]. The expression of NAMPT is 
upregulated in activated lymphocytes [76]. 
Furthermore, NAMPT protein and/or mRNA levels 
were also found to be upregulated upon stimulation of 
immune cells both in vivo and in vitro [77, 78], whereas 
a specific NAMPT inhibitor was found to inhibit 
cytokine production [79]. Notably, nicotinamide is 
known to inhibit the production of key inflammatory 
mediators [80-82], protects neurons against 
excitotoxicity [83, 84], and blocks replicative 
senescence of primary cells [85]. Moreover, a recent 
study suggested that intracellular NAD+ levels regulate 
TNF-# protein synthesis in a SIRT6-dependent manner 
[86]. Both, SIRT1 and SIRT6 also regulate NF-!B 
signaling with effects on senescence and possibly aging 
[87, 88]. 
 
Together, accumulating evidence suggests that cellular 
NAD+ biosynthesis and the NAD+-consuming reactions 
poly(ADP-ribosyl)ation and SIRT-dependent 
deacetylation are tightly interrelated and have functions 
in inflammation and age-related diseases. 
 
PARP1 is linked to age-related inflammation as 
transcriptional cofactor of NF-!B 
 
A body of experimental and clinical evidence suggests 
that the immune system is implicated in almost all age-
related or associated diseases [89, 90]. There is a well-
established connection between oxidative stress and the 
inflammatory immune response [37]. A prominent 
mechanism by which age-induced ROS modulate 
inflammation is by inducing the redox-sensitive 
transcription factor nuclear factor kappa B (NF-!B). 
This induction of NF-!B leads to the generation of pro-
inflammatory mediators and a state of chronic 
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inflammation [91, 92]. NF-!B plays an important role 
in inflammatory phenotypic changes in various 
pathophysiological conditions [49]. In fact, NF-!B has a 
fundamental role in mediating all the classical attributes 
of inflammation – rubor, calor, dolor and tumor – by 
regulating transcriptional programs in tissues containing 
epithelial and stromal cells, vascular endothelial cells 
and hematopoietic cells [93]. During the last decade, it 
has been clearly demonstrated that excessive activation 
or inappropriate regulation of immune and inflam-
mation cascades causes tissue and cellular damage, 
which can lead to cellular dysfunction and death [14]. 
Furthermore, it was suggested that chronic, low-grade 
inflammation is a possible converging process linking 
normal aging and the pathogenesis of age-related 
diseases [94]. This hypothesis is in accordance with the 
finding that constitutive activation of NF-!B, 
accompanied by elevated levels of inflammatory 
markers, is a ubiquitous phenomenon observed in 
various cell types in the aging phenotype [95].  
 
In most unstimulated cells, NF-!B is sequestered in the 
cytoplasm as an inactive transcription factor complex 
by its physical association with one of several inhibitors 
of NF-!B (I!B) [96-100]. The key regulatory event in 
NF-!B induction is the phosphorylation of I!B proteins 
by the I!B kinase (IKK) complex, which leads to I!B 
protein ubiquitylation and subsequent degradation [101, 
102]. ROS have been reported to induce the activation 
of NIK/IKK and MAPK pathways that lead to the 
degradation of I!B and subsequent NF-!B-dependent 
gene expression [74, 103]. Conversely, induction of NF-
!B itself results in the generation of ROS via the 
expression of inducible nitric oxide synthase (iNOS), 
thus activating a feedback loop that amplifies the 
process of damage and deterioration in target cells and 
organs [37]. 
 
Global screens for age-specific gene regulation have 
been performed from many tissues in mice and humans 
[3]. These analyses have recently provided evidence 
that the NF-!B binding domain is the genetic regulatory 
motif most strongly associated with the aging process 
and that NF-!B target genes show a strong increase in 
expression with age in human and mouse tissues as well 
as in stem cells [104-106]. Furthermore, NF-!B is 
implicated in age-dependent induction of cellular 
senescence in epithelial and hematopoietic progenitor 
cells [104, 107]. Blockade of NF-!B in the skin of aged 
mice can reverse the global gene expression program 
and tissue characteristics to that of younger animals 
[108]. Moreover, Donato et al. reported lately that in 
vascular endothelial cells of aged human donors nuclear 
NF-!B levels increase, I!B# levels decrease and that 
the expression of proinflammatory cytokines, such as 
interleukin 6 (IL-6), tumor necrosis factor-! (TNF-#) 
and monocyte chemoattractant protein 1 (MCP-1) is 
reduced [109]. NF-!B activity was also increased in 
aged rat vessels and kidneys, but reduced in rats under 
calorie restriction [110, 111]. 
 
Studies performed with Parp1 knockout mice have 
identified various detrimental functions of PARP1 in 
inflammatory and neurodegenerative disorders. Parp1 
gene-disruption protected from tissue injury in various 
oxidative stress-related disease models ranging from 
stroke, (MPTP)-induced parkinsonism, myocardial 
infarction, streptozotocin-induced diabetes, lipo-
polysaccharide-induced septic shock, arthritis, to colitis 
and zymosan-induced multiple organ failure [7, 73, 112, 
113]. There are striking similarities between the 
expression pattern of PARP1 and the detrimental 
transcriptional activity of NF-!B. In most tissues and 
cell types associated with high PARP1 expression, 
dysregulated NF-!B activity seems to contribute to 
cellular dysfunction and necrotic cell death during 
inflammatory disorders [14]. The strongest indication 
for a direct role of PARP1 in NF-!B-dependent 
transcription was the impaired expression of NF-!B-
dependent pro-inflammatory mediators in Parp1 
knockout mice [113]. Moreover, the upregulation of 
several inflammatory response genes after treatment 
with inflammatory stimuli was drastically reduced in 
Parp1 knockout mice [112, 114-116]. Our group 
provided first evidence that PARP1 is required for 
specific NF-!B-dependent gene activation and can act 
as transcriptional coactivator of NF-!B in vivo [117]. 
PARP1 is required and sufficient for specific 
transcriptional activation of NF-!B in response to pro-
inflammatory stimuli and cellular stress. Furthermore, 
Tulin and Spradling found that Drosophila mutants 
lacking normal PARP levels display immune defects 
similar to mice lacking the NF-!B subunit p50 [118]. 
These results imply that the role of PARP1 in NF-!B-
dependent gene expression during immune responses 
has been conserved during evolution. Together, several 
lines of evidence suggest a model in which PARP1 
functions as a promoter-specific cofactor for NF-!B-
dependent gene expression [7, 14].  
 
PARP as therapeutic target for age-associated 
diseases 
 
During the last two decades of intensive research, over 
50 potential PARP inhibitors were developed [119]. The 
involvement of PARP1 in cell death (both apoptosis and 
necrosis) and the capacity of PARP1 to promote the 
transcription of pro-inflammatory genes are particularly 
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important for drug development. On the basis of 
structural information available for the catalytic 
domains of PARP1 and PARP2 co-crystallized with 
NAD+ or certain PARP inhibitors, it became clear that 
the majority of PARP inhibitors mimic the nicotinamide 
moiety of NAD+ and bind to the donor site within the 
catalytic domain [120-122]. Although the physiological 
functions of PARPs and poly(ADP-ribosyl)ation is still 
under debate, numerous experimental studies during the 
last years have clearly demonstrated the beneficial 
effects of PARP inhibition from cell culture systems to 
pre-clinical animal models of acute and chronic 
inflammation [36, 119]. For instance, Vaziri and 
colleagues observed an extension of cellular life span 
when PARP activity was inhibited [123]. In animal 
studies, PARP inhibition and/or PARP1 deficiency is 
effective in different age-related diseases [119]. The 
PARP inhibitor 5-AIQ has been demonstrated to 
attenuate the expression of P-selectin and intracellular 
adhesion molecule-1 (ICAM-1) as well as the 
recruitment of neutrophils and leukocytes into the 
injured lung [124, 125]. Thus, application of inhibitors 
reduces the degree of acute inflammation and tissue 
damage associated with experimental lung injury. As 
ROS released from the recruited leukocytes cause an 
upregulation of adhesion molecules, treatment with 
PARP inhibitors contributes to the termination of this 
vicious cycle and inhibits the inflammatory process. 
Similar to the effects of pharmacological inhibitors, 
Parp1 knockout mice were found to be resistant against 
zymosan-induced inflammation and multiple organ 
failure when compared with the response of wild-type 
animals [126]. 
 
In murine models of arthritis, inhibition of PARP with 
nicotinamide delayed the onset of the disease and 
reduced the progress of established collagen-induced 
arthritis [127]. 5-iodo-6-amino-1,2-benzopyrone and 
PJ34, two novel PARP inhibitors, were beneficial in a 
mouse model of collagen-induced arthritis by reducing 
both the incidence of arthritis and the severity of the 
disease [128, 129]. Similarly, GPI 6150 was found to be 
highly effective in a rodent model of adjuvant-induced 
arthritis [130]. 
 
PARP activation also has a pathogenic role in 
hypertension, atherosclerosis and diabetic 
cardiovascular complications [119, 131]. In these 
diseases, the function of the vascular endothelium is 
impaired, resulting in a reduced ability of the 
endothelial cells to produce nitric oxide and other 
cytoprotective mediators. This then sets the stage for 
many manifestations of cardiovascular disease. The 
oxidant-mediated endothelial cell injury is dependent on 
PARP1 and can be attenuated by pharmacological 
inhibitors or genetic PARP1 deficiency [115, 132]. 
Furthermore, PARP inhibition improves aging-
associated cardiac and endothelial dysfunction [133]. 
 
In general, the severity of many inflammatory diseases 
is suppressed by PARP inhibitors and the production of 
multiple pro-inflammatory mediators is downregulated 
[48]. The inhibition of PARP also reduces the formation 
of nitrotyrosine in inflamed tissues, an indicator of 
reactive nitrogen species. This finding was, at first, 
unexpected because PARP activation is perceived to 
occur downstream of the generation of oxidants and free 
radicals in various diseases. The mechanism is probably 
related to the fact that PARP inhibition reduces the 
infiltration of neutrophils into inflammatory sites [126]. 
This in turn reduces oxygen- and nitrogen-centered 
free-radical production. The basis for the regulation of 
neutrophil infiltration by PARP might be related to the 
reduced expression of adhesion molecules [134, 135] 
and/or the preservation of endothelial integrity [115, 
132]. Alternatively, the reduction of nitrotyrosine could 
be explained by the finding that PARP1 is required for 
the expression of iNOS, the main producer of nitric 
oxide in inflamed tissues [116]. In summary, multiple 
studies suggest that a tight regulation of PARP activity 
is required to prevent a variety of age-related 
pathological conditions. 
 
Role of PARP1’s enzymatic activity in NF-!B -
dependent gene expression  
 
There is no consensus in the literature as to whether the 
modulation of NF-!B-mediated transcription by PARP1 
is dependent on poly(ADP-ribosyl)ation or, alterna-
tively, merely on the physical presence of PARP1 [14]. 
Genetic approaches provide strong evidence that 
poly(ADP-ribosyl)ation is not affecting the DNA 
binding activity of NF-!B and is not required for NF-
!B-dependent gene expression [14, 136]. Neither the 
enzymatic activity of PARP1 nor its binding to DNA 
was required for full activation of NF-!B in response to 
various stimuli in vivo when tested on transiently 
transfected reporter plasmids [137, 138]. Consistently, 
the enzymatic activity of PARP1 was not required for 
full transcriptional activation of NF-!B in the presence 
of the histone acetyltransferase p300 [72]. At first 
glance this seems not to be compatible with reports 
describing that PARP inhibitors abolish mRNA 
expression of iNOS, IL-6 and TNF-! in cultured cells 
[139] or that PARP inhibitors reduce the expression of 
inflammatory mediators in mice [124, 126, 140]. 
However, this discrepancy might be explained in three 
ways: First, it should be noted that the currently 
available PARP inhibitors do not discriminate well 
between PARP1 and other PARP family members or 
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even other NAD+-metabolizing enzymes, which are 
described to also play a role in inflammatory response 
pathways [139, 141]. In Parp1 knockout mice, PAR 
formation is indeed drastically reduced only in brain, 
pancreas, liver, small intestine, colon, and testis, 
whereas still moderate levels of residual poly(ADP-
ribose) formation can be observed in the stomach, 
bladder, thymus, heart, lung, kidney and spleen [7]. 
This residual activity can most likely be attributed to 
PARP2, which has the greatest similarity to PARP1 
among all PARP family members [8]. Interestingly, 
PARP2 is involved in T lymphocyte development and 
survival [142] and has been implicated in inflammatory 
immune responses [143, 144]. A putative role of PARP2 
in aging awaits further investigations. Second, based on  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
recent reports, one cannot exclude the possibility that 
PARP-inhibitors might even affect non-NAD+-
consuming targets such as AKT/PKB or MMPs [145]. 
Third, the enzymatic activity of PARP1 might be 
required for the transcriptional activity of transcription 
factors involved in inflammatory processes other than 
NF-!B. Several groups have shown that co-operative 
activities between transcription factors such as AP-1, 
STAT-1 or IRF-1 in the enhanceosomes of NF-!B 
dependent genes are required for full synergistic 
activation of target genes [146, 147]. Considering these  
constraints of all currently available PARP inhibitors, 
the specific contribution of PARP1 enzymatic activity 
for age-related diseases, in which PARP inhibition has 
beneficial effects, needs to be evaluated very carefully.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure!1.!PARP1!at!the!crossroad!of!metabolic!stress!and!inflammation!in!aging.!PARP1!is!activated!by!cellular
stress,!e.g.!by!oxidative!damage!due!to! increased! levels!of!reactive!oxygen!species! (ROS).!As!NAD+"dependent!enzyme,
PARP1! senses! energy! levels! and! crosstalks! with! other! NAD+"consuming! enzymes.! Over"activation! of! PARP1! leads! to
energy!depletion!and!cell!death.!On!the!other!hand,!PARP1!functions!as!cofactor!for!NF"!B"dependent!transcription!and
is! therefore! implicated! in!many! inflammatory!processes.!Both,!PARP1"mediated!metabolic! stress!and!PARP1"regulated
inflammation!can!lead!to!tissue!degeneration!underlying!many!age"related!pathologies.!See!text!for!further!details.!
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CONCLUSIONS 
 
Several publications in the past years indicate that the 
nuclear protein PARP1 represents a molecular link 
between energy metabolism and inflammation (Figure). 
As NAD+-consuming enzyme, PARP1 acts as nutrient 
or energy sensor, crosstalks with other NAD+-
consuming enzymes (such as sirtuins) and modulates 
(as regulator of NF-!B-dependent transcription of 
cytokines) inflammatory responses. Thus, PARP1 
seems to be an ideal candidate to integrate metabolic 
and inflammatory signals, which arise during the 
process of aging. As central integrator, PARP1 may 
mediate cellular stress response pathways and thereby 
participate in a multitude of age-related pathologies. 
PARP inhibition has proven beneficial in many cell 
culture and animal model systems of acute and chronic 
inflammation and age-related diseases. Clearly, addi-
tional research will further improve our understanding 
of the functions of PARP1 and their implications in age-
related diseases associated with metabolic stress and 
inflammation.  
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ABSTRACT
Poly(ADP-ribose) polymerase 1 (PARP1) synthesizes
poly(ADP-ribose) (PAR) using nicotinamide adenine
dinucleotide (NAD) as a substrate. Despite intensive
research on the cellular functions of PARP1, the
molecular mechanism of PAR formation has not
been comprehensively understood. In this study,
we elucidate the molecular mechanisms of
poly(ADP-ribosyl)ation and identify PAR acceptor
sites. Generation of different chimera proteins
revealed that the amino-terminal domains of
PARP1, PARP2 and PARP3 cooperate tightly with
their corresponding catalytic domains. The DNA-
dependent interaction between the amino-terminal
DNA-binding domain and the catalytic domain of
PARP1 increased Vmax and decreased the Km for
NAD. Furthermore, we show that glutamic acid resi-
dues in the auto-modification domain of PARP1
are not required for PAR formation. Instead, we
identify individual lysine residues as acceptor sites
for ADP-ribosylation. Together, our findings provide
novel mechanistic insights into PAR synthesis with
significant relevance for the different biological
functions of PARP family members.
INTRODUCTION
Poly(ADP-ribose) polymerases (PARPs) use nicotinamide
adenine dinucleotide (NAD) as substrate to synthesize
poly(ADP-ribose) (PAR) (1). On the cellular level,
PAR formation has been implicated in a wide range
of processes, such as maintenance of genomic stability,
transcriptional regulation, energy metabolism and cell
death (2).
PARP1 was the first protein described to catalyze
PAR formation in response to mitogenic stimuli or geno-
toxic stress (3–7). It contains three functionally distinct
domains: an amino-terminal DNA-binding domain
(DBD), an auto-modification domain (AD) and a car-
boxyl-terminal PARP homology domain that includes
the catalytic domain (CAT) responsible for PAR forma-
tion (8). The DBD extends from the initiator methionine
to threonine 373 in human PARP1. It contains two struc-
turally and functionally unique zinc fingers (FI: aa, amino
acid, 11–89; FII: aa 115–199) (2,9). Recently, a third
and so far unrecognized zinc-binding motif was discovered
(FIII: aa 233–373) (10,11). The DBD also contains
a bipartite nuclear localization signal (NLS) of the form
KRK-X(11)-KKKSKK (aa 207–226) that targets PARP1
to the nucleus (12). The PARP1 zinc fingers FI and FII are
thought to recognize altered structures in DNA rather
than particular sequences and have also been reported to
be involved in protein–protein interactions (13). PARP1
strongly associates with DNA single and double strand
breaks generated either directly by DNA damage or indi-
rectly by the enzymatic excision of damaged bases during
DNA repair processes (2,9). Several studies indicate that
the first zinc finger is required for PARP1 activation by
both DNA single and double strand breaks, whereas the
second zinc finger may exclusively act as a DNA single
strand break sensor (2,9).
The AD of PARP1 is located in the central region of
the enzyme, between residues 373 and 525 of human
PARP1 (14,15). It was identified as the domain containing
acceptor amino acids for the covalent attachment of PAR
(16). In addition, several recent studies identified a weak
leucine-zipper motif in the amino-terminal region of the
AD, which suggests that this motif might be involved in
homo- and/or hetero-dimerization (9). The AD of PARP1
also comprises a breast cancer 1 protein (BRCA1)
C-terminus (BRCT) domain (from aa 386 to 464 in
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human PARP1) as well as an unstructured loop that
connects the AD with the PARP homology domain.
PARP1 contains an 80–90 amino acid long trypto-
phane-, glycine-, arginine-rich (WGR) domain carboxyl
terminal of the AD. The WGR domain is named after
the most conserved central motif of tryptophane (W),
glycine (G), arginine (R) residues and may represent a
nucleic-acid-binding domain (2). This region of PARP1
has not been extensively characterized and its function is
still unknown. The CAT has been suggested to catalyze at
least three different enzymatic reactions: the attachment of
the first ADP-ribose moiety onto an acceptor amino acid
(initiation reaction), the addition of further ADP-ribose
units onto already existing ones (elongation reaction)
and the generation of branching points (branching reac-
tion) (8). The active site is formed by a phylogenetically
well-conserved sequence of !50 residues (aa 859–908
of hPARP1). This ‘PARP signature’ contains the NAD
acceptor sites and critical residues involved in the initia-
tion, elongation and branching of PAR.
Like PARP1, both PARP2 and PARP3 also contain a
WGR as well as a CAT (16). PARP2 and PARP3 lack,
however, most motifs present in the amino-terminal
half of PARP1. Neither zinc-binding motifs nor leucine-
zippers or BRCT domains have been described for PARP2
or PARP3. PARP2 contains an amino-terminal SAP/SAF
motif/module [named after scaffold-associated protein/
scaffold-associated factor SAF-A/B, Acinus and PIAS;
(17)] and a eukaryotic module proposed to be involved
in sequence- or structure-specific DNA and RNA binding
(18). Furthermore, PARP2 contains an amino-terminal
NLS which targets the protein to the nucleus. PARP3 is
the least studied and smallest PARP identified so far (19).
The protein domain structure of PARP3 is very similar to
that of PARP2, featuring a small putative DBD consisting
of only 54 residues and apparently containing a targeting
motif that is sufficient to localize the enzyme to the cen-
trosome (19,20).
Attempts to obtain structural information on the
full-length proteins PARP1, PARP2 and PARP3 by
X-ray crystallography or by nuclear magnetic resonance
(NMR) have not been successful up to now. The 3D struc-
tures of single domains, however, have been solved and
allow for a structure-based comparison of different PARP
family members (8,21) (PDB: 1A26, 1GS0 and 2PA9).
Although the amino acid identity between PARP1 and
PARP2 or PARP3 is only moderate (40% and 32% in
the CAT, respectively), the overall structure of the CATs
of these three proteins is nearly identical. This conserva-
tion suggests, in general, similar capabilities to generate
PAR. Both PARP1 and PARP2 have been shown to syn-
thesize very complex branched polymers at least in vitro
(2). The enzymatic activity of PARP3 and its isoforms has
not yet been investigated in detail.
An unresolved issue regarding the mechanism of
poly(ADP-ribosyl)ation is how DNA binding in the
amino-terminal DBD triggers enzyme activation in the
carboxyl-terminal CAT and how the different domains
of the different PARPs are coordinated during this pro-
cess. Furthermore, earlier studies suggested that the auto-
modification activity targets between 4 and 28 acceptor
residues located in the AD and in the DBD of PARP1
(14,22,23). For histone H1, a major target for trans-
poly(ADP-ribosyl)ation by PARP1, glutamic acid residues
have been described to function as acceptors for PAR
(24). This, together with the reported chemical similarity
between the ADP-ribose-PARP1 linkage and carboxyl
esters in mono-ADP-riboslyated histones (23), led to
the hypothesis that multiple glutamic acid residues present
in the AD of PARP1 might function as acceptor sites
for auto-poly(ADP-ribosyl)ation (16). However, despite
intensive research during the last 40 years, the acceptor
amino acids in PARP1 have not been confirmed by muta-
tional studies.
Here, we comprehensively analyze PAR formation by
PARP1, PARP2 and PARP3 and find a close cooperativ-
ity between the amino-terminal portions of the proteins
and their corresponding CATs. We define the DBD
(aa 1–373) and the WGR/CAT domain (aa 533–1014)
as the minimal domains of PARP1 required for PAR
formation. The DNA-dependent interaction between the
DBD and the CAT increased Vmax and decreased the Km
for NAD. Furthermore, by amino-acid substitutions,
we establish that glutamic acid residues within the AD
are not required for PAR formation and thus do not func-
tion as acceptor amino acids for PAR. Instead, we identify
lysine residues within the AD of PARP1 as acceptor sites
for ADP-ribosylation.
MATERIALS AND METHODS
Chemicals and antibodies
3H-NAD and protein A sepharose were purchased from
GE Healthcare and 32P-NAD was from PerkinElmer.
NAD was obtained from Sigma-Aldrich. Anti-PAR anti-
body LP96-10 was from Alexis Biochemicals or Becton
Dickinson, anti-PARP1cat antibody H250 from Santa
Cruz Biotechnology and anti-haemagglutinin (HA) anti-
body 16B12 from Covance.
Plasmids
The baculovirus expression vectors pQE-TriSystem
(Qiagen) and BacPak8 (Clontech) were used for the
expression of recombinant proteins in Sf21 insect cells as
described previously (25,26).
Cloning, expression and purification of recombinant
proteins
Wild-type hPARP1 (NCBI ID: BC037545), hPARP2
(NCBI ID: NM_001042618) and hPARP3 (NCBI ID:
BC014260) were cloned and expressed as carboxyl-
terminal His-tagged proteins. PARP family chimera were
generated by overlapping polymerase chain reaction
(PCR) at the position corresponding to amino acid 533
in hPARP1 and expressed as carboxyl-terminal His-
tagged proteins. Protein fragments and deletion mutants
were generated by PCR and expressed as carboxyl-
terminal His-tagged proteins as described before (25,26).
Amino-acid substitutions were introduced by site-
directed PCR-based mutagenesis and mutant proteins
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were expressed as described before (25,26). All recom-
binant proteins were purified by one step affinity chro-
matography using ProBond resin according to the
manufacturer’s recommendations (Invitrogen). Expres-
sion and purification of all recombinant proteins was
analyzed by SDS–PAGE followed by coomassie staining.
For the stacking gel a 4.5% acrylamide-bis solution
[37.5:1, 40% (w/v), Serva] and for the separating gel a
10–12.5% acrylamide-bis solution was used.
PAR formation assays
3H-NAD time course experiments. One hundred pico-
moles recombinant purified enzyme and 5 mg of protein
fragments in PAR reaction buffer (50mM Tris–HCl
pH 8.0, 4mM MgCl2, 250 mM DTT, 1 mg/ml pepstatin,
1 mg/ml bestatin, 1mg/ml leupeptin) in the presence of
50 pmol annealed double-stranded oligomer (50-GGAAT
TCC-30) were supplemented with 3H-NAD to a final con-
centration of 400 mM. PAR formation was allowed for 1,
3, 5, 15 and 60min at 308C. Reactions were stopped by
addition of ice-cold 10% TCA/2% Na4P2O7. Polymers
were precipitated for 10min on ice and then applied
onto filter papers. Counts per minute were obtained by
liquid scintillation counting. For the determination of
Vmax and Km, initial reaction velocities (V0) were obtained
by measuring PAR levels generated after 0, 1, 3 and 5min
incubation at different 3H-NAD concentrations and using
the GraphPad Prism software for nonlinear regression
analysis assuming a one-site binding model. Vmax and
Km were calculated from V0 according to Michaelis–
Menten.
Anti-PAR western blot. Unless otherwise stated, 10 pmol
recombinant purified enzyme and 0.5mg of protein frag-
ments in PAR reaction buffer in the presence of 5 pmol
annealed double-stranded oligomer (50-GGAATTCC-30)
were supplemented with NAD to a final concentration
of 400 mM. PAR formation was allowed for 5min at
308C. Reactions were stopped by addition of SDS–
PAGE loading buffer and boiling for 5min at 958C.
Samples were subjected to SDS–PAGE followed by anti-
PAR western blot.
32P-NAD auto-modification. Unless otherwise stated,
10 pmol recombinant purified enzyme and 0.5mg of pro-
tein fragments in PAR reaction buffer in the presence of
5 pmol annealed double-stranded oligomer (50-GGAATT
CC-30) were supplemented with 32P-NAD to a final con-
centration of 100 nM. Auto-modification was allowed for
10 s at 308C. Reactions were stopped by addition of SDS–
PAGE loading buffer and boiling for 5min at 958C.
Samples were subjected to SDS–PAGE followed by detec-
tion of auto-modification by autoradiography.
PAR detection by silver staining. Following synthesis
of PAR as for western blot analysis, PAR chains were
purified and separated by modified DNA sequencing gel
electrophoresis as described by Fahrer et al. (27).
In vitro co-immunoprecipitation. Ten picomoles recombi-
nant purified enzyme and 0.5 mg of protein fragments were
incubated for 5min at 308C in Co-IP buffer (50mM Tris–
HCl pH 8.0, 100mM NaCl, 4mM MgCl2, 0.2% NP-40,
250 mM DTT, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin) in the absence or presence of 5 pmol annealed
double-stranded oligomer (50-GGAATTCC-30). The CAT
of PARP1 was allowed to bind to the anti-PARP1cat anti-
body for 1 h at 48C. Protein A sepharose was added and
samples were incubated for another 2 h at 48C. Samples
were washed three times for 5min in Co-IP buffer contain-
ing 300mM NaCl before being subjected to SDS–PAGE
followed by western blot.
RESULTS
Purified full-length human PARP1 and PARP2 are
enzymatically active
In order to gain detailed insights into the mechanism of
PAR formation by different PARP family members, we
expressed and purified full-length human PARP1, PARP2
and PARP3 using the baculovirus expression system
(Figure 1A and B). PARP3 showed a slower migration
velocity than predicted in SDS–PAGE, possibly due to
the high content of hydrophobic amino acids in the
CAT. To measure PAR formation, the purified proteins
were incubated for different time periods with 400 mM
tritium-labeled NAD in the presence of double strand
break mimicking DNA. Reaction products were precipi-
tated by trichloroacetic acid (TCA) before they were ana-
lyzed using a beta counter. PARP1 generated PAR in a
time-dependent manner (Figure 1C, left panel). PARP2
also synthesized PAR in a time-dependent manner, how-
ever, not as efficiently as PARP1 (Figure 1C, middle
panel). The reduced amount of product formed by
PARP2 most probably represents a quantitative rather
than a qualitative difference, since the length distribution
of PAR chains formed by PARP2 was comparable to
the length distribution of PAR formed by PARP1
(Supplementary Figure 4B). Human PARP3 did not pro-
duce detectable amounts of PAR under the tested condi-
tions (Figure 1C, right panel).
Assuming that mono(ADP-ribosyl)ation preceeds PAR
formation, we assessed the auto-modification of the three
proteins after 10 s incubation with 100 nM radiolabeled
NAD (Figure 1D). The short incubation period and
the low concentration of NAD were chosen to pre-
vent polymer formation. The discrete bands observed
using this approach indeed suggest that under these con-
ditions mostly mono(ADP-ribosyl)ation occurred. In
line with the time-course experiments, PARP1 and
PARP2 were able to auto-modify themselves in an
NAD- and DNA-dependent manner while PARP3 was
not (Figure 1D).
PARP1 synthesized increasing PAR levels in a time-
and DNA-dependent manner detected also by western
blot and vacuum slot blot using 400 mM NAD
(Supplementary Figure 1A and B). PAR formation
after 5min incubation with 400 mM NAD caused a pro-
nounced shift of the coomassie blue-stained proteins in
the denaturing gel due to a severely reduced migration
velocity of the poly(ADP-ribosyl)ated proteins when
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compared to unmodified proteins (Supplementary
Figure 1C). The observed basal activity of PARP1 in
the absence of DNA can be explained either by a con-
tamination with DNA or by the intrinsic DNA-inde-
pendent activity of the CAT as described by Simonin
et al. (28). Analysis of PAR formation by silver stain-
ing after modified DNA sequencing gel electrophoresis
confirmed PAR formation by PARP1 and PARP2
and no PAR formation by PARP3 (Supplementary
Figure 4B).
Figure 1. Purified full-length human PARP1 and PARP2 are enzymatically active. (A) Domain organization of human PARP1, PARP2 and PARP3.
Letters A–F indicate domain nomenclature of PARP1 and numbers indicate amino acid positions. (B) Purity of PARP family members after one step
affinity chromatography. One microgram of each recombinant, purified protein was used for SDS–PAGE followed by coomassie staining. (C) Time
course of PAR formation by different PARP family members. 3H-NAD incorporation into TCA-precipitable polymers was determined by scintil-
lation counts. Substrate concentration: 400mM 3H-NAD. Reactions were performed in triplicates, error bars represent standard deviations. (D) Auto-
modification of different PARP family members detected by autoradiography. Substrate concentration: 100 nM 32P-NAD. Molecular size markers in
kilo Daltons are indicated.
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The carboxyl-terminal domains of PARP1, PARP2 and
PARP3 cannot compensate for each other
Next, we investigated the crosstalk between the different
amino-terminal domains of PARP1, PARP2 and PARP3
with their carboxyl-terminal domains (i.e. WGR/CAT).
Therefore, we generated chimera proteins by replacing
the WGR/CAT domain of PARP1 with the WGR/CAT
domain of PARP2 or PARP3 [named chimera PARP1-2
(aa 1–532 of PARP1 fused to aa 81–570 of PARP2) or
chimera PARP1-3 (aa 1–532 of PARP1 fused to aa 48–533
of PARP3)], respectively (Figure 2A and B). We analyzed
PAR formation by these proteins and found that replacing
the WGR/CAT domain of PARP1 by the one of PARP2
(i.e. chimera PARP1-2) resulted in an active enzyme that
showed roughly similar PAR formation in time course
experiments as PARP2 (Figure 2C, middle panel).
Replacement of the WGR/CAT domain of PARP1 by
that of PARP3 (i.e. chimera PARP1-3) resulted in an
enzyme that did not produce detectable amounts of
PAR under the tested conditions (Figure 2C, right panel
and Supplementary Figure 1D). In line with these findings,
chimera PARP1-2 was able to auto-modify itself whereas
chimera PARP1-3 was not (Figure 2D). Together
these results suggest that the WGR/CAT domains of the
investigated PARP proteins cannot compensate for each
other. The WGR/CAT domains cooperate tightly with
their corresponding amino-terminal domains and limit
poly(ADP-ribosyl)ation capacity and the ability for
auto-modification, despite high levels of structural similar-
ity between the CATs (see Supplementary Figure 2A).
The carboxyl-terminal domain of PARP1 is not activated
by the amino-terminal domains of PARP2 or PARP3
In a second set of chimera proteins we fused the WGR/
CAT domain of PARP1 to the amino-terminal domains of
PARP2 or PARP3, or deleted the amino-terminal domain
Figure 2. The carboxyl-terminal domains of PARP1, PARP2 and PARP3 cannot compensate for each other. (A) Domain organization of chimera
PARP1-2 and chimera PARP1-3. (B) Purity of chimera PARP1-2 and chimera PARP1-3 after one-step affinity chromatography. One microgram of
each recombinant, purified protein was used for SDS–PAGE followed by coomassie staining. (C) Time course of PAR formation by PARP1, chimera
PARP1-2 and chimera PARP1-3 as in Figure 1C. (D) Auto-modification of PARP1, chimera PARP1-2 and chimera PARP1-3 detected by auto-
radiography as in Figure 1D. Molecular size markers in kilo Daltons are indicated.
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of PARP1 [named chimera PARP2-1 (aa 1–80 of PARP2
fused to aa 533–1014 of PARP1), chimera PARP3-1
(aa 1–47 of PARP3 fused to aa 533–1014 of PARP1)
or PARPs-1 (aa 533–1014 of PARP1)], respectively
(Figure 3A and B). Analysis of these proteins revealed
that chimera PARP2-1, chimera PARP3-1 and PARPs-1
did not generate detectable levels of PAR (Figure 3C
and Supplementary Figure 1E). Furthermore, no auto-
modification of the three proteins was observed under
the tested conditions (Figure 3D). These results indicate
that the WGR/CAT domain of PARP1 is only stimulated
by its corresponding amino-terminal domain, but not by
the amino-terminal domains of PARP2 or PARP3.
The DBD of PARP1 is sufficient to stimulate its
WGR/CAT domain
To further investigate the cooperativity between the
amino-terminal domain of PARP1 and its WGR/CAT
Figure 3. The carboxyl-terminal domain of PARP1 is not activated by the amino-terminal domains of PARP2 or PARP3. (A) Domain organization
of chimera PARP2-1, chimera PARP3-1 and PARPs-1. (B) Purity of chimera PARP2-1, chimera PARP3-1 and PARPs-1 after one-step affinity
chromatography. One microgram of each recombinant, purified protein was used for SDS–PAGE followed by coomassie staining. (C) Time course of
PAR formation by chimera PARP2-1, chimera PARP3-1 and PARPs-1 as in Figure 1C. (D) Auto-modification of PARP1 (ctr.), chimera PARP2-1,
chimera PARP3-1 and PARPs-1 detected by autoradiography as in Figure 1D. Molecular size markers in kilo Daltons are indicated.
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domain, the inactive chimera PARP2-1 was co-incubated
with the PARP1 E988K mutant, which lacks the ability
to generate PAR. Surprisingly, co-incubation of chimera
PARP2-1 with PARP1 E988K strongly induced PAR
synthesis, suggesting that PARP1 E988K was able to stim-
ulate the WGR/CAT domain of chimera PARP2-1
(Figure 4A). To map the minimal domain of PARP1,
which was able to stimulate the WGR/CAT domain of
chimera PARP2-1, we expressed and purified different
fragments of PARP1 covering all domains from A to F
(see Figure 1A). Analysis of PAR synthesis by western
blot upon co-incubation of chimera PARP2-1 with these
fragments revealed that the DBD of PARP1 comprising
amino acid 1–373 was the only fragment able to stimulate
chimera PARP2-1 (Figure 4B). Further dissection of the
DBD revealed that only the complete and undisrupted
DBD from amino acid 1 to 373 containing FI, FII and
FIII was able to stimulate chimera PARP2-1 (Figure 4C).
The stimulation of chimera PARP2-1 by the DBD was
salt resistant up to 300mM NaCl (Supplementary
Figure 3B, left panel).
To further assess the specificity of the observed stimula-
tion, the DBD was incubated with different proteins (chi-
mera PARP2-1, chimera PARP3-1, PARPs-1 and PARP1
656–1014) and the time course of PAR formation
was analyzed using tritium-labeled NAD. Of note, besides
chimera PARP2-1, only chimera PARP3-1 and PARPs-1,
but neither the CAT of PARP1 nor full-length PARP2,
PARP3, chimera PARP1-2 or chimera PARP1-3, were
stimulated by the DBD of PARP1 (Figure 4D and
Supplementary Figure 4A and C). Analysis of PAR for-
mation by silver staining after polymer separation using
modified DNA sequencing gel electrophoresis confirmed
that the observed stimulation in the time course experi-
ments correlated with the synthesis of PAR containing 1
to more than at least 50 ADP-ribose units (Supplementary
Figure 4B).
The stimulation of chimera PARP2-1 by the DBD was
strongly dependent on DNA (Figure 4E, left panel), which
suggests that DNA tightly regulates the interaction neces-
sary for the activation of the CAT. Furthermore, our
observation that PARPs-1 but not PARP1 656–1014
together with the DBD was able to generate PAR indi-
cates that the WGR domain of PARP1 is absolutely essen-
tial for enzymatic activity.
Since chimera PARP2-1 does not exist physiologically,
PAR synthesis by a PARP1 DBD deletion mutant
(aa 373–1014) co-incubated with the DBD was analyzed.
Interestingly, the DBD was able to stimulate PARP1
373–1014 in a DNA-dependent manner and comparable
to PARP2-1 (Figure 4E, right panel and Supplementary
Figure 3B, right panel), suggesting that the observed stim-
ulation of PARP2-1 by the DBD represents a physiolog-
ical regulatory mechanism in the PARP1 full-length
context.
The DBD of PARP1 interacts with its CAT domain
The results described above suggest that the DBD of
PARP1 interacts with the CAT and/or the WGR
domain to stimulate PAR synthesis by the CAT. To test
this hypothesis experimentally, in vitro co-immunoprecipi-
tation assays were performed with purified proteins
and fragments. The complete DBD (aa 1–373), but not
aa 1–214 alone, specifically bound to chimera PARP2-1
in a manner that was stabilized by DNA (Figure 4F).
Similarly, the DBD also bound to PARP1 373–1014,
and this interaction was enhanced by DNA (Figure 4G,
left panel). Interestingly, the CAT domain of PARP1
without the WGR (aa 656–1014) was sufficient for the
DNA-dependent interaction with the DBD (Figure 4G,
right panel). Since PAR formation was only observed
when combining the DBD with PARPs-1 (expressing
WGR/CAT) but not with the CAT domain of PARP1
alone (Figure 4D and Supplementary Figure 4A), we con-
clude that an intact DBD (aa 1–373) interacts with the
CAT in a DNA-dependent manner and that the WGR
domain is additionally required to allow PAR formation.
The DBD bound to DNA activates the CAT by increasing
Vmax and decreasing Km
Next, we determined the enzymatic parameters of chimera
PARP2-1 stimulated by the PARP1 DBD in the absence
or presence of DNA. We measured the incorporation of
tritium-labeled NAD into TCA-precipitable polymers at
early reaction time points and obtained initial reaction
velocities (V0) for different substrate concentrations by
nonlinear regression analysis assuming one substrate-
binding site. In the absence of the DBD, chimera
PARP2-1 did not generate detectable levels of PAR inde-
pendent of the addition of DNA (Table 1, second and
third column), thus confirming our previous results. In
the presence of the DBD, PAR generation was strongly
dependent on DNA. Without DNA, the obtained PAR
levels were low, but still allowed for curve fitting and cal-
culation of Vmax and Km values (Table 1, fourth column).
Addition of DNA increased the maximum reaction veloc-
ity Vmax about 4-fold and reduced Km 8-fold (Table 1,
compare fifth to fourth column). The reaction efficiency
Kcat/Km was thereby increased by more than 30-fold.
DNA could thus be considered a V+K-type activator,
affecting both turnover rate and substrate affinity.
Remarkably, the enzymatic parameters obtained for chi-
mera PARP2-1 together with the PARP1 DBD closely
match the values reported for full-length PARP1
(Table 1, compare fifth to first column). Together, these
results provide evidence that DNA containing double
strand breaks is recognized and bound by the DBD of
PARP1, which subsequently binds to the CAT domain
to induce structural changes within the catalytic cleft
in order to increase the affinity for NAD and stabilize
reaction intermediates.
PARP1 forms a catalytic dimer which requires at least
one functional FI and FIII domain for activity
The CAT of PARP1 was previously described to dimerize
(29). To investigate whether our purified proteins were also
able to form dimers, the enzymatic activity of full-length
PARP1 was assessed by western blot analysis after
co-incubation with different molar ratios of two catalyti-
cally inactive PARP1 mutants (E988K or M890V/D899N,
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Figure 4. The DBD of PARP1 interacts with and is sufficient to stimulate its WGR/CAT domain. (A) PAR formation by chimera PARP2-1
co-incubated with catalytically inactive PARP1 E988K. PAR was detected by western blot using anti-PAR antibody LP96-10. Substrate concentra-
tion: 400mM NAD. (B) PAR formation by chimera PARP2-1 co-incubated with the indicated fragments of PARP1 or with PARP1 E988K. (C) PAR
formation of chimera PARP2-1 co-incubated with the indicated fragments or combination of fragments of PARP1. (D) Time course of PAR
formation by chimera PARP2-1, chimera PARP3-1, PARPs-1 and PARP1 656–1014 in the absence or presence of fragment 1–373 as in
Figure 1C. Black without fragment 1–373 and grey with fragment 1–373. (E) PAR formation of chimera PARP2-1 or PARP1 373–1014 co-incubated
with fragment 1–373 in the absence or presence of DNA. (F) In vitro interaction between chimera PARP2-1 and 1–373. Chimera PARP2-1 was
bound to protein A sepharose using an antibody against the CAT of PARP1 (a-PARP1cat) and was then incubated with HA-tagged fragment 1–373
or 1–214 in the absence or presence of DNA. HA-tagged fragments were detected by western blot. PARP1cat antibody coupled to beads without
chimera PARP2-1 served as control (ctr.). (G) In vitro interaction between PARP1 373–1014 or 656–1014 with 1–373. Experiments were performed as
described in (F). Molecular size markers in kilo Daltons and the border between stacking and separating gel (asterisk) are indicated.
8 Nucleic Acids Research, 2009
48
respectively) (Supplementary Figure 3A). A molar ratio
of 1:5 (wt:mutant) severely reduced PAR formation
(Figure 5B), suggesting that the different proteins are
indeed able to form dimers and to regulate each other.
We showed earlier that only the full-length DBD was
able to stimulate chimera PARP2-1 (Figure 4). This finding
suggests that disruption of the DBD of PARP1 by deleting
one of the DBD sub-domains would render the protein
inactive due to lost activation of the CAT. Deletion
of the regions containing zinc finger FI (!FI, aa 1–111)
or zinc-binding domain FIII (!FIII, aa 279–333) indeed
rendered PARP1 inactive, while a mutant lacking FII
(!FII, aa 117–201) was still able to synthesize PAR as
examined by western blot analysis (Figure 5A and C).
Thus, the presence of FI and FIII is required for enzy-
matic activity, while neither FII nor the spacing between
FI and FIII seem to be critical for PAR formation.
Surprisingly, co-incubation of the two inactive mutants
!FI and !FIII fully restored activity, suggesting
that the two proteins can interact and that the lack of the
critical domains containing FI and FIII could be inter-
molecularly complemented to form a functional active
dimer (Figure 5D). In line with this finding, the
mutants !FI and !FIII could also be complemented by
co-incubation with the catalytically inactive PARP1
mutants E988K and M890V/D899N or with the DBD
alone (Figure 5E).
The WGR domain is vital for enzymatic activity
We showed that the WGR domain is required for enzy-
matic activity of PARP1 (Figure 4). A PARP1 deletion
mutant lacking the WGR domain (!WGR, aa 525–656)
was indeed not able to generate PAR (Figure 5F).
Similarly, a PARP2 deletion mutant lacking the WGR
domain was also inactive (data not shown), suggesting
that the so far uncharacterized WGR domain of PARP
family members is absolutely required for the enzymatic
activity. Importantly, the PARP1 !WGR mutant could
functionally complement the two PARP1 mutants
!FI and !FIII by providing its DBD (Figure 5G).
Co-incubation of the PARP1 !WGR mutant with the
catalytically inactive PARP1 mutants E988K and
M890V/D899N, both possessing a functional WGR, how-
ever, did not restore enzymatic activity (Figure 5G). Thus,
the PARP1 DBD and the CAT can be regarded as inde-
pendent and flexible protein units in a catalytic dimer,
whereas the WGR domain is functionally tightly asso-
ciated with and required for the activation of the CAT.
Glutamic acid residues in the AD of PARP1
are not modified
It is widely believed that multiple glutamic acid residues
within the AD of PARP1 serve as acceptor sites for the
covalent attachment of PAR (16). To our knowledge,
however, this assumption has so far not been confirmed
by amino acid substitutions. Therefore, we decided to test
whether glutamic acid residues within the AD of PARP1
are required for the catalytic activity of the enzyme and
function as acceptors for PAR. First, we deleted the
BRCT domain as part of the AD (Figure 6A). A
PARP1 !BRCT mutant was as active as its wild-type
counterpart with regard to auto-modification (Figure 6B,
first four lanes) and PAR formation (Supplementary
Figure 5A, left panel). Next, in the context of the
PARP1 !BRCT mutant, we additionally mutated all
eight glutamic acid residues in the remaining auto-
modification loop between amino acids 484 and 557 to
glutamine (!BRCT/E) (Figure 6A). Surprisingly, these
substitutions also did not reduce auto-modification
(Figure 6B, last two lanes) or PAR formation
(Supplementary Figure 5A, right panel). These results
strongly indicate that glutamic acid residues within the
AD of PARP1 are not required for enzymatic activity
and are unlikely to serve as acceptors for PAR.
Lysine residues are acceptor sites in PARP1
In contrast to the deletion of the BRCT domain, deletion
of the remaining amino acids in the AD of PARP1 (!Ac,
aa 466–525) (Figure 6A), a region previously reported
to be acetylated (26), resulted in severely impaired auto-
modification (Figure 6C) and reduced PAR formation
(Supplementary Figure 5B), suggesting that acceptor
sites are localized in this region of PARP1. As PAR
levels generated by PARP1 !Ac were decreased but did
not drop completely, additional PAR acceptor sites are
likely to exist in other domains of PARP1. Trans-
poly(ADP-ribosyl)ation of different fragments of PARP1
by wild-type PARP1 indeed confirmed that not only the
AD but also a fragment containing amino acid 1–214 is
modified (Supplementary Figure 5C).
ADP-ribose has earlier been described to be a potent
histone glycation and glycoxidation agent in vitro, leading
to the formation of ketoamine glycation conjugates (30).
Table 1. Kinetic parameters of chimera PARP2-1
hPARP1a hPARP2-1
"1–373
"DNA
hPARP2-1
"1–373
+DNA
hPARP2-1
+1–373
+DNA
hPARP2-1
+1–373
+DNA
Vmax (mmol#min"1#mg"1) 0.2–2.4 NC NC 0.114$ 0.010 0.488$ 0.026
Km (mM) 59–278 NC NC 1111$ 127.7 140.8$ 19.72
Kcat (s
"1) 0.41 NC NC 0.121$ 0.011 0.521$ 0.028
Kcat/Km (s
"1#mM"1) 1.475–6.949 NC NC 0.109$ 0.022 3.696$ 0.715
NC: not calculable (product levels below detection limit).
aValues as reported in the literature.
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Figure 5. PARP1 forms a catalytic dimer which requires at least one functional FI and FIII domain for activity. (A) Domain organization of the
PARP1 deletion mutants used for this figure. (B) PAR formation by PARP1 when co-incubated with the indicated inactive proteins or fragments at a
molar ratio of 1:1 or 1:5. According to the manufacturer, the anti-PAR antibody LP96-10 cross reacts with bovine serum albumin (BSA) (band at
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When we analyzed the chemical linkage stability of auto-
modified PARP1, we found that it was stable up to pH
10 (but not at pH 13.5) and that incubation with 1M
hydroxylamine at pH 7 for 30min at 308C or 608C did
not release the modification (Supplementary Figure 5D).
This observation suggests that the protein-ADP-ribose
linkage indeed might occur on lysines. To exclude that
the investigated auto-modification of PARP1 was due
to traces of ADP-ribose within the provided NAD, the
inactive PARP1 mutant M890V/D899N was incubated
with radioactive NAD. Only upon long exposure a faint
labeling of PARP1 M890V/D899N was observed while
PARP1 E988K was able, as described earlier, to modify
itself (Supplementary Figure 5E), confirming that the
observed auto-modification of PARP1 was due to its enzy-
matic activity.
Next, we analyzed the trans-poly(ADP-ribosyl)ation of
a fragment comprising the AD (aa 373–525) of PARP1
by full-length PARP1. Although auto-modification of
PARP1 was much more efficient than trans-poly(ADP-
ribosyl)ation, specific labeling of the AD fragment was
observed (Figure 6D, second lane). In order to identify
individual lysine residues within the AD which serve as
acceptor sites for PAR, we analyzed trans-poly(ADP-ribo-
syl)ation of the AD fragment containing three lysine to
arginine substitutions (K498, K521 and K524, called
KTR). These sites were previously reported to be targets
for acetylation (26). Modification of the 373–525 KTR
fragment by full-length PARP1 was reduced as compared
to 373–525wt (Figure 6D, third lane). Since trans-
poly(ADP-ribosyl)ation of a protein fragment might
lead, due to structural constrains, to unspecific modifica-
tion of amino acids and might thus not be comparable
to modification of the full-length protein, we generated a
full-length PARP1 mutant which contains the three lysine
to arginine substitutions at position 498, 521 and 524.
around 64 kDa). (C) PAR formation by DBD deletion mutants !FI, !FII and !FIII. (D) PAR formation by a combination of the two DBD
deletion mutants !FI and !FIII. (E) PAR formation by the DBD deletion mutants !FI and !FIII when they were co-incubated with catalytically
inactive PARP1 mutants or with fragment 1–373. (F) PAR formation by PARP1 lacking the WGR domain. (G) PAR formation by PARP1 !WGR
in combination with DBD deletion mutants, catalytically inactive PARP1 mutants or with fragment 1–373. Molecular size markers in kilo Daltons
and the border between stacking and separating gel (asterisk) are indicated.
Figure 6. Lysine residues within the AD of PARP1 are target sites for poly(ADP-ribosyl)ation. (A) Domain organization of the PARP1 mutants used
for this figure. (B) Auto-modification of the indicated PARP1 mutants lacking either the BRCT domain (!BRCT) or the BRCT domain and
carrying substitutions for all glutamic acid residues in the remaining stretch of the AD (!BRCT/E). (C) Auto-modification of a PARP1 deletion
mutant lacking aa 466–525 (!Ac), a region that was previously shown to be acetylated. (D) Trans-poly(ADP-ribosyl)ation of the AD from amino
acid 373–525 by PARP1. KTR, K498/521/524R. (E) Auto-modification of a PARP1 K498/521/524R mutant. Molecular size markers in kilo Daltons
are indicated.
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Importantly, this mutant showed strongly reduced auto-
modification, very much comparable to the levels
observed for the PARP1 !Ac mutant (Figure 6E).
Overall, these experiments provide evidence that not glu-
tamic acid residues but instead at least three lysine resi-
dues within the auto-modification loop (aa 466–525)
and additional residues within the first 214 amino acids
of PARP1 are target sites for enzymatic auto-ADP-
ribosylation.
DISCUSSION
In this study we analyzed the poly(ADP-ribosyl)ation
capacity of PARP1 and the closely related proteins
PARP2 and PARP3 under standardized reaction condi-
tions and investigated the molecular mechanism of PAR
formation. Human PARP1 and PARP2 were able to
auto-modify themselves and generate PAR, although to
different levels. Neither polymer formation nor auto-
modification was observed for PARP3 under the tested
conditions.
PARP1 deletion mutants and fusion proteins had been
successfully employed before to study different aspects of
poly(ADP-ribosyl)ation (31,32). Here, we have generated
PARP family chimera to analyze the molecular mecha-
nism of PAR formation. The PARP chimera revealed
that the WGR/CAT domains of PARP1, PARP2 and
PARP3 tightly cooperate with their corresponding
amino-terminal domains. Closer examination of PARP1
revealed that FI, FIII and the WGR/CAT domain of
PARP1 are required and sufficient for PAR formation.
FII and the BRCT domain, however, were not essential
for the enzymatic activity. The DBD interacted directly
with the CAT domain of PARP1. DBD bound to DNA
increased Vmax and reduced the Km of the CAT for NAD.
We also provide evidence that PARP1 forms a catalytic
dimer in which lack of either FI or FIII could be func-
tionally complemented by a protein containing these
domains. Finally, we identified three lysine residues
within the AD and additionally the first 214 amino acids
of the DBD as target sites for enzymatic covalent auto-
poly(ADP-ribosyl)ation by PARP1.
We employed three different methods to assess
poly(ADP-ribosyl)ation. First, 3H-NAD at a concentra-
tion of 400 mM was used to measure TCA-precipitable
polymer formation in time course experiments. Second,
32P-NAD at a concentration of only 100 nM was used to
measure auto-modification after short incubation periods
(10 s). This approach resulted in distinct bands corre-
sponding to the modified protein and most likely repre-
senting mono(ADP-ribosyl)ation or short oligomers of
ADP-ribose attached to the labeled protein. Third, unla-
beled NAD at a concentration of 400 mM was used to
measure PAR formation detected by western blot. The
anti-PAR antibody typically detected high molecular
weight polymers, most of which remained as a smear at
the top of the separating gel or even in the stacking gel.
This approach was not very suitable to make quantitative
statements but could be readily applied to analyze whether
a protein was active or not.
Human PARP3 was previously described by Augustin
et al. to be an active enzyme, as detected by autoradiogra-
phy after 15min incubation with 10 mM 32P-NAD (19).
Augustin and co-workers did not, however, compare the
activity of PARP3 to that of PARP1 or any other PARP
family member under these conditions. We analyzed
PARP3 in comparison to PARP1 and PARP2 under stan-
dardized reaction conditions and could not observe
any activity for this protein. However, when we applied
the conditions provided by Augustin et al. to measure
PARP3 activity by autoradiography, we could also
observe PARP3 auto-modification (data not shown), sug-
gesting that the protein possesses some degree of activity
under certain well-defined conditions. Further investiga-
tions are needed to analyze the extent of PAR formation
by PARP3 as well as its physiological relevance.
The DBD of PARP1 interacted in a coordinated
and DNA-dependent manner with the CAT domain of
PARP1, but not with that of PARP2 or PARP3. Thus,
despite the high level of structural similarity between the
CATs of PARP1, PARP2 and PARP3, these domains
cannot compensate for each other and may possess unan-
ticipated intrinsic regulatory functions. Since the PARP1
DBD is not or only partially present in other PARP family
members, the newly identified intra-molecular interaction
might provide a promising surface for the development of
PARP1 specific inhibitors.
In our study, several enzymatic dead mutants with
deletions in the DBD could be functionally complemented
by another inactive PARP1 mutant containing the missing
domain, thus implicating that PARP1 is forming a dimer
for poly(ADP-ribosyl)ation. The existence of catalytically
active protein dimers in which each monomer is lacking
a domain required for enzymatic activity was surprising
and suggests that PARP1 is a highly flexible molecule
with rather loose domain architecture.
Consistent with earlier reports (33,34) our results
showed that zinc finger FI is absolutely required for the
DNA-dependent activation of the protein, whereas zinc
finger FII is dispensable. Zinc finger FII may, however,
determine the binding specificity for DNA single strand
breaks as suggested previously by Gradwohl et al. (35).
Our data revealed that the recently discovered zinc-
binding motif FIII is essential for the interaction of
the DBD with the CAT and thus also for the activation
of the enzyme. Furthermore, the so far uncharacterized
WGR domain is an indispensable prerequisite for PAR
formation, although this domain is not necessary for the
interaction between the DBD and the CAT.
The interaction between the DBD bound to DNA and
the CAT domain increased the maximum reaction velocity
Vmax by a factor of four and reduced the Km for NAD
roughly from 1mM to 140 mM (Table 1). The reaction
efficiency Kcat/Km was thereby increased by a factor of
more than 30. The total cellular NAD concentration was
previously estimated to be around 350 mM (36). Zhang
et al. argued that NAD cofactors should readily pass
through nuclear pores, which would suggest that cytoplas-
mic NAD levels reflect nuclear NAD concentrations (37).
The same group estimated the free nuclear NAD concen-
tration to be around 70 mM (38). Despite this uncertainty
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in the estimation of free nuclear NAD concentrations,
we believe that increasing the affinity of PARP1 for
NAD by binding to DNA double strand breaks might
be an important regulatory step to allow PAR formation
at physiological NAD concentrations. Release of PARP1
from DNA would consequently reduce the affinity
of PARP1 for NAD and terminate PAR formation.
Importantly, the nuclear concentration of NAD can be
modulated by NMN adenylyl transferase 1 (NMNAT-1),
which catalyzes the final step of NAD biosynthesis. A
recent study revealed that NMNAT-1 is able to interact
with and stimulate PARP1 (39). It is thus tempting to
speculate that PARP1 activation by its binding to DNA
strand breaks is supported by the localized action of
NMNAT-1.
Our results suggest that activation of PARP1 occurs
in defined sequential steps (Figure 7A). First, the DBD
binds to certain damages within the DNA. This
enhances the interaction between the DBD and the
CAT domain. As a consequence, minor structural rear-
rangements within the catalytic cleft occur, resulting in
an increased affinity for NAD. Increasing substrate
affinity and additionally substrate turnover rates then
allows for high reaction efficiency and very rapid auto-
modification at distinct lysine residues followed by PAR
chain elongation. An analogous model can be envi-
sioned for the protein chimera PARP2-1, which is
activated by the PARP1 DBD in the presence of
double strand breaks mimicking DNA (Supplementary
Figure 6A).
Figure 7. Model for PARP1 activation and ADP-ribosylation of lysine residues. (A) Model for the sequential activation and regulation of PARP1.
The DNA-dependent interaction between the DBD and the WGR/CAT induces a state of high substrate affinity and high turnover rate in PARP1.
Subsequently, acceptor amino acids in the auto-modification loop as well as in the DBD are poly(ADP-ribosyl)ated. (B) Proposed reaction mech-
anism for NADase-dependent auto-ADP-ribosylation of lysine residues by PARP1 via Schiff base formation. (C) Scheme depicting the identified
PAR acceptor lysine residues in PARP1. (D) A revised view of ADP-ribose metabolism. PARP1 catalyzes lysine mono(ADP-ribosyl)ation via
its NADase activity and subsequently PAR chain elongation. PARG cleaves glycosidic ribose–ribose bonds to generate PARP1-Lys-ADP-KA,
which is then substrate for an ADP-ribosyl protein lyase. See discussion for details. NAM, nicotinamide; Lys, lysine; ADP-KA, ADP-ketamine;
ADPR, ADP-ribose; ADP-DP, ADP-300-deoxypentose-200-ulose.
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The assumption that PARP1 is modified at glutamic
acid residues was based mainly on the chemical stability
of the ADP-ribose-PARP1 linkage, which was very heter-
ogeneous but in part of a similar type as carboxyl esters
in mono-ADP-riboslyated histones isolated from cells
(23). The presented mutation analysis studies revealed
that neither deletion of all glutamic acid residues in the
BRCT domain (aa 385–476, containing nine glutamic acid
residues) nor additional mutation of the remaining gluta-
mic acid residues to glutamine in the AD (aa 477–557,
containing eight glutamic acid residues) affected auto-
modification or PAR formation and thus provide strong
evidence that these amino acids in the AD are not the
acceptor sites for poly(ADP-ribosyl)ation. Interestingly,
mutation of the three lysines K498, K521 and K524 in
the AD of PARP1 to arginines strongly reduced the
auto-modification of the enzyme, suggesting that these
residues in fact are acceptors for PAR. A longer exposure
of the gel revealed a weak labeling of PARP1 KTR (data
not shown) and it may well be that additional lysine resi-
dues serve as acceptor sites in this domain. Furthermore,
acceptor sites can also be expected in the DBD of PARP1.
Whether these sites are also lysine residues or whether
outside the AD other amino acids serve as PAR acceptors
is currently not known.
Modification of proteins by ADP-ribose can be charac-
terized according to their chemical properties. ADP-ribo-
sylated lysine residues were described to be stable in the
presence of 1M hydroxylamine at pH 7, while chemically
modified glutamic and aspartic acid residues would rap-
idly release the ADP-ribose moiety (40,41). Our chemical
analysis of modified PARP1 revealed that the observed
linkage most likely corresponds to the glycation linkage
described above. Thus we propose that ADP-ribosylation
of PARP1 is catalyzed by its NADase activity, which sub-
sequently allows modification of lysine residues positioned
close to the catalytic active site to Lys-ADP-ribose
ketamine (Figure 7B, C and D). This moiety could then
serve as acceptor for the elongation reaction, which is
catalyzed by glutamic acid residue E988 in human
PARP1. We are currently investigating whether other
ADP-ribose acceptor proteins are modified by PARP1 in
the same manner.
To date two enzymes, poly(ADP-ribose) glycohaydro-
lase (PARG) and ADP-ribosyl protein Lyase, have been
described to be involved in PAR catabolism (42,43). While
PARG possesses both exo- and endoglycosidic activities,
the Lyase was described to cleave the bond between pro-
teins and mono(ADP-ribose). ADP-ribosylation of lysines
creates a chemical bond, which is not a substrate for
PARG, which cleaves the ribose–ribose bonds. Breaking
a lysine-ADP-ribose linkage would instead require the
activity of a Lyase (Figure 7D). Alternatively, the last
ADP-ribose moieties might remain on PARP1 to serve
as elongation sites for the next round of PAR formation
or to mark the chromatin to memorize the location of
previous DNA damage repair.
Lysine residues K498, K521 and K524 were previously
identified as targets for acetylation by p300 and P300/
CBP-associated factor (PCAF) in a stimulus-dependent
manner (26). Remarkably, simple addition of PCAF
reduced poly(ADP-ribosyl)ation by PARP1 (unpublished
observation), suggesting that the interaction domain of
PARP1 with PCAF is overlapping with the ADP-ribose
acceptor sites. Furthermore, we recently showed that acet-
ylation of PARP-2 strongly reduced the enzymatic activity
(44). Already more than 20 years ago, a possible interre-
lation between poly(ADP-ribosyl)ation reactions and
post-translational protein acetylation had been discussed
(45,46). Our finding that acetylation of lysine residues
interferes with ADP-ribosylation supports this idea and
points at an interesting crosstalk between acetylation of
and ADP-ribosylation by PARP family members. This
crosstalk hypothesis is further strengthened by the finding
that the enzymatic activity of PARP1 is not required for
the function as transcriptional co-activator of NF-kB,
a role which requires acetylation of PARP1 (47).
During apoptosis, PARP-1 is cleaved by different cas-
pases to generate 89-kDa and 24-kDa fragments, a well-
characterized hallmark of apoptosis. The data shown pro-
vide a functional explanation for the observed inactivation
of PARP1 upon caspase cleavage, as this cleavage is sepa-
rating FI and FII (aa 1–214) from FIII (aa 214–373), thus
no longer allowing the DBD to interact as an intact poly-
peptide with the CAT domain for subsequent activation.
Our chemical and mutational analyses provide evidence
that lysine residues are acceptor sites for auto-modifica-
tion by PARP1 in vitro (Figure 6B). As PARP1 is the main
acceptor protein for poly(ADP-ribosyl)ation in vivo
(48,49), our findings are most likely also relevant in vivo.
Confirming acceptor sites in vivo, however, is very difficult
for different reasons. First, mutations within the DBD
to eliminate the acceptor sites in this region and to allow
only the analysis of the three lysine residues in the auto-
modification domain would affect the activation of
PARP1 by DNA. Second, PARP1 is known to be mod-
ified by PARP2 and possibly by other PARP family mem-
bers. Whether theses proteins are modifying PARP1 also
at the auto-modification sites or at other residues is cur-
rently not known. In any case, however, this crosstalk
would interfere with in vivo analysis of PARP1 auto-
modification.
In conclusion, we propose that PARP1 forms a catalytic
dimer that allows the interaction of the DNA-binding
domain with the CAT to modify distinct lysine residues
as ADP-ribose acceptor sites in the AD as well as addi-
tional acceptor sites in the DNA-binding domain. These
insights will allow further investigations to elucidate the
biological functions of PARP1 and its enzymatic activity.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Supplementary Figure Legends 
 
Supplementary Figure 1:  
(A) Time-dependent PAR formation by PARP1 in the absence or presence of DNA 
as revealed by western blot. (B) Time-dependent PAR formation by PARP1 in the absence 
or presence of DNA as revealed by vacuum slot blot. (C) PAR formation by PARP1, 
PARP2 and PARP3. (D) PAR formation by PARP1, chimera PARP1-2 and chimera 
PARP1-3. (E) PAR formation of chimera PARP2-1, chimera PARP3-1 and PARPs-1. 
PARP1 served as control (ctr.). Molecular size markers in kDa and the border between 
stacking and separating gel (asterisk) are indicated. 
 
Supplementary Figure 2:  
(A) Overlay of the crystal structures available for the catalytic domains of chicken 
PARP1 (PDB: 1A26), mouse PARP2 (PDB: 1GS0) and human PARP3 (PDB: 2PA9). PDB 
files were obtained from RCSB PDB (www.rcsb.org/pdb/home/home.do), the alignment 
was performed using the Magic Fit function of the Swiss-PDBViewer with the catalytic 
domain of chicken PARP1 as template. Yellow: PARP1, blue: PARP2, green: PARP3. (B) 
Sequence alignment of the conserved carboxyl-termini of PARP1, PARP2 and PARP3. The 
alignment was performed using Clustal2W (www.ebi.ac.uk/Tools/clustalw2/index.html). 
The conserved residues VDP at position 533 to 535 in hPARP1 used to generate the 
different PARP family chimera are marked.  
 
Supplementary Figure 3:  
(A) PARP1 E988K and PARP1 M890V/D899N are enzymatically inactive as revealed by 
western blot. (B) The stimulation of PARP2-1 by fragment 1-373 is resistant to high salt 
conditions (left panel). The stimulation of PARP2-1 by fragment 1-373 is not due to a PAR 
carrier effect of fragment 1-373 (middle panel). * 1-373 was added after the reaction. The 
stimulation of PARP1 373-1014 by fragment 1-373 is resistant to high salt conditions (right 
panel). Molecular size markers in kDa and the border between stacking and separating gel 
(asterisk) are indicated. 
 
Supplementary Figure 4:  
(A) PAR formation after long incubation of PARP2-1, PARP3-1, PARPs-1 and 
PARP 656-1014 in the absence or presence of DNA and PARP1 fragment 1-373 as 
revealed by western blot (60 minutes incubation, upper panel), coomassie staining (60 
57
 minutes incubation, middle panel) or auto-modifcation as detected by autoradiography (5 
minutes incubation, lower panel). Molecular size markers in kDa and the border between 
stacking and separating gel (asterisk) are indicated. (B) PAR formation after 5 minutes 
incubation by PARP family members and PARP chimera in the absence or presence of 
PARP1 fragment 1-373 as revealed by silver staining. Equal molar amounts of proteins 
were used. (C) Time course of PAR formation by PARP2, PARP3, PARP1-2 and PARP1-3 
in the absence or presence of fragment 1-373. Reactions were performed in triplicates, error 
bars represent standard deviations.  
 
Supplementary Figure 5:  
(A) PAR formation by the PARP1 mutants !BRCT and !BRCT/E. (B) PAR 
formation by the PARP1 mutant !Ac. (C) Trans-poly(ADP-ribosyl)ation of different 
PARP1 fragments by full-length PARP1. 1, aa 1-214; 2, aa 215-373; 3, aa 373-525; 4, aa 
525-656; 5, aa 656-1014. (D) Stability of the PARP1-ADP-ribose linkage under different 
pH conditions. Auto-modified PARP1 was incubated for 30 minutes at 60°C (top) or 30°C 
(bottom) under the indicated conditions and subsequently subjected to SDS-PAGE and 
detection by autoradiography. Tris-HCl pH 8.0 served as control. (E) Auto-modification of 
PARP1 mutants. * PARP inhibitor 3-aminobenzamide (3-AB) was added after the reaction. 
A long exposure was required to detect the shown levels of auto-modification. Molecular 
size markers in kDa and the border between stacking and separating gel (asterisk) are 
indicated.  
 
Supplementary Figure 6:  
 (A) Model for the sequential activation and regulation of chimera PARP2-1 by the 
PARP1 DBD bound to double strand break mimicking DNA. The DNA-dependent 
interaction between the PARP1 DBD and the PARP1 WGR/CAT induces a state of high 
substrate affinity and high turnover rate. Subsequently, acceptor amino acids most likely 
situated in the amino-terminal region of chimera PARP2-1 and in the PARP1 DBD are 
poly(ADP-ribosyl)ated. (B) Scheme depicting PAR acceptor lysine residues in chimera 
PARP2-1 in accordance with our previous finding, that lysines 36 and 37 of mPARP2 are 
targets for auto-ADP-ribosylation (1). 
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AhPARP1   WGAEVKAEPVEVVAPRGKSGAALSKKSKGQVKEEGINKSEKRMKLTLKG-GAAVDPDSGL 539
hPARP2   --------------------VAGGKANKDRTEDK---QDESVKALLLKG-KAPVDPECTA 87
hPARP3   ------------------------GRQAGREEDPFRSTAEALKAIPAEKRIIRVDPTCPL 54
                                   . .: ::      *    :  :     *** .
hPARP1   EH-SAHVLEKGGKVFSATLGLVDIVKGTNSYYKLQLLEDDKENRYWIFRSWGRVGTVIGS 598
hPARP2   KVGKAHVYCEGNDVYDVMLNQTNLQFNNNKYYLIQLLEDDAQRNFSVWMRWGRVGKMGQH 147
hPARP3   SSNPGTQVYED---YNCTLNQTNIENNNNKFYIIQLLQD-SNRFFTCWNRWGRVGEVGQ- 109
         .   .    :.   :.  *. .::  ..*.:* :***:*  :. :  :  ***** :
hPARP1   NKLEQMPSKEDAIEHFMKLYEEKTGNAWHSKN-FTKYPKKFYPLEIDYG---QDEEAVKK 654
hPARP2   SLVACSGNLNKAKEIFQKKFLDKTKNNWEDREKFEKVPGKYDMLQMDYATNTQDEEETKK 207
hPARP3   SKINHFTRLEDAKKDFEKKFREKTKNNWAERDHFVSHPGKYTLIEVQAEDEAQEAVVKVD 169
         . :      :.* : * * : :** * * .:: * . * *:  ::::     *:     .
hPARP1   ---LTVNPG--TKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAA 709
hPARP2   EESLKSPLK--PESQLDLRVQELIKLICNVQAMEEMMMEMKYNTKKAPLGKLTVAQIKAG 265
hPARP3   RGPVRTVTKRVQPCSLDPATQKLITNIFSKEMFKNTMALMDLDVKKMPLGKLSKQQIARG 229
            :         ..*   .*.**. * . : ::: *   . : :* *****:  **  .
hPARP1   YSILSEVQQAVS-QGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKAEMLDNL 768
hPARP2   YQSLKKIEDCIR-AGQHGRALMEACNEFYTRIPHDFGLRTPPLIRTQKELSEKIQLLEAL 324
hPARP3   FEALEALEEALKGPTDGGQSLEELSSHFYTVIPHNFGHSQPPPINSPELLQAKKDMLLVL 289
         :. *. :::.:    . .  : : ...*** ***:**   ** :.. . :. * ::*  *
hPARP1   LDIEVAYSLLRGGSDD----SSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHAT 824
hPARP2   GDIEIAIKLVKTELQ-----SPEHPLDQHYRNLHCALRPLDHESYEFKVISQYLQSTHAP 379
hPARP3   ADIELAQALQAVSEQEKTVEEVPHPLDRDYQLLKCQLQLLDSGAPEYKVIQTYLEQTGSN 349
          ***:*  *     :     .  .*:* .*. *:  :: :*  : * ::*  *::.* :
hPARP1   THNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEA 884
hPARP2   THSDYTMTLLDLFEVEKDGEKEAFR--EDLHNRMLLWHGSRMSNWVGILSHGLRIAPPEA 437
hPARP3   HR---CPTLQHIWKVNQEGEEDRFQAHSKLGNRKLLWHGTNMAVVAAILTSGLRIMP--- 403
          :      : .:::::::** : ::  ..* ** *****:. :  ..**: **** *
hPARP1   PVTGYMFGKGIYFADMVSKSANYCHTSQG--DPIGLILLGEVALGNMYELKHASHISK-L 941
hPARP2   PITGYMFGKGIYFADMSSKSANYCFASRL--KNTGLLLLSEVALGQCNELLEANPKAEGL 495
hPARP3   -HSGGRVGKGIYFASENSKSAGYVIGMKCGAHHVGYMFLGEVALGREHHINTDNPSLKSP 462
           :*  .*******.  ****.*    :   .  * ::*.*****.  .:   .   :
hPARP1   PKGKHSVKGLGKTTPDP--SANISLDGVDVPLGTGISSGVNDT---SLLYNEYIVYDIAQ 996
hPARP2   LQGKHSTKGLGKMAPSS--AHFVTLNGSTVPLGPASDTGILNPDGYTLNYNEYIVYNPNQ 553
hPARP3   PPGFDSVIARGHTEPDPTQDTELELDGQQVVVPQGQPVPCPEFSSSTFSQSEYLIYQESQ 522
           * .*. . *:  *..     : *:*  * :  .      :    ::  .**::*:  *
hPARP1   VNLKYLLKLKFNFKTSLW 1014
hPARP2   VRMRYLLKVQFNFLQ-LW 570
hPARP3   CRLRYLLEVHL------- 533
          .::***::::
B
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a b s t r a c t
Poly-ADP-ribose polymerase-2 (PARP-2) was described to regulate cellular functio
prising DNA surveillance, inflammation and cell differentiation by co-regulating d
transcription factors. Using an in vitro and in vivo approach, we identified PARP-2 a
substrate for the histone acetyltransferases PCAF and GCN5L. Site directed muta
indicated that lysines 36 and 37, located in the nuclear localization signal of PARP-2
main targets for PCAF and GCN5L activity in vitro. Interestingly, acetylation of the sa
PARP-2 residues reduces the DNA binding and enzymatic activity of PARP-2. Finally
with mutated lysines 36 and 37 showed reduced auto-mono-ADP-ribosylation wh
pared towild type PARP-2. Together, our results provide evidence that acetylation of
is a key post-translational modification that may regulate DNA binding and conse
also the enzymatic activity of PARP-2.
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protein (Yang et al., 1996). PCAF and GCN5L show se
conservation in the regions responsible for the HAT
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We have recently reported that PARP-1 can be
ically acetylated by p300/CBP. Here, we provide e
that PARP-2 is acetylated in mammalian cells and
and that the two lysine residues K36 and K37 are th
direct target sites for PCAF and GCN5L-mediated a
tion. Interestingly, acetylation of PARP-2 strongly
the DNA binding and enzymatic activity of PARP-2.
PARP-2 with mutated lysines 36 and 37 showed r
auto-mono-ADP-ribosylation when compared to w
PARP-2, indicating that lysines 36 and 37 may also
target sites for auto-ADP-ribosylation of PARP-2.
2. Materials and methods
2.1. Plasmids
Mammalian expression vectors for wild type m
2 and different mPARP-2 mutants (K19/20R, K
K19/20/36/37R, K36R and K37R) were obtained by
the corresponding PCR products into pphCMV-H
ulovirus expression vectors for His-tagged mPC
hGCN5L were obtained by cloning the corre
ing PCR products into pBACPAK8 (Clontech La
ries). Baculovirus expression vectors for His-tagg
type PARP-2 and the different PARP-2 mutant
obtained by cloning the corresponding PCR produ
pphBACPAK9-MC-PrSc-HA-HIS or pphBACPAK9-M
HIS. The corresponding baculoviruses were ge
using the BACPAK6-based bacmid system from
tech Laboratories. All PARP-2 mutants were ge
by a site directed mutagenesis procedure an
firmed by sequencing. Mammalian expression
for mPCAF and hGCN5L were obtained by clon
corresponding PCR products into pphCMVkm (H
al., 2005). The bacterial expression vectors for G
full-length fusion proteins (mPCAF and hGCN5L
obtained by cloning the corresponding PCR produ
pGex6P1.
2.2. Expression and purification of recombinant prot
Recombinant hp300,mCBP,mPCAF and hGCN5L
as mPARP-2 full-length, fragments and mutant p
were expressed as carboxy-terminal His-tagged p
in Sf21 insect cells as described previously (Hass
2003, 2005). Recombinant proteins were purified b
dard nickel-NTA affinity chromatography accordin
manufacturer’s protocol in the presence of 1M Na
NP-40. GST-tagged proteins were expressed in E. co
BL21-DE3-Gold as described previously (Hassa et a
2005). Recombinant histones H2A/H2B (refolded)
kind gift from Tobias Stuwe (European Molecular
Laboratory (EMBL), Gene Expression Unit, 69117
berg, Germany). All purified proteins were analy
Coomassie staining and confirmedbyWestern blot a
using the corresponding antibodies.
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2.3. Cell culture and transient transfections
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2.6.2. HAT assay used for electro-mobility shift assays
(EMSA) and poly-ADP-ribose product analysis
Five microgram of purified GST, GST-mPCAF or GST-
length,
T assay
NaCl,
TA (pH
in A at
Acetyl-
mPCAF
harose
ly-ADP-
control,
tly sep-
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as per-
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ap DNA
t 25 ◦C
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rotease
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r non-
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t 30 ◦C
H 7.8),
urifiedGlutamax-I (Invitrogen) containing 4.5 g/L gluco
10% FCS US/certified (Invitrogen) and supple
with 50U/ml penicillin, 50g/ml streptomycin (
gen) and MEM-non-essential amino acids (MEM
Invitrogen). Cells were transfected using calcium
phate procedures as previously described (Perkin
1997).
2.4. Immunoprecipitation and Western blot analysis
Co-immunoprecipitation for PARP-2 and mP
hGCN5L was performed as described previously
et al., 2003, 2005). In brief, IP-buffers contained
Tris–HCl (pH 8.0), 120mM NaCl, 0.5% NP-40, 0.5m
protease inhibitors and, where indicated, histone d
lase inhibitors (2M TSA, 2mM sodium butyrate
nicotinamide). Western blot analyses were perfor
described previously (Hassa et al., 2003, 2005). An
9E10 (sc-2027) antibodies were obtained from San
Biotechnology, anti-HA (MMS-101P) was obtaine
COVANCE SA, anti-acetyl-lysine antibodies (AKL5C
provided by Dr. Ito (RIKEN, Japan) or purchased from
Cruz Biotechnology (sc-32268) (dilution for WB 1
Antibodies against mouse PARP-1 and PARP-2 were
ated in house (the generation of antibodies against
and human PARP-1 was described previously Hass
2005; Petrilli et al., 2004).
2.5. In vitro interaction and GST pull-down assays
Purified recombinant proteins fused to GST were
to Glutathione Sepharose 4B beads according
manufacturer’s protocols (Amersham Bioscience
pull-down assays were performed as described (H
al., 2003, 2005). GST pull-down-buffers contained:
Tris–HCl (pH 8.0), 150mM NaCl, 0.5% NP-40,
DTT and protease inhibitors. Bound proteins we
solved by boiling and subsequently analyzed by W
blot.
2.6. Histone-acetyltransferase (HAT) assays
2.6.1. HAT assays used for identification of acetylated
lysines and for auto-mono-ADP-ribosylation assays
Onemicrogramof baculo-purified PARP-2 full-le
2g of baculo-purified PARP-2 fragments were in
with 0.5g of baculo-purified histone acetyltran
and 1.5nmol radiolabelled (0.1Ci/mmol [14C], M
Movarek Biochemicals) or unlabelled Acetyl-CoA
HAT-Buffer (50mM Tris–HCl (pH 8.0), 5% (v/v) g
50mMNaCl, 0.1% (v/v)NP-40, 1mMDTT, 1mMPMS
sodium butyrate) at 30 ◦C for 30min. Proteins we
sequently separated by SDS-PAGE. Gels were stain
Coomassie and subjected to autoradiography, or W
blot analysis was performed with the indicated a
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hGCN5L and 10g of target protein (PARP-2 full-
PARP-2 aa 1–91 or aa 1–209) were incubated in HA
buffer containing 50mM Tris–HCl (pH 7.8), 100mM
10% (v/v) glycerol, 1mMDTT, 1mMPMSF, 0.1mMED
8.0), 2mM sodium butyrate and 50M Trichostat
30 ◦C for 2h, in the presence or absence of 100M
CoA. The final reaction volume was 50l. GST, GST-
or GST-hGCN5L were then bound to Glutathion Sep
4B beads and the supernatants were used for po
ribosylation and electro-mobility shift assays. As
aliquots of the reaction mixtures were subsequen
arated on 12% SDS-PAGEs and processed for Coo
staining and Western blot analysis.
2.6.3. Tris-glycine based electro-mobility shift assays
(EMSA) procedure
Acetylated or non-acetylated (i.e. reaction w
formed without Acetyl-CoA) wild type full-length
or DBD fragments of PARP-2 were incubated with fl
oligonucleotide in 20–25l EMSA binding buffer a
for 10–20min. Molar ratios of oligonucleotide to
are indicated in the figure legends. EMSA-binding
30mM Hepes (pH 7.9), 100mM NaCl, 10mM Mg
5% sucrose. To equilibrate pH, NaCl, Acetyl-CoA a
tein concentrations, the reaction was compensate
HAT Buffer (+/− Acetyl-CoA) containing BSA. Re
were stopped with 10X sucrose based gel loading
Complexes were subsequently resolved on nativ
polyacrylamide gels (AA:BA, 19:1 or 40:1, “UltraPur
Grade” Acrylamide, Ambion/Amersham Bioscenc
in Tris-glycine buffer (250mM glycine, 50mM Tr
(pH 8.3)) at 4 ◦C for 5–8h at 4W. Free DNA prob
DNA/PARP-2 complexes were stained with toluidi
O (TBO).
2.6.4. In vitro poly-ADP-ribosylation assays
If not otherwise stated, for poly-ADP-ribosylation
1g of purified PARP-2 was incubated with 4
NAD+, 2Ci 32P-labelled NAD+ (Amersham Biosc
and 1g activated DNA (obtained from Trevig
flap-oligonucleotides at 30 ◦C for 10min (Buffer:
Tris–HCl (pH 8.0), 4mM MgCl2, 0.5mM DTT and p
inhibitors) in a total volumeof 50l. Proteinswere r
by SDS-PAGE, stainedwith Coomassie and exposed t
films (Contatyp).
2.6.5. Poly-ADP-ribose polymer product analysis
Hundred nanogram of in vitro acetylated o
acetylated PARP-2 full-length proteins were pre-inc
in 25l poly-ADP-ribosylation reaction buffer in th
ence of increasing amounts of DNAflap-oligonucleo
indicated in the figure legends) for 20min at roo
perature. 75l of poly-ADP-ribosylation reaction
containing 166.6mM NAD+ was then added to th
tion (final NAD+ concentration: 125mM) and the m
further incubated in a thermo mixer for 5min a
and 550 rpm. Reaction buffer: 100mM Tris–HCl (p
10mM MgCl2 125mM NaCl, 2mM DTT, +/− p
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recombinant histone H2A/H2B protein. The molar ratio of
PARP-2 to histone H2A/H2B protein was 1:2. The reactions
were stopped by addition of 1 volume 20% ice-cold TCA.
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staining of poly-ADP-ribosylation products was per
according tomanufacturer‘s procedures (PIERCE; C
ver Stain Kit).
2.6.6. Oligonucleotides used in this study
Flap-dsDNA 106mer:
• 5′-AAGGGCAAGGCTGCTGCTGTGGAGTGTTGCATTC
ATATATAATATATAAAA-3′,
• 5′-TACCTGCTGGACCCTGCTGTGGGCTGGAGAACAA
TGATCTGCGCTCTGGTCGT-3′,
• 5′-ACGACCAGAGCGCAGATCACCTTGTTCTCCAGCC
CAGCAGGGTCCAGCAGGTACCTGGCCGCCCAGAGA
ATGCAACACTCCACAGCAGCAGCCTTGCCCTT-3′.Fig. 1. PARP-2 is acetylated in vivo and in vitro by PCAF and GCN5L. (A) H
precipitation was performed using a monoclonal anti-HA antibody. Sa
was then incubated with an antibody specific to acetylated lysine residu
Recombinant His-tagged histone acetyltransferases (HATs) were express
by SDS-PAGE and stained with Coomassie. (C) Purified PARP-2 was sub
quently separated by SDS-PAGE and transferred to a PVDFmembrane, fo
is acetylated mainly by PCAF and to a lower extent by GCN5L. (D) PARP-
PARP-2 in HEK293T cells and immunoprecipitated using an anti-Myc an
served as IP control. (E) PARP-2 interacts with GCN5L in vivo. Myc-tagge
immunoprecipitated using an anti-HA antibody and bound GCN5L was
68d
”
r
d
l-
a desalting column.
3. Results
3.1. PARP-2 is acetylated in vivo
Acetyltransferases are known tomodify a variety
teins, such as histones and transcription factors (
and Berger, 2000). To investigate whether PARP-2m
acetylated in vivo, we immunoprecipitated overex
HA-tagged PARP-2 under high salt conditions from
cell extracts of 293T cells. Western blot analysis
specific anti-AcK antibody revealed that PARP-2wa
lated in vivo (Fig. 1A and Supplementary Fig. 1). No i
in acetylation was observed in the presence of th
inhibitors sodium butyrate, nicotinamide or trich
A (Supplementary Fig. 2), suggesting that acetylaEK293T cells were transfected with HA-tagged PARP-2 as indicated, then immuno-
mples were separated by SDS-PAGE and transferred to a PVDF-membrane, which
es. Untransfected cells were used as negative control for immunoprecipitation. (B)
ed in Sf21 cells and purifiedwith NTA-Nickel beads. Purified proteins were resolved
jected to in vitro acetylation by p300, CBP, PCAF or GCN5L. Proteins were subse-
llowed by incubationwith the indicated antibodies. Under these conditions, PARP-2
2 interacts with PCAF in vivo. Myc-tagged PCAF was co-expressed with HA-tagged
tibody. Bound PARP-2 was detected using an anti-HA antibody. Untransfected cells
d GCN5L was co-expressed with HA-tagged PARP-2 in HEK293T cells. PARP-2 was
detected by Western blot against the Myc-tag.
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PARP-2 is a stable modification in mammalian cells. Sev-
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2 mRNA was detected in these cells by RT-PCR
observations indicate that the translation or degr
of PARP-2 is tightly controlled (suppl Fig. 3 and d
shown).
3.2. PARP-2 is acetylated in vitro by both PCAF and
GCN5L and forms a complex with PCAF and GCN5L in
Next, we tested whether PARP-2 can be ace
in vitro. Recombinant purified full-length PARP
incubatedwith different recombinant purified acet
ferases (Fig. 1B) in the presence of Acetyl-CoA and r
by SDS-PAGE followed by Western blot analysis us
indicated antibodies. PARP-2 was acetylated in v
PCAF and to a weaker extent by GCN5L, but not b
CBP, HAT-1 or TIP-60 (Fig. 1C and data not shown).
mation of the acetylation efficiency revealed that
minor portion of PARP-2 was acetylated under the
conditions in vitro. PCAF and GCN5L are known
weak acetyltransferase activity compared to p3
CBP.
Since these results strongly suggested that the t
tone acetyltransferases PCAF and GCN5L might ph
interact with PARP-2 in vivo, we co-expressed Myc
PCAF and HA-tagged PARP-2 in HEK293T cells, im
precipitated PCAF complexes from whole cell extra
tested the presence of HA-tagged PARP-2 by West
analysis using an anti-HA antibody. PARP-2 formed,
a complex with PCAF in vivo (Fig. 1D). Similar expe
with GCN5L and PARP-2 revealed that also GCN5
ciates with PARP-2 (Fig. 1E).
3.3. PARP-2 is acetylated at K36 and K37.
In order to map the PARP-2 domains, which ar
lated by PCAF, in vitro acetylation assays were per
with different PARP-2 fragments corresponding to
acids 1–91, aa 92–207, aa 1–207 or aa 208–559
presence of radiolabelled Acetyl-CoA. These expe
revealed that PCAF strongly acetylated the PARP-2
corresponding to aa 1–91 (Fig. 2A). To identify th
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Acetylated proteins were resolved by SDS-PAGE a
jected to autoradiography (Fig. 2 C and data not
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ther confirm that both lysines are targets for acet
we repeated similar assays with single mutants of
(K36R andK37R, respectively). These experiments r
that indeed both lysines are acetylated in vitro by PC
GCN5L (Fig. 2D).
We furthermore investigatedwhether lysines 36
of PARP-2 may serve as the main acceptor sites for a
tion in vivo. Overexpressed HA-tagged PARP-2 wild
mutants were immunoprecipitated under high salt
tions from whole cell extracts of 293T cells in the p
of deactylase inhibitors (Fig. 2E). The presence of
lated forms of PARP-2 was tested by Western blot a
using an anti-AcK antibody. While wild type PARP
the PARP-2 mutant K19/20R were acetylated in v
PARP-2 mutants harboring the two lysines K36 a
mutated to arginines were no longer acetylated (F
Overexpression of PCAF or GCN5L did not increase
lation of PARP-2, indicating that the endogenou
of PCAF or GCN5L were high enough to maintain
2 in the acetylated status (data not shown). Dur
course of our experiments we observed that the K
PARP-2 mutant is, in contrast to its wild type coun
not localized to the nucleus (Supplementary Fig
manuscript in submission). Since both PCAF and
were mainly localized in the nucleus under the test
ditions (Supplementary Fig. 5), the absence of acet
of the PARP-2 mutants K36/37R and K19/20/36/3
very likely due to their localization in a different
lular compartment. The additional involvement of
mentioned lysines in the nuclear translocation of
thus did not allow further in vivo analysis of the in
mutants.
3.4. Acetylation of Lysines 36 and 37 inhibits DNA
binding of PARP-2
Itwashypothesizedearlier that theamino-termi
of PARP-2 might contain a DNA binding domain
Thus, the amino-terminal fragments of PARP-2 c
ing the postulated DBD alone (aa 1–91) or togeth
the WGR domain (aa 1–207) were expressed in Sf2
cells, purified, and tested in electro-mobility shift
(EMSA) for their binding to a flap DNA oligonuc
Previous reports and own experiments had reveal
PARP-2 preferentially binds to DNA oligonucleotid
taining long flaps or gaps but only very weakly to
short gapped and single stranded DNA (Ame et al
Dantzer et al., 2006b and data not shown). The EMS
formed confirmed that PARP-2 is able to bind DNA a
the aa 1–91 fragment is sufficient for this function
A and B). The WGR domain alone was not able to
DNA. In vitro acetylation of full-length PARP-2 or
by PCAF or GCN5L and subsequent repetition of the
iments with acetylated proteins revealed that the
to DNA was severely reduced by acetylation (Fig. 3
C). Acetylation of the different tested proteins w
trolled byWestern blot analysis using an anti-AcK an
(Supplementary Fig. 6).
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Fig. 2. PARP-2 is acetylated at lysines 36 and 37. (A) The postulated DNA binding domain of PARP-2 (aa 1–91) is acetylated by PCAF in vitro. Purified
recombinant PARP-2 fragments aa 1–91, aa 92–207, aa 1–207 and aa 208–559 expressed in Sf21 cells were in vitro acetylated with PCAF and analyzed by
autoradiography. (B) Schematic illustration of PARP-2 mutant proteins used in this study. Lysines K19, K20, K36 and K37 were changed to arginine using
site directed mutagenesis. Single, double and quadruple mutants were generated. (C) Purified recombinant wild type (wt) PARP-2 or the indicated double
and quadruple mutants were incubated with purified recombinant PCAF in the presence of radiolabelled Acetyl-CoA. Auto-acetylated PCAF and acetylated
PARP-2were detected by autoradiography. (D) Purified recombinant wild type (wt) PARP-2 or the indicated single and doublemutants were incubatedwith
purified recombinant PCAF in the presence of Acetyl-CoA. Acetylated PARP-2 was analyzed by Western blot using an anti-AcK antibody. (E) The PARP-2
mutants K36/37R and K19/29/36/37R are no longer acetylated in vivo. HA-tagged wild type (wt) PARP-2 and the mutant proteins K19/20R, K36/37R and
K19/20/36/37R were transfected into HEK293T cells, then immunoprecipitation was performed using an anti-HA antibody. Proteins were separated by
SDS-PAGE and subsequently tested for acetylation by Western blot analysis with an anti-AcK specific antibody.
3.5. Acetylation of PARP-2 inhibits its enzymatic activity
In order to test whether acetylation also inhibits the
thwil
T-PCA
ly-ADP
ribosylation assays in the presence of 125M NAD+.
Analysis of the poly-ADP-ribose polymer products revealed
that the activity of PARP-2 was strongly stimulated by long
4A and
-2 was
ly-ADP-enzymatic activity of PARP-2, recombinant full-leng
type PARP-2was acetylated in vitrowith purified GS
and GST-hGCN5L and subsequently tested in po70d
F
-
gap and flap containing DNA oligonucleotides (Fig.
B, left panels and data not shown), although PARP
able to auto-ADP-ribosylate itself and to form po
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Fig. 3. Acetylation of PARP-2 by mPCAF and hGCN5L inhibits PARP-2 DNA binding activity. (A) Increasing amount of purified fragments representing the
postulated DNA binding region of PARP-2 were tested in electro-mobility shift assays (EMSA) for binding to a flap DNA oligonucleotide. Molar ratios of
oligonucleotide to PARP-2 fragment: 1:1, 1:2, 1:4 and 1:8. (B) Increasing amount of purified fragments representing the DNA binding region of PARP-2 were
acetylated in vitro with purified GST-mPCAF and subsequently tested in EMSA for binding to a flap DNA oligonucleotide. Molar ratios of oligonucleotide to
PARP-2 fragment: 2:1 1:1, 1:2 and 1:4. (C) Increasing amount of purified full-length wild type PARP-2 was acetylated in vitro with purified GST-mPCAF or
GST-hGCN5L and subsequently tested in EMSA for binding to a flap DNA oligonucleotide. Molar ratios of oligonucleotide to PARP-2 fragment: 1:1, 1:2, 1:3
and 1:4.
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3.5.1. Lysines 36 and 37 of PARP-2 are important for
auto-mono-ADP-ribosylation
To investigate the relevanceof lysines36and37 f
mono-ADP-ribosylation, wild type and PARP-2
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in the presence of ethidium bromide to avoid c
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Together these experiments revealed that lysines
37 are important for mono-ADP-ribosylation of
potentially by serving as acceptor sites for ADP
Interestingly, the same experiments in the pres
100M NAD+ revealed that the PARP-2 mutant K
was still able to synthesize poly-ADP-ribose po
(Fig. 5).
4. Discussion
The aim of this study was to investigate whethe
2 might be regulated by post-translational modifi
such as acetylation. Here, we provide both biochem
functional evidence for acetylation of PARP-2 by PC
GCN5L. We identified two lysine residues (K36 an
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Fig. 4. Acetylation of PARP-2 bymPCAF and hGCN5L inhibits PARP-2 enzymatic activity. Product analysis of poly-ADP-ribose produced in vitro by acetylated
and non-acetylated PARP-2 in the absence (left panels) or presence (right panels) of histones H2A/H2B. (A) Full-length wild type PARP-2 was acetylated
in vitro with purified GST-mPCAF and subsequently tested in poly-ADP-ribosylation assays. Poly-ADP-ribose products were purified, separated by 20%
Urea-PAGE and processed for silver staining. Molar ratios of PARP-2 to flap-DNA oligonucleotide: 2:1, 1:1, 1:2, 1:3, 1:4 and 1:8. (B) Full-length wild type
PARP-2 was acetylated in vitro with purified GST-hGCN5L and poly-ADP-ribosylation was tested as described for Fig. 4A.
that are acetylated in mammalian cells and are also direct
substrates for PCAF in vitro. In vitro acetylation of the DNA
binding domain (aa 1–91) of PARP-2 inhibited its binding
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Fig. 5. Lysines 36- and 37 are important for auto-mono-ADP-ribosylation.Wild type (wt) PARP-2 and themutant K36/37Rwere expressed in Sf21 insect cells
and purified in the presence of ethidiumbromide to avoid copurification of DNAor RNA. Purified proteinswere then used for in vitroADP-ribosylation assays
in the presence of 2M NAD+, which favors auto-mono-ADP-ribosylation, or in the presence of 100M - NAD+, which stimulates poly-ADP-ribosylation of
PARP-2. Products were analyzed by SDS-PAGE and autoradiography, inputs were controlled by Coomassie staining. The lower band reflects the mono-ADP-
ribosylated PARP-2. The two upper bands represent auto-poly-ADP-ribosylated forms of PARP-2, as indicated.
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Taken together, our experiments identified PARP-2 as
substrate for acetylation in vitro and in vivo. Lysines 36
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Abstract
Background: The enzymes responsible for the synthesis of poly-ADP-ribose are named poly-
ADP-ribose polymerases (PARP). PARP-2 is a nuclear protein, which regulates a variety of cellular
functions that are mainly controlled by protein-protein interactions. A previously described non-
conventional bipartite nuclear localization sequence (NLS) lies in the amino-terminal DNA binding
domain of PARP-2 between amino acids 1–69; however, this targeting sequence has not been
experimentally examined or validated.
Results: Using a site-directed mutagenesis approach, we found that lysines 19 and 20, located
within a previously described bipartite NLS, are not required for nuclear localization of PARP-2. In
contrast, lysine 36, which is located within a predicted classical monopartite NLS, was required for
PARP-2 nuclear localization. While wild type PARP-2 interacted with importin α3 and to a very
weak extent with importin α1 and importin α5, the mutant PARP-2 (K36R) did not interact with
importin α3, providing a molecular explanation why PARP-2 (K36R) is not targeted to the nucleus.
Conclusion: Our results provide strong evidence that lysine 36 of PARP-2 is a critical residue for
proper nuclear targeting of PARP-2 and consequently for the execution of its biological functions.
Background
Poly-ADP-ribosylation reactions occur both in multi- and
unicellular organisms and play a major role in a wide
range of biological processes, such as maintenance of
genomic stability, transcriptional regulation and cell
death (reviewed in [1,2]). The enzyme responsible for the
synthesis of poly-ADP-ribose was named poly-ADP-ribose
polymerase (PARP) (reviewed in [1,2]). For a long time,
PARP-1 was thought to be the only enzyme with pol
ADP-ribosylation activity in mammalian cells; howeve
primary cells derived from parp-1 knockout mice can st
synthesize poly-ADP-ribose polymers after DNA damag
[3]. This led to the identification of five novel poly-AD
ribosylating enzymes, indicating that PARP-1 belongs to
family of at least six members ([4-6] and reviewed 
[1,2]). PARP-2 and PARP-1 can homo- and heterodime
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ize and display partially redundant functions as indicated
by the embryonic lethality of the parp1-parp2-double gene
opartite and bipartite cNLS [18,19]. Through alanine
scanning of the Myc, monopartite SV40, and artificial
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disruption ([7] and reviewed in [8]).
Mouse PARP-2 was described as a 66 kDa nuclear protein
with poly-ADP-ribosylating activity [9]. The amino-termi-
nal region of PARP-2 (aa 1–90), containing the DNA
binding SAP domain, has no significant homology with
any other PARP [1]. However, it is rich in basic amino
acids (27% Lys or Arg), which are likely to be involved in
DNA binding (reviewed in [1]). On the other hand, these
basic residues could be involved in the nuclear and/or
nucleolar targeting of the protein [10]. Previous studies
suggested that the nuclear localization signal (NLS) of
mPARP-2 is indeed located in the amino-terminal part
between aa 1–69 of the protein [9,11]. Meder et al. postu-
lated a bipartite NLS for PARP-2, but did not provide fur-
ther experimental evidences to support their hypothesis
[11]. Interestingly, the amino-terminal region of human
and mouse PARP-2 shows higher sequence variability
compared to the highly conserved carboxy-terminal cata-
lytic region (62% identity between the amino-terminus of
mPARP-2 and hPARP-2). In cells, PARP-2 has been
described to regulate different processes via protein-pro-
tein interactions mediated by its amino-terminal domain
(aa 1–208; reviewed in [1]).
Karyopherins, including both importins and exportins,
consitute a conserved family of mobile targeting receptors
that mediate the bidirectional trafficking of macromole-
cules across the nuclear envelope [12,13]. Most karyo-
pherins interact directly with cargo molecules that contain
nuclear import and export signals. However, importin α
functions as an adaptor that links classical NLS (cNLS)-
containing proteins to importin β, which, in turn, docks
the ternary complex at the nuclear-pore complex (NPC).
The importin α/β heterodimer is predicted to target hun-
dreds of proteins to the NPC and facilitate their transloca-
tion across the nuclear envelope [14]. The importin α
gene family has undergone considerable expansion dur-
ing the course of eukaryotic evolution. Whereas the yeast
S. cerevisiae genome encodes a single importin α, the
human genome encodes six genes that fall into three phy-
logenetically distinct groups [15].
The nuclear targeting signal in the simian virus 40 (SV40)
large T antigen was characterized more than 20 years ago
[16,17]. Since then, several pathways for nucleocytoplas-
mic transport have been described, of which the classical
nuclear import pathway is the best characterized. cNLSs
are typified by either a single cluster of basic amino acids
(monopartite NLS) or two clusters of basic amino acids
separated by a 10–12 amino acid linker (bipartite NLS).
The SV40 large T antigen (PKKKRKV) and nucleoplasmin
(KRPAATKKAGQAKKKK) cNLSs are the prototypic mon-
bipartite SV40 cNLS, Hodel and colleagues found that th
binding affinity of a cNLS for importin measured in vit
correlated with the steady state nuclear accumulation an
import rate of the corresponding cNLS cargo in vi
[20,21].
Here, we demonstrate that lysine 36 in the DNA bindin
domain (DBD) of PARP-2, which lies within a predicte
cNLS motif, is required for complex formation with th
importin proteins and subsequent nuclear import 
PARP-2.
Results
Lysine 36 and/or lysine 37 of PARP-2 are required for 
nuclear translocation of PARP-2
Previous experiments with GFP-fusion proteins reveale
that the nuclear targeting signal of PARP-2 may be loca
ized between aa 1–69 ([11] and Fig. 1A). This region 
the protein was previously postulated to contain a bipa
tite cNLS; however, this sequence would be an atypic
bipartite cNLS as the linker separating the two bas
regions is longer than the typical 10–12 amino acid linke
This region does contain a predicted monopartite cNL
that closely matches the canonical SV40 cNLS sequenc
To assess whether these sequences are important f
nuclear translocation of PARP-2, mutant forms of PAR
2, K19/20R, K36/37R, and K19/20/36/37R, were gene
ated by replacing the lysine residues with arginine res
dues to maintain the positive charge of the amino acid
(Fig. 1B). To exclude the possibility that these amino ac
changes altered the stability of the mutated PARP-2, wi
type and all mutant forms were expressed as HA-tagge
proteins in 293T cells and detected by immunoblot usin
an anti-HA antibody (Fig. 1C). Immunoblot analys
revealed that all mutants were expressed at a level comp
rable to wild type PARP-2.
The PARP-2 mutants were transiently transfected an
localization was assayed by microscopy of PARP-2 pr
teins. While wild type PARP-2 and the K19/20R muta
localized in the nucleus, the K19/20/36/37R and K36/37
mutants exclusively localized in the cytoplasm (Fig. 2A
To investigate whether substitution of K36 and K37 wi
other amino acids altered the localization of PARP-2, sim
ilar experiments were repeated with different amino ac
susbstitutions. Overexpression of PARP-2 with K19/2
K36/37 or all four residues mutated to glutamate o
methionine showed that K → E or K → M substitution 
K36/37, but not of K19/20 altered the localization 
PARP-2 to a similar extent as the K → R substitution (Fi
2B and 2C), suggesting that K36 and/or K37 are require
for the nuclear translocation of PARP-2, whereas K19 an
K20 did not seem to play a role in this process.82
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The putative NLS of PARP-2 contains several conserved lysine residuesFigure 1
The putative NLS of PARP-2 contains several conserved lysine residues. A) Three lysines in the putative NLS of 
PARP-2 are conserved between different mammalian species. Sequences were obtained from NCBI and alignments were per-
formed using ClustalW2. B) Schematic illustration of PARP-2 K → R mutant proteins used in this study: K19, K20, K36 and 
K37 were changed to arginine using site-directed mutagenesis. Double and quadruple mutants were generated. C) HA-tagged 
wild type (wt) PARP-2 or the indicated double or quadruple mutants were expressed in HEK293T cells and expression was 
analyzed by western blot using a monoclonal anti-HA antibody. 100 μg of whole cell extracts were used, endogenous PARP-1 
levels served as loading control.
C
w
t
K
3
6
/3
7
R
K
1
9
/2
0
R
K
1
9
/2
0
/3
6
/3
7
R
HA-PARP-2
anti-HA
anti-PARP-1
u
n
tr
a
n
s
fe
c
te
d
1-MAPRRQRSGSGRRVLNEAKKVDNGNKATEDDSPPGKKMRT-40
1-MAPRRQRSGSGRRVLNEARRVDNGNKATEDDSPPGKKMRT-40
1-MAPRRQRSGSGRRVLNEAKKVDNGNKATEDDSPPGRRMRT-40
1-MAPRRQRSGSGRRVLNEARRVDNGNKATEDDSPPGRRMRT-40
wt:
K19/20R:
K36/37R:
K19/20/36/37R:
B
- COOHPRDWGRNH2
1
17691 208 342 554
mPARP-2
DNA binding domain catalytic domain
5591 NLS
                   19/20 36/37
A
Homo sapiens      1 MAARRRRSTGGGRARALNESKRVNNGNTAPEDSSP-AKKTRRCQRQESKKMPVAGGKANK 59
Mus musculus      1 MAPRRQRS-GSGR-RVLNEAKKVDNGNKATEDDSPPGKKMRTCQRKG----PMAGGKD-A 53
Macaca mulatta    1 MAARRRRSTRGGRARALNESKRVNNGNTAPEDSSP-AKKTRRCQRQGSKKMPVTGGNANE 59
Pan troglodytes   1 MAARRRRSTGGGRARALNESKRVNNGNTAPEDSSP-AKKTRRCQRQESKKMPVAGGKANK 59
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Lysine 36 and/or lysine 37 of PARP-2 are required for nuclear localizationFigure 2
Lysine 36 and/or lysine 37 of PARP-2 are required for nuclear localization. A) HEK293T cells were transfected with 
HA-tagged wild type (wt) PARP-2 or with the indicated mutants. Cells were fixed with methanol for subsequent detection of 
HA-tagged proteins by immunofluorescence using an anti-HA antibody and a FITC-conjugated anti-mouse antibody. Represent-
ative confocal images are presented. B) Lysines 19, 20, 36 and 37 of PARP-2 were changed to glutamic acid or methionine as 
indicated. C) The nuclear localization is independent of the charge but dependent on the structure of the NLS. As for Fig. 2A, 
HEK293T cells were transfected with HA-tagged wild type (wt) PARP-2 or with the indicated K → E and K → M mutants and 
overexpressed proteins were detected as described for Fig. 2A. Representative confocal images are presented.
84
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Leptomycin B does not change cellular localization of 
PARP-2 mutant K36/37R
Lysine 36 but not lysine 37 of PARP-2 is required for 
nuclear localization of PARP-2
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Next, we investigated whether the cytoplasmic localiza-
tion of the mutated PARP-2 protein K36/37R is caused by
an abrogated nuclear import or by an accelerated nuclear
export of a transiently nuclear localized PARP-2 mutant.
Cells were transfected with wild type or mutant PARP-2
and subsequently treated with Leptomycin B (LMB), a
well-characterized inhibitor of CRM-1-mediated nuclear
export [22-24]. Treatment with LMB did not induce any
changes in the cellular localization of the PARP-2 mutant
K36/37R (Fig. 3), indicating that K36 and/or K37 are
more likely to impact nuclear import of PARP-2 than a
classical NES-mediated export process.
In order to further investigate the requirement for K3
and K37 in the nuclear localization of PARP-2, K → R si
gle mutants were created at each position. Interestingl
similar experiments performed with the wild type and th
single mutants of PARP-2 possessing K36R and K37R su
stitutions revealed, that both mutants were stab
expressed at levels comparable to wild type PARP-2 an
that only lysine 36 was important for the nuclear accum
lation of PARP-2 (Fig. 4A and 4B). In contrast to earli
reports [11], no nucleolar staining was observed under th
tested conditions. These experiments identified K36 as a
important residue for the nuclear localization of PARP
in vivo.
Lysine 36 but not lysine 37 of PARP-2 is critical for nuclearlocalizationFigure 4
Lysine 36 but not lysine 37 of PARP-2 is critical for 
nuclear localization. A) HA-tagged wild type (wt) PARP-
or the indicated single mutants were expressed in HEK293
cells and expression was analyzed by western blot using a 
monoclonal anti-HA antibody. 50 μg of whole cell extracts 
were used, endogenous PARP-1 levels served as loading co
trol. B) HEK293T cells were transfected with HA-tagged 
wild type (wt) PARP-2 or with the PARP-2 mutants K36R 
and K37R. HA-tagged proteins were detected by immunofl
orescence as described for Figure 2A. Representative image
are presented.
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Leptomycin B does not alter localization of the PARP-2 mutant K36/37RFigure 3
Leptomycin B does not alter localization of the 
PARP-2 mutant K36/37R. HEK293T cells were trans-
fected with HA-tagged wild type (wt) PARP-2 (upper panel) 
or with the mutant K36/37R (lower panel) and treated with 
Leptomycin B (LMB) to inhibit nuclear export, followed by 
immunofluorescence as described in Fig. 2. Representative 
images are presented.85
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Lysine 36 is important for binding to importin α3
One possibility to confirm the functional cNLS targeting
ing pocket [27]. This interaction is not exceptionally
strong because cNLS cargos can still bind to importin α in
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sequence is to perform interaction studies with the classi-
cal NLS import receptor, importin α. In order to test
whether PARP-2 interacts with importin α, we performed
GST pull-down experiments with different recombinant
purified GST-fusion proteins of human importin α (α1,
α3, α5 and α7; Fig. 5A) and cell extracts containing over-
expressed wild type or different mutated PARP-2 proteins.
PARP-2 was detected in the bound fraction following the
pull-down assay by western blot analysis. Wild type PARP-
2 formed a complex with importin α3 and to a very weak
extent also with importin α1 and importin α5, but not
with importin α7 (Fig. 5B). Experiments with purified
wild type and mutated PARP-2 (K36/37R, K36R and
K37R) revealed that the mutant proteins K36/37R and
K36R did not bind importin α3, while the K37R mutant
did bind, suggesting that K36 is a critical residue of PARP-
2 essential for its interaction with importin α3 and its
nuclear translocation (Fig. 5C and 5D).
Discussion
PARP-2 regulates different cellular functions. Here, we
provide both biochemical and functional evidence that
substitution of lysine residue 36 efficiently inhibits local-
ization of PARP-2 to the nucleus. Functional analyses
revealed that lysine 36 is important for complex forma-
tion with importin α3.
Lysine residues are central components of classical NLS
motifs (reviewed by [25]) as their positive charge medi-
ates the interaction with importin receptors [26]. Here we
provide evidence that K36 of PARP-2 is an important res-
idue required for the nuclear translocation of PARP-2 and
for complex formation with importin α3, as mutation of
this residue was sufficient to disrupt association with the
import machinery and subsequently alter PARP-2 nuclear
localization. Interestingly, lysine 36 is conserved between
mouse and human PARP-2, suggesting that the described
findings might also apply for the human counterpart.
Together, our data indicate that the nuclear import of
human and murine PARP-2 is mediated by a conserved
classical monopartite NLS but not through a bipartite NLS
as previously proposed [11].
The formation of the importin-α/β-cNLS cargo ternary
complex is the first step in the nuclear transport of hun-
dreds of different nuclear proteins, and, as such, is tightly
regulated [15]. The relationship of importin α/β with its
cNLS cargo is by necessity bipolar, because it forms highly
selective and tight complexes in the cytoplasm and then
switches to an extremely low affinity state in the nucleus
to release the cargo. When importin α is not bound to
importin β, an autoinhibitory sequence within the amino-
terminal domain apparently interacts with the NLS-bind-
the absence of importin β, albeit with significantly low
affinity. The order of importin α binding to cNLS carg
and importin β is not known. The observed lack of impo
tin α3 binding by the PARP-2 mutant (K36R) clearly ind
cates that this lysine is required for the interaction wi
importin α and subsequently for nuclear translocation.
Recently, it has become evident that importin α recepto
have independent roles in the assembly of macromolec
lar structures. Genetic analyses of yeast importin 
mutants identified several alleles that confer defects 
chromosome and nuclear segregation, altered mitot
spindle structure and deficits in the ubiquitin-mediate
protein degradation pathway [28-31]. Mechanistic studi
on the roles of importin αs in mitosis, spindle assemb
and nuclear envelope biogenesis point more directly 
activities which are independent of the housekeepin
roles of importin α in nuclear transport. The observe
interaction of PARP-2 with importin α might thus n
only be important for its nuclear translocation but mig
have an additional physiological function in maintainin
the integrity of the genome. Inactivation of the parp
gene in mice revealed that PARP-2 may be involved in th
surveillance and maintenance of genome integrity, ind
cated by the sensitivity of these mice to ionizing radiatio
[7].
Others have reported that PARP-2 is enriched within th
whole nucleolus and partially colocalizes with the nucl
olar factor nucleophosmin/B23 [11]. Using partial cDN
fragments in-frame with the carboxy-terminus of EGF
the authors described a putative nuclear localization si
nal and a nucleolar localization signal within the amin
terminal domain of PARP-2 (aa 1–69). Our studi
revealed that overexpressed PARP-2 was only foun
equally distributed in the nucleus, but in contradiction 
this previous report, was never observed in the nucleolu
of the cell. This discrepancy could be explained by the d
ferent experimental approaches used. Meder et al. studie
the nucleolar localization of PARP-2 with GFP-fusion pr
teins, while our studies were performed with non-GF
tagged full-length proteins. Remarkably, PARP-1 nucle
lar accumulation was not observed when endogenous 
overexpressed PARP-1 localization was analyzed by a co
ventional immunofluorecence protocol as described 
Methods using specific anti-PARP-1 antibodies (data n
shown). Only applying the fixation protocol described 
Meder et al. [11], which led to the decomposition of th
cell and loss of cytoplasm, revealed the reported nucleol
staining of PARP-1, suggesting that the fixation protoc
influences the nucleolar localization of proteins or th
detection of proteins within the nucleolus.86
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Lysine 36 of PARP-2 is necessary for the binding of PARP-2 to importin α3Figure 5
Lysine 36 of PARP-2 is necessary for the binding of PARP-2 to importin α3. A) Importins α1, α3, α5 and α7 were 
expressed as GST-fusion proteins in E. coli and purified with Glutathione Sepharose 4B beads. Expression was checked by SDS-
PAGE followed by Coomassie staining. B) PARP-2 binds mostly to importin α3 and to a lower extent to importin α1 and α5. 
Purified GST-importins were incubated with whole cell extracts from HEK293T cells, either untransfected or transfected with 
wild type HA-PARP-2, then western blot analysis was performed using an anti-HA antibody. C) Lysines 36/37 are required for 
the binding of PARP-2 to importin α3. Purified GST-importin α3 was incubated with whole cell extracts from HEK293T cells 
transfected with either wild type (wt) HA-PARP-2 or with the indicated double and quadruple mutants. Proteins were sepa-
rated by SDS-PAGE and analyzed by western blot using an anti-HA antibody. D) Lysine 36 but not lysine 37 is required for the 
binding of PARP-2 to importin α3. GST-importin α3 was bound to Glutathione Sepharose 4B and incubated with whole cell 
extracts from HEK293T cells expressing either wild type (wt) PARP-2 or the indicated single mutants. PARP-2 bound to 
importin α3 was detected using an anti-HA antibody.
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Recently, acetylation of lysine residues by histone acetyl-
transferases (HATs), such as p300/CBP (CREB-binding
secondary antibodies in the presence of 2% BSA/0.1% Tri-
ton X-100 according to the manufacturer's protocol (Cov-
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protein) and PCAF (p300/CBP-associated factor), has
been proposed as a new mechanism for modulating cellu-
lar localization [32-36]. HATs trigger the transfer of an
acetyl group from acetyl coenzyme A to the epsilon-amino
group of a lysine residue not only on core histones but
also on about 40 transcription factors and on more than
30 other proteins [37]. We recently published that both
lysines 36 and 37 of PARP-2 are indeed acetylated in vitro
and in vivo and that acetylation influences both DNA
binding and auto-ADP-ribosylation of PARP-2 [38].
Conclusion
Taken together, our results provide evidence that PARP-2
accumulates in the nucleus and that lysine 36, which is
located within a monopartite cNLS, is important for bind-
ing of PARP-2 to importin α3 and for the nuclear translo-
cation of PARP-2.
Methods
Plasmids
Mammalian expression vectors for wild type PARP-2 and
all mutants used in this study were obtained by cloning
the corresponding PCR products into pphCMV-HA.
PARP-2 mutants were generated by a site directed muta-
genesis procedure and confirmed by sequencing. Bacterial
expression vectors for human GST-importins α1, α3, α5
and α7 were provided by Dr. Riku Fagerlund (Depart-
ments of Viral Diseases and Immunology and Epidemiol-
ogy and Health Promotion, National Public Health
Institute, FIN-00300, Helsinki, Finland, [39]).
Expression and purification of recombinant proteins
GST-tagged importins were expressed in E. coli strain
BL21-D3-Gold. All purified proteins were analyzed by
Coomassie staining and confirmed by western blot analy-
sis using the corresponding antibodies.
Cell culture and transient transfections, treatment with 
LMB and immunofluorescence
HEK293T cells were grown in Hepes-buffered DMEM-
Glutamax-I (Invitrogen) containing 4.5 g/L glucose and
10% FCS US/certified (Invitrogen) and supplemented
with 50 U/ml penicillin, 50 μg/ml streptomycin (Invitro-
gen) and MEM non-essential amino acids (MEM NEAA,
Invitrogen). Cells were transfected using calcium phos-
phate procedures as described in [40]. For the experiments
with Leptomycin B (LMB), cells were treated with a final
concentration of 20 ng/ml LMB for 4–16 hrs. For detec-
tion of overexpressed proteins by immunofluorescence,
HEK293T cells were fixed for 10 minutes in ice-cold 100%
methanol in the absence of detergents and unspecific
binding sites were blocked with 2% BSA/0.1% Triton X-
100 prior to staining with primary and FITC-conjugated
ance) using confocal (Leica SP2, 40× oil-immersion, N
1.25, zoom-in) or standard fluorescence microscop
(Olympus Mx51, 100× oil-immersion, NA 1.3).
Western blot analysis and antibodies
Western blot analyses were performed as described prev
ously [41]. Anti-myc-9E10 (sc-2027) antibodies we
obtained from Santa Cruz Biotechnology, anti-HA (MM
101P) was obtained from COVANCE. Antibodies again
mouse PARP-1 and PARP-2 were generated in house (th
generation of antibodies against mouse PARP-1 has bee
described previously [42,43]).
In vitro interaction and GST pull-down assays
Purified recombinant proteins fused to GST were boun
to Glutathione Sepharose 4B according to the manufa
turer's protocols (Amersham Biosciences). GST pull-dow
assays were performed as described previously [41,42
GST pull-down-buffers contain: 50 mM Tris [pH 8.0], 15
mM NaCl, 0.5% NP-40, 0.5 mM DTT, 1 mM PMSF, 10
μM bestatin, 3 μM pepstatin A, 5 μM leupeptin. Boun
proteins were dissolved by SDS PAGE and subsequent
analyzed by western blot.
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Sumoylation of poly(ADP-ribose) polymerase 1 inhibits
its acetylation and restrains transcriptional
coactivator function
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ABSTRACT Poly(ADP-ribose) polymerase 1 (PARP1)
is a chromatin-associated nuclear protein and functions
as a molecular stress sensor. At the cellular level,
PARP1 has been implicated in a wide range of pro-
cesses, such as maintenance of genome stability, cell
death, and transcription. PARP1 functions as a tran-
scriptional coactivator of nuclear factor B (NF-B)
and hypoxia inducible factor 1 (HIF1). In proteomic
studies, PARP1 was found to be modified by small
ubiquitin-like modifiers (SUMOs). Here, we character-
ize PARP1 as a substrate for modification by SUMO1
and SUMO3, both in vitro and in vivo. PARP1 is
sumoylated at the single lysine residue K486 within its
automodification domain. Interestingly, modification
of PARP1 with SUMO does not affect its ADP-ribosy-
lation activity but completely abrogates p300-mediated
acetylation of PARP1, revealing an intriguing crosstalk
of sumoylation and acetylation on PARP1. Genetic
complementation of PARP1-depleted cells with wild-
type and sumoylation-deficient PARP1 revealed that
SUMO modification of PARP1 restrains its transcrip-
tional coactivator function and subsequently reduces
gene expression of distinct PARP1-regulated target
genes. Messner, S., Schuermann, D., Altmeyer, M.,
Kassner, I., Schmidt, D., Scha¨r, P., Mu¨ller, S., and
Hottiger, M. O. Sumoylation of poly(ADP-ribose) poly-
merase 1 inhibits its acetylation and restrains transcrip-
tional coactivator function. FASEB J. 23, 000–000
(2009). www.fasebj.org
Key Words: NAD  SUMO  hypoxia  PARP-1
Poly(ADP-ribose) polymerase 1 (PARP1) is an abun-
dant nuclear chromatin-associated multifunctional en-
zyme found in higher eukaryotes that belongs to a
family of 5 “bona fide” PARP enzymes (1). PARP1 has an
amino-terminal DNA-binding domain (DBD) contain-
ing 3 zinc finger motifs, as well as a central automodi-
fication domain (AMD), which functions as a target of
direct covalent automodification. The carboxyl-termi-
nal catalytic domain polymerizes linear or branched
chains of ADP-ribose from the donor nicotinamide
adenine dinucleotide (NAD). ADP-ribose is mainly
attached on PARP1, but also other proteins are modi-
fied (2). Together, the DBD and the automodification
domain allow PARP1 to interact with genomic DNA
and chromatin. Although originally characterized as a
key factor in DNA single strand-break repair, a wealth
of studies over the past decade have demonstrated a
role of PARP1 in the regulation of gene expression
under basal, signal-activated, and stress-activated condi-
tions (1, 3). Recent studies have highlighted the role of
PARP1 in distinct modes of transcriptional regulation
and provided novel insight into the cellular signaling
systems that interface with PARP1 in the nucleus (4).
The basal enzymatic activity of PARP1 is very low, but
it is stimulated dramatically under conditions of cellu-
lar stress (2, 3). Activation of PARP1 results in the
synthesis of poly(ADP-ribose) (PAR) from NAD and
the release of nicotinamide as a reaction by-product
(1). Following PARP1 activation, intracellular PAR lev-
els can rise 10- to 500-fold (1), caused by a mechanism
that remains to be resolved. Very recently, we identified
3 lysine residues in the automodification domain of
PARP1 as acceptor sites for auto-ADP-ribosylation (5).
PARP1 is the main acceptor for poly(ADP-ribosyl)ation
in vivo, and automodification of PARP1 abolishes its
affinity for NAD and DNA (5). Remarkably, the same
3 ribosylated lysines (K498, K521, K524) were previ-
ously identified as targets for acetylation by the histone
acetyltransferase p300 (6). Acetylation of PARP1 has
been reported to be important for its transactivation
activity (6). Recently, we also highlighted the role of
PARP1 as a transcriptional coactivator of hypoxia in-
ducible factor 1- (HIF1-). On hypoxic induction of
cells, PARP1 was shown to interact with HIF1- and to
regulate the transcriptional activity of HIF1--depen-
dent genes (7).
1 Correspondence: Institute of Veterinary Biochemistry and
Molecular Biology, University of Zurich, Winterthurerstrasse
190, 8057 Zurich, Switzerland. E-mail: hottiger@vetbio.uzh.ch
doi: 10.1096/fj.09-137695
10892-6638/09/0023-0001 © FASEB
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is no evidence to link macrodomains to the binding of ADPR moieties 
in mono-, oligo- and poly-ADP-ribosylated (n-ADP-ribosyl) PARP1. 
Furthermore, because the splice variant macroH2A1.2 cannot bind 
ADPR, it might differ in its interaction with n-ADP-ribosyl-PARP1. 
We thus set out to test whether macrodomains recognize nuclear sites 
in human cells with high PAR metabolism, such as sites where  activated 
PARP1 n-ADP-ribosylates target proteins or, alternatively, where PARG 
mediates the rapid degradation of PAR to ADPR, thus producing a 
 transiently high, local ADPR concentration.
RESULTS
The macrodomain senses PARP1 activation
Distinct mechanisms activate PARP1, many of which do not involve 
DNA damage. However, to test whether macrodomains recruit to 
nuclear regions where PAR is generated, accumulates and is  subsequently 
degraded to ADPR, we took advantage of a robust model system that 
activates PARP1 using pulsed-laser DNA microirradiation,  providing 
a convenient  readout for transient PAR accumulation11,12 within a 
 spatially defined region (the ‘laser cut’). We therefore used a ‘low’ 
laser power to microirradiate HeLa nuclei expressing  fluorescent 
protein–tagged full-length Af1521 and macroH2A1.1  macrodomain 
(in the absence of  macroH2A’s histone fold region; note that HeLa 
and other  proliferating cells do not express  detectable amounts 
Post-translational modifications, ATP-dependent remodelers, histone 
variants and histone H1 dynamically alter chromatin structure1. One of 
the oldest and least understood post-translational modifications is the 
poly-ADP-ribosylation (PARylation) of proteins, including histones, a 
modification that is mediated by poly-ADP-ribose (PAR) polymerases 
including PARP1 and PARP2 (refs. 2,3). Nuclear PARP1 is the main PAR 
acceptor, and its activity is induced by stress-response pathways, such as 
metabolic stress, mitogen-activated protein kinase (MAPK) signaling, 
DNA breaks4, promoter–stem-loop and cruciform DNA structures and 
changes in polyamines, as well as Mg2+ and Ca2+ concentration5. Genetic 
and biochemical data indicate that PAR has roles in chromatin biology, 
differentiation and apoptosis2,3.
PARP1 activation by stress-response pathways motivated the search for 
proteins that recognize PAR. PAR-binding linear motifs and atypical zinc 
fingers have been described6, but no globular protein module—typical 
of signaling pathways—has been identified. We reported that globular 
macrodomains, including those in histone macroH2A1.1, bind NAD+ 
metabolites related to ADP-ribose (ADPR), a PAR  metabolite produced 
by PAR glycohydrolase (PARG), and O-acetyl-ADPR, which is produced 
by sirtuins7. However, slot-blot assays suggested that  macroH2A1.1 
 macrodomains do not bind PAR, whereas  archaebacterial Af1521 
 macrodomains retain PAR7. Thus, despite biochemical data  implicating 
macroH2A or its C-terminal macrodomain in PARP1  binding7–10, there 
A macrodomain-containing histone rearranges  
chromatin upon sensing PARP1 activation
Gyula Timinszky1,6, Susanne Till1,6, Paul O Hassa1,6, Michael Hothorn2,5,6, Georg Kustatscher1,5,  
Bianca Nijmeijer1, Julien Colombelli3,5, Matthias Altmeyer4, Ernst H K Stelzer3, Klaus Scheffzek2,  
Michael O Hottiger4 & Andreas G Ladurner1,2
Poly-ADP-ribosylation is a post-translational modification catalyzed by PARP enzymes with roles in transcription and chromatin 
biology. Here we show that distinct macrodomains, including those of histone macroH2A1.1, are recruited to sites of PARP1 
activation induced by laser-generated DNA damage. Chemical PARP1 inhibitors, PARP1 knockdown and mutation of ADP-ribose–
binding residues in macroH2A1.1 abrogate macrodomain recruitment. Notably, histone macroH2A1.1 senses PARP1 activation, 
transiently compacts chromatin, reduces the recruitment of DNA damage factor Ku70–Ku80 and alters γ-H2AX patterns, whereas 
the splice variant macroH2A1.2, which is deficient in poly-ADP-ribose binding, does not mediate chromatin rearrangements upon 
PARP1 activation. The structure of the macroH2A1.1 macrodomain in complex with ADP-ribose establishes a poly-ADP-ribose cap-
binding function and reveals conformational changes in the macrodomain upon ligand binding. We thus identify macrodomains as 
modules that directly sense PARP activation in vivo and establish macroH2A histones as dynamic regulators of chromatin plasticity.
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Abstract 
 
BACKGROUND & AIMS: The immune system comprises an innate and an adaptive 
immune response to combat pathogenic agents. The human enteropathogen Salmonella 
enterica serovar Typhimurium invades the intestinal mucosa and triggers an early innate 
pro-inflammatory host gene response, which results in diarrheal disease. 
Several host factors are involved in the acute early response to Salmonella infection. 
Transcription factors and transcription co-regulators have an especially important function, 
because they are required for the expression and synthesis of pro-inflammatory cytokines, 
chemokines and adhesion molecules. A central transcription factor involved in 
inflammation is NF-κB, which requires the nuclear protein PARP1 as co-factor for the 
expression of some of its target genes. Here, we investigated the role of PARP1 during 
Salmonella infection. 
METHODS: To study enterocolitis by Salmonella Typhimurium, the streptomycin mouse 
model system was employed. Histopathologic signs of inflammation and cecum 
colonization at various time-points after infection of wild type and PARP1 knockout mice 
were analyzed. PARP1 expression in the gut mucosa was studied by quantitative RT-PCR, 
Western blot and immunofluorescence. Gene expression profiles of infected and control 
infected mice in the wild type or PARP1 knockout background were obtained by whole 
mouse genome arrays and confirmed by quantitative RT-PCR. 
RESULTS: PARP1 is expressed in the proliferative zone of cecum crypts and is associated 
with a faster pro-inflammatory response after Salmonella infection. The accelerated 
PARP1-dependent host response involves higher expression of pro-inflammatory genes, 
many of which are related to IFNγ signaling, and more severe inflammation with increased 
infiltration of immune cells. 
CONCLUSION: PARP1 facilitates pro-inflammatory gene expression, which accelerates 
Salmonella-induced inflammation. 
 
Keywords: PARP-1; Salmonella Typhimurium; colitis; inflammation 
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Introduction 
 
The innate immune system constitutes the first line of host defense during infection. Innate 
immunity is therefore crucial for the early recognition of invading pathogens and for the 
subsequent pro-inflammatory response 1. Recognition of pathogen-associated molecular 
patterns (PAMPs) is achieved by pattern recognition receptors (PRRs), such as the family 
of Toll-like receptors (TLRs) 2. Upon PAMP recognition, PRRs trigger pro-inflammatory 
and anti-microbial responses by activating a multitude of intracellular signaling pathways 
and inducing inflammation-related transcription factors 3. Ultimately, this results in the 
expression and synthesis of a broad range of molecules, including cytokines, chemokines, 
and adhesion molecules, which together orchestrate the early host response to infection and 
significantly contribute to inflammation.  
 The intestinal mucosa is constantly exposed to numerous microbes, some of which 
may be pathogenic. Whereas in the absence of pathogens the healthy intestine is 
characterized by homeostasis of the immune system with the commensal microbial flora, in 
the presence of pathogens this homeostasis is disturbed. In such a situation of acute 
infection, pro-inflammatory responses are triggered by the innate immune system to limit 
infection.  
The human enteropathogen Salmonella enterica subspecies 1 serovar Typimurium 
(S. Typhimurium) invades the intestinal mucosa, causes self-limiting gut infection and 
elicits mucosal inflammation and diarrhea. Salmonella infection is a global threat to human 
health, but the molecular mechanisms underlying Salmonella-induced enteric diseases are 
not sufficiently understood. A mouse model system to study S. Typhimurium 
enteropathogenesis was described several years ago 4. In this model system, streptomycin-
pretreated mice develop severe colitis after infection with serovar Typhimurium, which 
largely resembles the human infection. The streptomycin-pretreated mouse model has been 
used frequently as an appropriate and well-established model system to study the 
mechanisms of pathogenesis and the host responses to acute enteric salmonellosis 5-9. 
The protein poly(ADP-ribose) polymerase 1 (PARP1) is an abundant nuclear 
chromatin-associated enzyme with a variety of cellular functions. PARP1 has been 
implicated in DNA damage signaling and repair, chromatin remodeling and transcriptional 
regulation 10. PARP1 knockout mice are viable and fertile, have normal life span and show 
no increase in spontaneous tumor frequency 11. They are, however, protected from tissue 
injury in various inflammation-related disease models ranging from myocardial infarction, 
streptozotocin-induced diabetes, to LPS-induced septic shock and arthritis 11-13. These 
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phenotypes suggest an important role for PARP1 during inflammation. The protective 
effects observed in PARP1 knockout animals correlate with the reduced expression of pro-
inflammatory cytokines under the control of the inducible transcription factor nuclear 
factor-kappaB (NF-κΒ) 14. In line with these observations, PARP1 was found to function as 
co-activator for NF-κB-dependent gene expression 15.  
Here, we investigated a possible role for PARP1 in Typimurium-induced colitis. 
Employing the streptomycin mouse model for enterocolitis, we analyzed the impact of 
PARP1 on the Salmonella-triggered innate immune response and early development of 
cecal inflammation. We demonstrate that PARP1 is strongly expressed in the proliferative 
zone of the cecum and is associated with a faster pro-inflammatory host response. This 
accelerated response involves higher expression of pro-inflammatory genes and more 
severe inflammation with increased infiltration of immune cells. Our findings link, for the 
first time, PARP1 to Salmonella-induced pro-inflammatory gene expression and suggest an 
important role for PARP1 in timing the host response to enteric Salmonella infection. 
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Materials and Methods 
 
Bacteria 
Salmonella Typhimurium (S.tm) strains were isogenic derivatives of the naturally 
streptomycin-resistant wild type strain SL1344 16. S.tmavir is SL1344, ΔinvG 17. Strains 
were grown at 37°C in LB (0.3M NaCl) overnight and subcultivated for 4 hours as 
described before 18. 
Mice 
Wild type and isogenic PARP1 knockout mice 11 were bred in a C57Bl/6J background. 
Regular back-crossings were performed to maintain isogenicity. Animals were genotyped 
by PCR (primer sequences for wild type: 5`-GTTGTGAACGACCTTCTGGG-3` and 5`-
CCTTCCAGAAGCAGGAGAAG-3`; primer sequences for PARP1 knockout: 5`-
GTTGTGAACGACCTTCTGGG-3` and 5`-GCTTCAGTGACAACGTCGAG-3`). All 
mice were bred and kept in a specified pathogen free area. Streptomycin pretreated mice 
(20 mg/animal) were infected by gavage (5 x 107 cfu) as published previously 4, 9. Live 
bacterial loads in cecal content were determined by plating 5, 9. Experiments were approved 
and performed as legally required (Licence 201/2007). 
Histology 
HE-stained cecum cryosections were scored as described, evaluating submucosal edema, 
PMN infiltration, goblet cells, and epithelial damage, yielding a total score of 0-13 points 4, 
5.  
Immunofluorescence Microscopy 
PARP1 and PAR were detected by immunofluorescence microscopy as described 19 using 
cryosections stained with rabbit anti-PARP1 antibody H-250 (Santa Cruz), mouse anti-
PAR antibody 10H (kindly provided by Dr. Alexander Bürkle), FITC-conjugated or Cy3-
conjugated secondary antibodies (Covance), and DAPI. Images were taken using an 
Olympus Mx51, NA 1.3 fluorescence microscope. 
Western Blot  
Cecum tissues were washed in ice-cold PBS, shock frozen in liquid nitrogen, mechanically 
pulverized and lysed in 50mM Tris-HCl pH 7.5, 400mM NaCl, 25mM NaF, 1% (v/v) 
Triton X-100. The lysate was used for standard Western blot procedures using anti-PARP1 
antibody H-250 (Santa Cruz) or anti-Tubulin (Sigma). 
RNA Isolation 
The intestinal tract was excised and the cecum was isolated. The cecum was then cut into 
four slices. Slices 1 and 3 were washed in cold PBS to remove cecum content and 
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afterwards frozen in liquid nitrogen in 300 µl RLT-buffer (RNeasy Mini Kit, Qiagen) with 
1% β-Mercaptoethanol and stored at -80°C till RNA-extraction. Frozen tissue was 
homogenized in RLT for 3 minutes at 25 Hz using a Tissue Lyser (Qiagen). RNA was 
processed using the RNeasy Mini Kit (Qiagen) and the RNase-Free DNase Set (Qiagen) 
according to the manufacturer’s instruction. Slices 2 and 4 were cryo-embedded for HE 
staining. 
Quantitative RT-PCR 
Total RNA isolated from cecum was reverse-transcribed using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) and used in quantitative real-time (RT) 
PCR. Reactions were performed with SensimixPlusSYBR (Quantace) and gene-specific 
primer pairs in Rotor-Gene3000 (Corbett Life Science). Rps12 was used to normalize for 
differences in cDNA input. RNA from n ≥ 5 individual mice per condition was pooled 
(except for the 12h time-point, where RNA from only 2 individual mice was pooled). All 
reactions were performed in triplicates. Primer pairs (5`-3`): 
mRps12: GAAGCTGCCAAAGCCTTAGA and AACTGCAACCAACCACCTTC 
mGAPDH: GCTACACTGAGGACCAGGTTG and GCCCCTCCTGTTATTATGGGGG 
mPARP1: GCAGTCACCCATGTTCGATGG and GCTTCTCTGGATCCACCATC 
mCxcl9: GGAGTTCGAGGAACCCTAG and CTTCTTCACATTTGCCGAGTCC 
mGbp2: CTTGAAGATGTTGAGAAGGGTGACAACC and GATCAGTTAGCTCCGTCACATAGTGC 
mCxcl10: GCACGAACTTAACCACCATCTTCC and CTACCCATTGATACATACTTGATGACAC 
mIigp1: GATAGTAGTGTGCTCAATGTTGC and GGTATATTGGGGTGTTTGTATGG 
mTgtp: CTCAGGGAGATCCAACTGTCCATCC and CTGTATGGTAGAAGCTCAGCAGTGG 
mIgtp: GCTTTGTAAGGCTTCTGAGCAGG and CTGATGAGGCGCTTGAGATAATTTGC 
mCd274: CTCCTCGCCTGCAGATAGTTCC and CTTCCTTTTCCCAGTACACCACTAACG 
mMpa2l: CTTGGAGAAGCCTACTTCGTCTCT and AAATCTGCCAGCAGACCCTAACCT 
mIFNg: CATGGCTGTTTCTGGCTGTTACTG and GTTGCTGATGGCCTGATTGTCTTT 
Whole mouse genome arrays 
Agilent whole mouse genome arrays 4x44K (Agilent Technologies) were used for the 
analysis of host gene expression profiles. Total RNA integrity was verified by capillary gel 
electrophoresis using the 2100 Bioanalyzer (Agilent Technologies). Microarray slides were 
scanned with an Agilent DNA Microarray scanner and the scans were quantified using the 
Agilent Feature Extraction software. Background subtraction and dye normalization for 
each array was performed within the Agilent Feature Extraction software with default 
settings. The quantified data was subsequently loaded into GeneSpring GX 10 for further 
analysis. Data from individual mice were grouped according to condition. For the 10h time-
point, data from two S.tmavir-infected and three S.tm-infected wild type mice were 
compared. For the 6h time-point, data from three S.tm-infected wild type and three S.tm-
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infected knockout animals were compared. P values were obtained by unpaired t-test using 
GeneSpring GX 10. Gene ontology (GO) and pathway analyses were also performed with 
GeneSpring GX 10.  
Statistical analysis 
Pathoscores were analyzed by Mann-Whitney-U-Test, gene expression data was analyzed 
by unpaired T-Test. Values p<0.05 were regarded statistically significant. 
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Results 
 
Salmonella Typhimurium induces colitis and a pro-inflammatory gene expression 
response in streptomycin pretreated mice 
To study the molecular mechanisms of the host response to enteric salmonellosis, we 
employed an established mouse model system for Salmonella-induced colitis, which relies 
on the treatment of mice with streptomycin prior to Salmonella infection 4. This system 
resembles key features of human gut infection by Salmonella enterica subspecies 1 serovar 
Typhimurium 4. We employed wild type S. Typhimurium (S.tm) and an isogenic serovar 
Typhimurium mutant SB161 (S.tmavir; SL1344 ΔinvG), which lacks an essential subunit of 
the SP1 type III secretion apparatus and therefore is incapable of actively invading the gut 
mucosa. The latter served as a negative control strain. Infection of streptomycin-pretreated 
wild type C57Bl/6J mice with wild type S.tm resulted in severe colitis 10h post infection 
(p.i.), with classical hallmarks of cecal inflammation including pronounced edema in the 
submucosa, disruption of the crypt architecture, loss of goblet cells, epithelial erosion and 
infiltration of polymorphonuclear granulocytes (PMNs) (Figure 1A and B). In contrast, and 
in line with earlier work 4, infection with the mutant S.tmavir did not trigger any measurable 
inflammatory response in the cecum by 10h p.i., although the cecum lumen was heavily 
colonized. 
In order to obtain insights into the Salmonella-induced changes at the level of host 
gene expression, we analyzed gene transcript profiles 10h p.i. by whole mouse genome 
arrays of cecum from C57Bl/6J mice infected with either wild type S.tm. or mutant S.tmavir. 
These microarray studies revealed that 2193 probes corresponding to 1684 genes were up-
regulated more than two-fold in S.tm infected mice as compared to S.tmavir infected control 
mice (Figure 1C and Supplementary Table 1). 2466 probes corresponding to 1964 genes, 
on the other hand, were down-regulated more than two-fold in S.tm infected mice 
(Supplementary Table 2). Whereas the up-regulated genes were mainly involved in the 
immune response as revealed by gene ontology analysis (Figure 1C and Supplementary 
Table 3), the down-regulated genes had more diverse functions not primarily related to 
immune system processes (Figure 1C and Supplementary Table 4). To confirm the 
microarray results by quantitative RT-PCR, we chose two representative up-regulated 
genes, the neutrophil chemoattractant protein Cxcl9 and the interferon-inducible, antiviral 
guanylate-binding protein 2 (Gbp2). Both genes were indeed highly induced by S.tm as 
compared to S.tmavir (Figure 1D). Thus, the severe inflammation caused by Salmonella 
Typhimurium correlates with pro-inflammatory gene expression 10h p.i.. 
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The protein family nuclear factor-kappaB (NF-κB) comprises an important group of 
inducible transcription factors involved in pro-inflammatory gene expression and is 
responsible for the expression of a plethora of cytokines, chemokines, adhesion molecules 
and inflammatory mediators 20. A pathway analysis of S.tm-induced genes suggested that 
NF-κB might be involved in the observed expression profile (Supplementary Table 5). 
Moreover, a search for NF-κB binding sites in the promoter regions of S.tm-induced genes 
identified NF-κB consensus binding sequences in 204 promoters, representing 12 % of all 
S.tm-induced genes. When restricting the search to the most up-regulated genes (with a fold 
induction of greater than 10), 25 % of the promoters contained NF-κB consensus binding 
sequences. Together, these analyses suggest an important role of NF-κB for Salmonella-
induced gene expression.  
NF-κB requires several co-activators and co-repressors for the regulation of target 
gene expression. PARP1 is one of the known transcriptional co-regulators of NF-κB and 
PARP1 knockout mice are protected from tissue injury in various inflammation-related 
disease models 21. This led us to hypothesize that PARP1 might also be important for S.tm-
induced colitis.  
 
PARP1 is expressed in the proliferative zone of cecum crypts 
We first analyzed whether PARP1 was expressed in the mouse cecum, where S.tm-
induced inflammation was most severe. PARP1 mRNA was detected in the cecum of wild 
type but not isogenic PARP1 knockout mice as revealed by quantitative RT-PCR (Figure 
2A). PARP1 was also detected at the protein level by Western blot analysis of cecal 
extracts (Figure 2B). Immunofluorescence staining confirmed PARP1 expression in the 
cecum, predominantly in the proliferative zone of the crypts, whereas PARP1 was absent in 
knockout animals (Figure 2C).  
After having confirmed that PARP1 was expressed in the mouse cecum, we 
infected wild type and PARP1 knockout mice with either wild type S.tm or with the mutant 
strain S.tmavir. Neither PARP1 mRNA nor protein levels changed in the cecum of wild type 
animals after S.tm infection (Supplementary Figure 1A and data not shown). Although we 
were able to detect poly(ADP-ribose), the reaction product of PARP1, in H2O2-treated 
transformed gastric epithelial cells (Supplementary Figure 1B), we were not able to detect 
poly(ADP-ribose) in cecum cryosections at 6h to 12h after Salmonella infection 
(Supplementary Figure 1C). Thus, neither PARP1 expression nor its catalytic activity is 
significantly altered after S.tm infection. 
 
103
 10 
PARP1 accelerates Salmonella-induced inflammation 
Next, we analyzed S.tm-induced pathology in wild type and PARP1 knockout mice, 
which had been sacrificed 6h, 8h, 10h, or 12h p.i.. Whereas at 6h p.i., neither the wild type 
nor the PARP1 knockout animals showed signs of mucosal pathology when infected with 
S.tm, at 8h p.i. the wild type mice showed considerable signs of inflammation (Figure 3A, 
black symbols). Strikingly, PARP1 knockout animals had significantly lower pathoscores 
at this time-point. Submucosal edema, partly disrupted crypts, beginning erosion of the 
epithelium and loss of goblet cells were observed in wild type mice but were significantly 
less pronounced in knockout mice 8h p.i. (Figure 3B). At 10h p.i., first signs of 
inflammation were also observed in PARP1 knockout mice (Figure 3A). The difference 
between wild type and PARP1 knockout animals was eventually lost 12h p.i. (Figure 3A). 
Thus, we observed a significant delay in the host response to Salmonella Typhimurium 
infection in PARP1 knockout mice as compared to wild type control animals. This delay 
was not due to differences in cecum colonization, because wild type and isogenic PARP1 
knockout mice had comparable bacteria loads (Figure 3C). Neither wild type nor PARP1 
knockout mice reacted to the S.tmavir control strain with an inflammatory response (Figure 
3D), but S.tmavir was able to colonize the cecum lumen of wild type and knockout mice as 
efficiently as S.tm (Figure 3E). We therefore conclude that PARP1 knockout animals have 
a specific defect in the early pro-inflammatory response. Accordingly, PARP1 is a novel 
host factor, which accelerates inflammation caused by Salmonella Typhimurium infection. 
To assess if the accelerated inflammation observed in PARP1 proficient mice was a 
consequence of increased production of cytokines, we analyzed pro-inflammatory gene 
expression in cecum preparations from wild type and PARP1 knockout mice by 
quantitative RT-PCR. Remarkably, the expression of Cxcl9 and Gbp2 was robustly 
increased at 6 and 8h p.i. in ceca from wild type mice but not from PARP1 knockout 
animals (Figure 3F). In line with the histopathologic data, both genes were almost as 
efficiently transcribed in knockout animals as compared to wild type controls at the later 
time-points 10 and 12h p.i. (Figure 3F). Together, these data suggest an impaired 
immediate gene expression response to S. Typhimurium infection in PARP1 knockout 
mice. 
 
PARP1 is required for the efficient expression of a subset of Salmonella-induced genes 
No signs of inflammation could be observed by histopathologic analysis of the 
cecum of wild type or PARP1 knockout animals at the earliest time-point we investigated 
(6h p.i.). The pro-inflammatory gene expression at this time-point therefore most likely 
104
 11 
represents an early, primary host response of the mucosal epithelial cell layer to the 
invading pathogen, which precedes and is still independent of the infiltration of immune 
cells. We thus decided to focus on this early time-point to study the mechanism, which 
might be responsible for the delayed onset of colitis in PARP1 knockout mice. 6h p.i., the 
basal levels of pro-inflammatory genes in control-infected animals were normal in mice 
lacking PARP1 (Figure 3F). Moreover, so-called housekeeping genes like GAPDH were 
also expressed normally in PARP1 knockout mice (Supplementary Figure 2). However, the 
induction of Cxcl9 and Gbp2 after S.tm infection was clearly reduced in knockout animals 
already at this early time-point, strongly suggesting that the immediate gene expression 
response of the host tissue was impaired. To determine the extend of pro-inflammatory 
genes, which depend on PARP1 for efficient expression after Salmonella infection, whole 
genome arrays from wild type and PARP1 knockout mice infected with S.tm for 6h were 
performed. We were primarily interested in genes, which were induced by S.tm (Figure 1C) 
and showed reduced expression in PARP1 knockout animals. 65 genes fulfilled these 
criteria, as they were Salmonella-induced and showed at least a 1.5-fold reduction in S.tm-
infected PARP1 knockout mice as compared to S.tm-infected wild type animals (Figure 4A 
and Supplementary Table 6). In contrast, only 4 genes were repressed by Salmonella 
infection and lower expressed in PARP1 knockout mice as compared to wild type controls. 
Thus, of the 1684 genes, which showed an up-regulation 10h after Salmonella infection, 65 
genes, or 3.86%, were dependent on PARP1 at 6h p.i. (Figure 4B). This suggests, that 
PARP1 acts as transcriptional co-activator for a defined subset of Salmonella-induced 
genes. A gene ontology analysis revealed that many of these PARP1-dependent genes are 
involved in the immune response (Figure 4C and Supplementary Table 7) and, according to 
a pathway analysis, are related to IFNγ signaling (Figure 4D and Supplementary Table 8). 
In detail, besides Cxcl9 and Gbp2, these genes include interferon-inducible protein 10 (IP-
10/Cxcl10), interferon-inducible GTPase 1 (Iigp1), T-cell specific GTPase (Tgtp), IFNγ-
induced GTPase (Igtp), CD274 antigen, macrophage activation 2 like (Mpa2l), and others 
(Supplementary Table 6). When we directly tested IFNγ transcript levels after S.tm 
infection in wild type and PARP1 knockout animals by quantitative RT-PCR, we found a 
slight but not significant difference in IFNγ gene expression, suggesting that IFNγ levels 
per se may not be the primary cause for the impaired expression of some IFNγ-related 
genes in PARP1 knockout mice (Figure 5A). We confirmed several PARP1 dependent 
genes 6h p.i. by quantitative RT-PCR and also extended the analysis to the 8h time-point. 
In confirmation of the microarray results, many tested genes showed a clear dependence on 
PARP1 for efficient transcription 6h after infection (Figure 5B), and in line with the 
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pathological differences between wild type and PARP1 knockout mice 8h p.i., all genes 
were greatly reduced in knockout animals at this later time-point (Figure 5C). A summary 
of all analyzed genes is provided in Table 1. Together, our data provide evidence that 
PARP1 is required for the efficient expression of a subset of Salmonella-induced genes in 
vivo. Efficient PARP1-dependent expression of these genes likely contributes to the 
activation of resident immune cells and/or recruitment of inflammatory cells to trigger an 
inflammatory response. Thus, our data identify PARP1 as a host factor controlling the early 
phase of Salmonella-induced inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106
 13 
Discussion  
 
Here we show that the nuclear protein PARP1 is linked to salmonellosis. In an in vivo 
mouse model system for Salmonella-induced colitis, we demonstrate that PARP1 is a novel 
host factor, which accelerates inflammation after Salmonella infection. PARP1 is 
predominantly expressed in the proliferative zone of the crypts and is required for the 
efficient early expression of several Salmonella-induced pro-inflammatory genes. Reduced 
early pro-inflammatory gene expression in mice lacking PARP1 correlates with and may be 
causally responsible for delayed infiltration of immune cells and consequently delayed 
onset of inflammation. Together, our findings reveal that PARP1 is required for an efficient 
early innate immune response against Salmonella infection. 
 While we observed a significantly reduced pro-inflammatory response in PARP1 
knockout mice at early time-points after Salmonella infection, PARP1 knockout animals 
also developed severe colitis later on. Therefore, the innate immune system does not 
completely rely on PARP1-dependent mechanisms, but instead can compensate for the lack 
of PARP1 at later time-points. We would speculate that the immune system senses the 
dampened response to Salmonella infection in the absence of PARP1 and then triggers 
delayed compensatory, PARP1-independent mechanisms to achieve an adequate host 
response. 
The function of PARP1 as transcriptional co-regulator is now well established 21. 
Besides NF-κB, also other transcription factors, including nuclear factor of activated T 
cells (NFAT), activator protein-1 (AP-1), forkhead box O transcription factor 1 (FOXO1), 
and nuclear respiratory factor 1 (NRF-1), were described to depend on PARP1 for efficient 
target gene expression 22-25. PARP1-dependent genes typically are not completely silenced 
in cells lacking PARP1, but instead show a 30-70% reduced expression (own unpublished 
observation). Moreover, PARP1 seems to be more important for induced gene expression 
after cell stimulation as compared to basal gene expression under non-stimulated 
conditions. For example, in a study by Saenz et al., only 93 genes (0.66%) were found 
differentially expressed under normal conditions in wild type and PARP1 knockout T cells, 
while 203 genes (1.44%) were found differentially expressed after anti-CD3/anti-CD28 
stimulation 26.  
IFNγ is the sole type II interferon and an important mediator of immunity and 
inflammation 27. Consequently, IFNγ is found among the cytokines whose expression is 
most prominently induced during Salmonella infection 28. We observed increased IFNγ 
expression after Salmonella infection by both microarray analysis and quantitative RT-
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PCR. Production of IFNγ in the early phase of intestinal inflammation contributes to 
antimicrobial responses in the intestinal mucosa 29 and may be required to amplify initial 
responses generated by bacterial host cell interaction 28. Moreover, IFNγ priming increases 
TLR expression, promotes NF-κB activation, and induces transcription factors, which are 
essential for expression of certain TLR-responsive genes 27. Our data revealed that a subset 
of IFNγ response genes requires PARP1 for early efficient expression. These genes may be 
driven by NF-κB alone or may require multiple transcription factors, possibly including 
NF-κB, STAT-1, and IRFs, at their promoter sites for efficient expression after Salmonella 
infection. Many of the identified genes, including Cxcl9, Cxcl10, Iigp1 and Cd274, are 
reported NF-κB target genes or contain κB-sites (http://people.bu.edu/gilmore/nf-
kb/index.html and data not shown). In line with the notion that NF-κB may be involved in 
the regulation of PARP1-dependent IFNγ response genes, STAT-1, the primary 
transcription factor down-stream of IFNγ signaling, is often necessary but not sufficient for 
transcription of target genes 30, 31. In fact, the ability of STAT-1 to activate gene expression 
often depends on the presence of other transcription factors binding to the promoter 
element 32. Thus, in many cases, synergistic gene induction by a combination of pro-
inflammatory stimuli may be a result of the combined presence of STAT-1 and NF-κB at 
the promoter elements of responsive genes.  
In conclusion, our data directly link PARP1 to the pathogenesis of Salmonella-
induced inflammation and provide a plausible mechanistic explanation how PARP1 
accelerates colitis. These findings increase our understanding on how the nuclear multi-
functional protein PARP1 is involved in pro-inflammatory gene expression and how it is 
implicated in pro-inflammatory diseases. Our results also shed light on the regulation of the 
early host response after Salmonella infection and may prove beneficial for the design of 
new therapeutic strategies to combat salmonellosis. 
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Figure Legends 
 
Figure 1: Salmonella-induced inflammation 10h post infection in wild type mice. (A) 
Signs of inflammation and cecum colonization were analyzed in wild type C57Bl/6J mice 
infected with Salmonella strain S.tmavir or S.tm. Cecal pathology was scored and bacteria 
loads were determined as described in the Methods section. n=5 animals in each group 
were analyzed. Medians are indicated. (B) Representative HE-stained cecum cryosections. 
L, lumen; g, goblet cell; SM, submucosa; e, edema; er, erosion of the epithelial layer. Bar = 
100µm. (C) Whole mouse genome array data from wild type mice infected with either 
S.tmavir or S.tm for 10h. Total numbers of up-regulated genes (>2-fold, p<0.05) and down-
regulated genes (>2-fold, p<0.05) are indicated. Highest scoring GO-terms for up-regulated 
genes (top) and down-regulated genes (bottom) are listed. (D) Quantitative RT-PCR 
confirmation for the indicated genes. Values obtained for S.tmavir-infected mice were set 1. 
Reactions were performed in triplicates, mean values ± SD are shown. 
 
Figure 2: PARP1 is expressed in the proliferative crypts of the cecum. (A) Quantitative 
RT-PCR analysis of PARP1 mRNA levels in mouse cecum from wild type (wt) and 
PARP1 knockout (ko) mice. Wild type mRNA expression levels were set 1. Reactions were 
performed in triplicates, mean values ± SD are shown. (B) Western blot analysis of PARP1 
protein expression in mouse cecum from wild type and PARP1 knockout mice. (C) PARP1 
immunofluorescence in cecum cryosections from wild type and PARP1 knockout mice. L, 
lumen. Bar = 100µm. 
 
Figure 3: PARP1 accelerates Salmonella-induced inflammation. (A) Histopathologic 
analysis of wild type (wt) and isogenic PARP1 knockout (ko) mice after 6h (n=8 per 
group), 8h (n=15 for wt, n=12 for ko), 10h (n=5 per group), and 12h (n=2 per group) after 
S.tm infection. Medians are indicated. p-values were obtained by Mann-Whitney-U-Test. 
(B) Representative HE-stained cecum cryosections 8h after S.tm infection. L, lumen; g, 
goblet cell; SM, submucosa; er, erosion of the epithelial layer. Bar = 100µm. (C) Cecum 
colonization of wild type and PARP1 knockout mice after 6h (n=8 per group), 8h (n=15 for 
wt, n=12 for ko), 10h (n=5 per group), and 12h (n=2 per group) after S.tm infection. 
Medians are indicated. (D) Histopathologic analysis of wild type and PARP1 knockout 
mice after 6h (n=8 per group), 8h (n=15 for wt, n=12 for ko), 10h (n=5 per group), and 12h 
(n=2 per group) after S.tmavir infection. Medians are indicated. (E) Cecum colonization of 
wild type and PARP1 knockout mice after 6h (n=8 per group), 8h (n=15 for wt, n=12 for 
110
 17 
ko), 10h (n=5 per group), and 12h (n=2 per group) after S.tmavir infection. Medians are 
indicated. (F) Quantitative RT-PCR analysis of the indicated genes at the indicated time-
points. Values obtained for S.tmavir-infected wild type mice were set 1. Reactions were 
performed in triplicates, mean values ± SD are shown. 
 
Figure 4: A subset of Salmonella-induced genes requires PARP1 for efficient expression. 
(A) Comparison of whole mouse genome microarray data. Salmonella-induced and 
Salmonella-repressed genes (S.tm over S.tmavir, 10h p.i.) are shown in grey. Salmonella-
induced and Salmonella-repressed genes (S.tm over S.tmavir, 10h p.i.), whose expression 
was lower in S.tm-infected PARP1 knockout mice as compared to S.tm-infected wild type 
mice (6h p.i.), are shown in black and are indicated by numbers. (B) Relative number of 
PARP1-dependent, Salmonella-induced genes. (C) Pathway analysis of PARP1-dependent, 
Salmonella-induced genes. (D) Gene ontology (GO) analysis of PARP1-dependent, 
Salmonella-induced genes. 
 
Figure 5: Impaired gene induction in PARP knockout mice 6h p.i. persists and is more 
dramatic 8h p.i.. (A) Quantitative RT-PCR analysis of IFNγ 6h p.i.. Fold inductions over 
S.tmavir-infected controls are presented. Reactions were performed in triplicates, mean 
values ± SD are shown. (B) Quantitative RT-PCR analysis of the indicated genes 6h p.i.. 
Fold inductions over S.tmavir-infected controls are presented. Reactions were performed in 
triplicates, mean values ± SD are shown. (B) Quantitative RT-PCR analysis of the 
indicated genes 8h p.i.. Fold inductions over S.tmavir-infected controls are presented. 
Reactions were performed in triplicates, mean values ± SD are shown. 
 
Table Legends 
 
Table 1: Summary of gene expression analysis for selected genes and time-points after 
Salmonella infection. Gene expression data obtained by whole mouse genome arrays and 
quantitative RT-PCR are presented.  
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Supplementary Figure Legends 
 
Supplementary Figure 1: (A) Quantitative RT-PCR for PARP1 at 6h p.i.. Values 
obtained for S.tmavir-infected mice were set 1. Reactions were performed in triplicates, 
mean values ± SD are shown. (B) Poly(ADP-ribose) (PAR) immunofluorescence in 
AGS gastric epithelial cells after treatment for 10 minutes with 10mM H2O2. Bar = 
10µm. (C) PAR immunofluorescence in cecum cryosections from wild type and 
PARP1 knockout mice infected with S.tmavir or S.tm for the indicated time-periods. 
Bar = 100µm. 
 
Supplementary Figure 2: Quantitative RT-PCR for GAPDH at 6h p.i.. Values 
obtained for S.tmavir-infected mice were set 1. Reactions were performed in triplicates, 
mean values ± SD are shown. 
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2.4 Unpublished data: 
 
2.4.1 Biochemical characterization of PARP family members 
2.4.1.1 Recombinant PARP1 preparation 
In vitro PARylation analyses were generally performed with recombinant purified 
full-length human PARP1 containing a carboxyl-terminal His-tag (hPARP1-His) 
[150]. We noted that expression and one-step purification via Ni-beads of insect cell-
expressed hPARP1-His resulted in a second protein band at about 80kDa (Figure 4A). 
This band was not present when PARP1 contained an additional Myc- or HA-tag at 
the amino-terminus (Figure 4A and data not shown). The band at about 80kDa in 
hPARP1-His preparations was readily detected by an antibody against the catalytic 
domain of PARP1 (Figure 4B), suggesting that this band corresponds to a carboxyl-
terminal degradation product of PARP1. The degradation product did not alter auto-
modification of PARP1 (Figure 4C) or PARylation activity (Figure 4D). Together, we 
conclude that an additional amino-terminal tag prevents PARP1 cleavage during 
expression and purification using the baculovirus system. The degradation product 
present in hPARP1-His preparations does not influence PARP1 enzymatic activities. 
     
Figure 4: A degradation product of 
recombinant purified hPARP1-His has no 
influence on enzymatic activity. (A) 
hPARP1 was expressed with either only a 
carboxyl-terminal His-tag or with an 
amino-terminal Myc-tag and a carboxyl-
terminal His-tag in Sf21 insect cells and 
purified via nickel beads as described 
[150]. 1 µg of each purified protein was 
analyzed by SDS-PAGE followed by 
Coomassie staining. (B) 10 ng of each 
purified protein was analyzed by SDS-
PAGE followed by Western blot. The 
second protein band at around 80kDa in 
the hPARP1-His preparation is detected 
by an antibody directed against the 
catalytic domain of PARP1 and most 
likely represents a PARP1 degradation 
product. (C) The PARP1 degradation 
product has no influence on auto-
modification of PARP1 or (D) on PAR 
formation. Reactions were performed as 
described previously [150]. 
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2.4.1.2 Characterization of in vitro synthesized PAR 
Analytical anion exchange HPLC can be used to characterize PARP1-generated 
heterogenous mixtures of PAR, which contain polymers of different chain lengths and 
branching frequency [61]. We used a TSK-GEL anion exchange column to separate in 
vitro generated PAR via HPLC. With a multi-step NaCl gradient it was possible to 
obtain a resolution of one ADP-ribose moiety and to separate PAR chains differing in 
only one unit (Figure 5A). PAR ranging from 1-2 ADP-ribose units up to 40-45 units 
were readily detected with 7.14 nmol PAR input (Figure 5A). The detection limit of 
this method probably is in the range of 4-5 nmol PAR input (Figure 5A and 5B). 
Thus, anion exchange chromatography is a suitable method to characterize in vitro 
generated PAR but most likely is not sensitive enough to analyze in vivo synthesized 
PAR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: A purified heterogenous mixture of PAR chains can be separated according to chain length 
by TSK-GEL anion exchange HPLC. (A) PAR was generated in vitro, purified and separated via a 
TSK-GEL anion exchange column (DEAE-NPR, 2.5µm particle size, length x I.D. 3.5cm x 4.6mm, 
from Tosoh Bioscience) using a multi-step NaCl gradient as described in [61]. 7.14 nmol PAR was 
used as input. PAR chains contained up to 45 units and could be separated with a resolution of one 
ADP-ribose moiety. (B) As in (A) with only 2 nmol PAR input.  
 
 
 
 
 
124
2.4.1.3 Characterization of PARP3 enzymatic activity 
Using standardized reaction conditions to compare the catalytic activities of PARP1, 
PARP2 and PARP3, we did not observe auto-modification or PARylation by human 
PARP3 [150]. An increase in substrate concentration by a factor of 100 from 100 nM 
to 10 µM together with an increase in incubation time by a factor of 90 from 10 
seconds to 15 minutes resulted in detectable auto-modification of PARP3 (Figure 
6A). The addition of 250 µM DTT resulted in a slight reduction of PARP3 auto-
modification activity (Figure 6B, compare lanes 6 and 7). Together, human PARP3 
shows auto-modification activity under certain well-defined experimental conditions. 
No indication for PARylation activity by PARP3 (e.g. no shift in coomassie stained 
gels, no detectably PAR formation in Western blots using anti-PAR antibodies, no 
TCA-precipitable PAR formation) was observed. Thus, it remains to be 
experimentally shown whether PARP3 is truly a PAR polymerase or merely a mono-
ADP-ribosyl transferase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: hPARP3 has auto-modification activity. (A) 1: 0.5µg hPARP3, 100nM 32P-NAD, 5pmol 
EcoRI, 10 sec, PARP reaction buffer [150]; 2: 0.5µg hPARP3, 100nM 32P-NAD, 5pmol EcoRI, 15 
min, PARP reaction buffer [150]; 3: 1µg hPARP3, 10µM 32P-NAD, 10 sec, 100mM Tris-HCl pH 8.0; 
4: 1µg hPARP3, 10µM 32P-NAD, 15 min, 100mM Tris-HCl pH 8.0; 5: 3.5µg hPARP3, 10µM 32P-
NAD, 15 min, 100mM Tris-HCl pH 8.0. (B) 1: 0.5µg hPARP3, 100nM 32P-NAD, 5pmol EcoRI, 10 
sec, PARP reaction buffer [150]; 2: 0.5µg hPARP3, 100nM 32P-NAD, 15 min, PARP reaction buffer 
[150]; 3: 0.5µg hPARP3, 10µM 32P-NAD, 15 min, PARP reaction buffer [150]; 4: 0.5µg hPARP3, 
10µM 32P-NAD, 15 min, 100mM Tris-HCl pH 8.0; 5: 0.5µg hPARP3, 10µM 32P-NAD, 15 min, 
100mM Tris-HCl pH 8.0, P/B/L; 6: 0.5µg hPARP3, 10µM 32P-NAD, 15 min, 100mM Tris-HCl pH 8.0, 
P/B/L, 4mM MgCl2; 7: 0.5µg hPARP3, 10µM 32P-NAD, 15 min, 100mM Tris-HCl pH 8.0, P/B/L, 
4mM MgCl2, 250µM DTT; 8: 0.5µg hPARP3, 100nM 32P-NAD, 15 min, 100mM Tris-HCl pH 8.0; 9: 
0.5µg hPARP3, 10µM 32P-NAD, 15 min, 100mM Tris-HCl pH 8.0, 100mM NaCl. P/B/L: 1µg/ml 
pepstatin, 1µg/ml bestatin, 1µg/ml leupeptin. 
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2.4.1.4 Mechanism of PARP1 activation and identification of PAR acceptor 
amino acids 
In order to test whether PARP1 was only activated by double strand break mimicking 
DNA or also by double stranded blunt ended RNA, we used protein chimera PARP1-
2 in in vitro PARylation assays [150]. This chimera contains the amino-terminus of 
PARP1, which harbors three zinc-binding motifs and binds to DNA single and double 
strand breaks, and the carboxyl-terminus of PARP2. PARP1-2 is activated by a 
double strand break mimicking DNA oligonucleotide when etheno-NAD+ is used as 
substrate (Figure 7A). When we tested a double strand break mimicking RNA 
oligonucleotide of the same sequence, we did not observe PARP1-2 activation, 
suggesting that the DNA binding domain of PARP1 does not recognize blunt ended 
double stranded RNA (Figure 7A).  
 By using a triple lysine-to-arginine mutant of PARP1 for in vitro auto-
modification reactions, we had identified the lysine residues K498, K521 and K524 in 
the auto-modification loop as putative acceptor sites for ADP-ribose [150]. Two 
additional PARP1 mutants were subsequently tested for auto-modification activity. 
While the double mutant K498/521R still showed residual auto-modification activity, 
the activity of the double mutant K521/524R was more drastically impaired (Figure 
7B). Therefore, K521 and K524 are primary targets for auto-modification. 
 Besides auto-modification, PARP1 also catalyzes the transfer of ADP-ribose 
moieties onto PAR acceptor proteins. To test whether lysine residues might also be 
the target amino acids for trans-ribosylation, poly-L-lysine, poly-L-arginine, and 
poly-L-glutamate were coupled to cyanogen bromide-activated beads. The beads were 
incubated with purified PARP1 in the presence of 32P-NAD+. After removal of 
PARP1 and free NAD+, the labeling was determined by measuring scintillation 
counts. Interestingly, poly-L-glutamate was not a target for trans-ribosylation by 
PARP1 under the tested conditions (Figure 7C). Instead, poly-L-lysine and, to a lesser 
extend, poly-L-arginine became modified by PARP1. This finding supports our 
published conclusions that glutamic acid residues are not the target sites for covalent 
ADP-ribose attachment by PARP1, but that instead lysine residues are enzymatically 
modified by ADP-ribose via Schiff base formation [150]. 
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Figure 7: The DBD of PARP1 is activated by double-stranded DNA, but not by RNA, and PARP1 
modifies basic amino acids. (A) The enzymatic activity of 10 pmol of the protein chimera hPARP1-2 is 
activated by 5 pmol of a double stranded DNA oligonucleotide but not by 5 pmol of a double stranded 
RNA of comparable sequence. Reactions were performed as described previously [150]. (B) hPARP1 
with mutations of the amino-acids K498, K521, and K524 in the auto-modification loop has impaired 
auto-modification activity. 10 pmol of each purified protein was incubated with 100nM 32P-NAD as 
described previously [150]. (C) Poly-L-arginine and poly-L-lysine but not poly-L-glutamate are 
modified by hPARP1. Poly-L-amino acids were coupled onto cyanogen-bromide activated agarose 
beads over night as suggested by the provider (Sigma-Aldrich). Excess poly-L-amino acids were 
washed away and unoccupied reactive sites were blocked over night. The beads were washed and 
equilibrated in PARP1 reaction buffer. Reactions were performed for 5 minutes at 30°C in the presence 
of 100nM 32P-NAD. The beads were washed 3 times in PARP1 reaction buffer containing 500mM 
NaCl before scintillation counts in two different channels were determined. 
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2.4.2 PARP1 modifies lysine residues in core histone tails 
Histones are known acceptors for ADP-ribose, however single acceptor amino acids 
have not been identified by either site-directed mutagenesis or mass spectrometry. 
Having established that lysine residues are the targets for ADP-ribose attachment by 
PARP1, we tested whether the amino-terminal core histone tails, which are extremely 
rich in basic amino acids (Figures 8A and B), are substrates for PARP1-mediated 
ADP-ribosylation. The four core histone tails of H2A, H2B, H3 and H4 were 
expressed as GST-fusion proteins in bacteria and subsequently purified over 
glutathione beads. All four tails but not GST alone were labeled by PARP1 in vitro 
(Figure 8C). Modification of the histone tails was not observed when the tails had 
been added after termination of the reaction with the PARP inhibitor 3-
aminobenzamide, strongly indicating that the observed labeling represents covalent 
modification rather than a non-covalent binding to PAR chains. Furthermore, to 
demonstrate that the modification of histone tails was catalyzed by PARP1 and not 
due to non-enzymatic ADP-ribose attachment or due to co-purified NAD+-consuming 
enzymes, two PARP inhibitors (PJ34 and DAM-TIQ-A) were used. Both inhibitors 
blocked both PARP1 auto-modification and modification of the H2B tail (Figure 8D). 
This finding strongly indicates that histone tail modification by PARP1 occurs via an 
enzymatic reaction and not by non-enzymatic chemical modification. The tails of 
H2A, H3 and H4 do not contain glutamic acid residues. The tail of H2B, however, 
harbors a single glutamate at position 2, which had been proposed to function as 
acceptor for ADP-ribose [151]. To directly test whether this glutamate is an acceptor 
site for ADP-ribose, we generated an H2B E2A mutant. This mutant was as 
efficiently trans-ribosylated by PARP1 as the wild type control (Figure 8E). Again, 
this finding suggests that also in the H2B tail glutamate 2 is not an acceptor site for 
ADP-ribosylation synthesized by PARP1. 
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Figure 8: The amino-terminal basic core histone tails are covalently modified by PARP1. (A) Crystal 
structure of the nucleosome core particle. Blue: H3; green: H4; yellow: H2A; red: H2B; [152]. (B) 
Amino acid sequence of the amino-terminal human core histone tails. (C) Core histone tails were 
cloned into pGEX vectors, expressed in bacteria as GST-fusion proteins and purified using glutathione 
sepharose according to the provided instructions (GE Healthcare). 1.5µg of each purified GST-histone 
tail were used in PARP1 mediated trans-ADP-ribosylation reactions for 5 minutes at 30°C as described 
previously [150]. Histone tails were either included during the reaction (pre) or added after the reaction 
had been stopped with a 100-fold excess of 3-aminobenzamide over 32P-NAD (post) to exclude non-
covalent interaction of the histone tails with PAR. (D) Trans-ADP-ribosylation of the H2B tail is 
inhibited by the PARP inhibitors PJ34 (0.01µM-100µM) and DAM-TIQ-A (10µM). (E) Trans-ADP-
ribosylation of H2B is not impaired in an H2B E2A mutant, in which the only glutamic acid residue is 
substituted by an alanine. Shown are autoradiographies and coomassie stainings.  
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In order to confine the regions within the core histone tails, which are required for 
PARP1-mediated ADP-ribosylation, we generated a set of tail deletion mutants 
(Figure 9A). Successive shortening of the histone tails resulted in loss of ADP-
ribosylation (Figure 9B-E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Successive shortening of histone tails leads to loss of trans-ADP-ribosylation by PARP1. (A) 
Schematic representation of the histone tail deletion mutants, which were generated, expressed and 
purified. (B) Trans-ADP-ribosylation of H2A deletion mutants by PARP1. (C) Trans-ADP-ribosylation 
of H2B deletion mutants by PARP1. (D) Trans-ADP-ribosylation of H3 deletion mutants by PARP1. 
(E) Trans-ADP-ribosylation of H4 deletion mutants by PARP1. Shown are autoradiographies and 
coomassie stainings.  
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The shortest histone tail deletion mutant, which was still modified by PARP1 was 
used to generate single and combinational lysine and arginine mutations. Following 
this approach, for H2A the lysines at position 13 and 15, and an arginine at position 
20 were identified as putative PAR acceptor sites and/or PARP1 interaction sites 
(Figure 10A). For H2B, seven lysines and arginines between position 27 and 34 had 
to be mutated in order to lose modification completely (Figure 10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Point mutations of lysine and/or arginine residues in the tails of H2A and H2B impair trans-
ADP-ribosylation by PARP1. (A) The indicated wild type or mutant H2A tails were used in PARP1 
mediated trans-ADP-ribosylation assays. (B) The indicated wild type or mutant H2B tails were used in 
PARP1 mediated trans-ADP-ribosylation assays. Shown are autoradiographies and coomassie 
stainings.  
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Mutagenesis of the H3 tail revealed putative PAR acceptor sites and/or PARP1 
interaction sites at lysines 23 and 27, and at arginine 26 (Figure 11A). For histone H4, 
mutation of lysines 16 and 20, and of arginines 17 and 19 resulted in severely reduced 
modification by PARP1 (Figure 11B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Point mutations of lysine and/or arginine residues in the tails of H3 and H4 impair trans-
ADP-ribosylation by PARP1. (A) The indicated wild type or mutant H3 tails were used in PARP1 
mediated trans-ADP-ribosylation assays. (B) The indicated wild type or mutant H4 tails were used in 
PARP1 mediated trans-ADP-ribosylation assays. Shown are autoradiographies and coomassie 
stainings.  
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Interestingly, the identified regions in the four core histone tails, which are required 
for PARP1 mediated ADP-ribosylation, overlap with the regions where the tails exit 
the nucleosomal core (Figures 12A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Summary of identified putative ADP-ribosylation sites in core histone tails. (A) Schematic 
representation of the secondary structure of the four core histones (PDB: 2NZD). (B) Identified 
putative PARP1 target sites in the amino-terminal tails of the four core histones. Lysines are marked in 
red, arginines in purple. Asterisks indicate the approximate point where the tails exit the DNA 
superhelical gyres to the exterior of the nucleosome [153]. 
 
 
Remarkably, a structural modeling for PARP1`s catalytic domain and the tail of H4 
revealed nice fitting of the histone tail into the major pocket of the PARRP1 catalytic 
domain, bringing the putative ADP-ribose acceptor lysines close to the catalytic core 
(Figure 13A). Furthermore, in line with the finding that PARP2 is not able to modify 
histone tails (Simon Messner, unpublished results), the structural modeling revealed 
that an additional loop present in the PARP2 catalytic domain would displace the H4 
tail from the catalytic pocket (Figure 13B). Together, these data demonstrate that (1) 
the amino-terminal histone tails of all four core histones are targets for covalent 
modification by PARP1 at specific lysine residues, (2) that histone modification is 
specific for PARP1 because an additional loop within the PARP2 catalytic domain 
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impedes histone tail binding, and (3) glutamic acid residues are not required for trans-
ribosylation of histone tails and are not the target sites for ADP-ribose attachment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: The histone H4 tail fits into the catalytic cleft of PARP1. (A) The H4 tail (aa 1-22) was 
modeled into the catalytic cleft of PARP1. PDB files were obtained from RCSB PDB 
(www.rcsb.org/pdb/home/home.do), the modeling was performed using the Swiss-PDBViewer. 
Molecular surfaces were calculated and used as constraints for model making. The H4 tail was arranged 
in a way that H4 K16 comes into close proximity to PARP1 E988, K903 and the substrate. (B) The 
catalytic domain of PARP2 was aligned with the catalytic domain of PARP1 using the Magic Fit 
function of the Swiss-PDBViewer. An additional loop of PARP2 is not compatible with H4 binding. 
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2.4.3 PARP1 modulates pro-inflammatory gene expression 
PARP1 is a known co-regulator for NF-κB target gene expression [3]. Which subset 
of NF-κB target genes requires PARP1 for efficient transcription and how exactly 
PARP1 influences pro-inflammatory gene expression is only poorly understood. We 
thus set out to identify and characterize the subset of PARP1-dependent NF-κB target 
genes using customized NF-κB target gene microarrays and quantitative RT-PCR 
(qPCR). Raw264.7 macrophages were treated with LPS for 4 hours before total RNA 
was isolated and used for microarray analysis. LPS treatment resulted in the up-
regulation of 211 NF-κB target or NF-κB related genes (of a total number of 524 
genes covered by the array) at least 1.6-fold (Figure 14A). Interestingly, pre-treatment 
of cells with the potent PARP inhibitor DAM-TIQ-A, which blocks genotoxic stress 
induced PAR formation (data not shown), did not significantly alter the gene 
expression profile, suggesting that PAR formation is not a prerequisite for NF-κB 
target gene expression (Figure 14A). PARP1 knockdown by shRNA (Figure 14B), on 
the other hand, dramatically changed the gene expression profile after LPS treatment 
(Figure 14C). Overall, gene induction after LPS treatment was reduced in shPARP1 
cells and gene repression after LPS treatment was increased. More specifically, the 
microarray data revealed that the induction of several NF-κB target genes, including 
Mpa2l, Ccl7, MIP-2, and IκBε, was impaired in Raw264.7 cells lacking PARP1 
(Figure 14D). Other NF-κB targets such as IL-6 were induced independently of 
PARP1. These data support a transcriptional co-activator function of PARP1 for a 
subset of NF-κB target genes. In order to confirm the microarray results by qPCR, we 
followed the gene expression of Mpa2l at different time-points after LPS treatment. A 
time-dependent gene induction was observed, which was markedly reduced in 
shPARP1 cells (Figure 14E). Furthermore, the microarray data was also confirmed for 
other genes by qPCR (Figure 14F). Together, these findings indicate that PARP1 is 
required for the efficient expression of a subset of NF-κB target genes after LPS 
treatment of Raw264.7 macrophages. 
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Figure 14: PARP1 influences LPS-induced NF-κB target gene expression in Raw264.7 macrophages. 
(A) Treatment of PARP1 proficient cells with 10µM PARP inhibitor DAM-TIQ-A 1 hour prior to 
treatment with 10µg/ml LPS for 4 hours has no gross effect on upregulated gene expression as revealed 
by customized microarray analysis for NF-κB target genes. (B) PARP1 was stably depleted from 
Raw264.7 macrophages by shRNA and protein levels were analyzed by Western blot. (C) Depletion of 
PARP1 by shRNA reduces the number of upregulated genes after LPS stimulation (upper panel) and 
increases the number of downregulated genes after LPS stimulation (lower panel) as revealed by 
customized microarray analysis. Each bar represents a single gene probe on the customized microarray. 
Fold changes after LPS stimulation are shown and genes are ranked by fold change. (D) Microarray 
results for single genes comparing PARP1 deficient and control cells. (E) Time-course of Mpa2l gene 
expression after LPS treatment in PARP1 deficient and control cells as revealed by quantitative RT-
PCR. (F) Validation of microarray results for single genes 4 hours after LPS treatment by quantitative 
RT-PCR. 
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Next, we analyzed PARP1-dependent gene expression in peritoneal macrophages 
isolated from wild type or PARP1 knockout mice. Cells isolated from wild type 
animals generated PAR in response to oxidative stress, and PAR formation was 
efficiently blocked by the PARP inhibitor DAM-TIQ-A (Figure 15A). Cells isolated 
from PARP1 knockout mice, on the other hand, did not synthesize PAR in response to 
oxidative stress (Figure 15B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: PARP inhibition reduces PAR formation in peritoneal macrophages after H2O2 treatment. 
Peritoneal macrophages were treated as indicated and PAR formation was analyzed by 
immunofluorescence. Macrophages had been isolated from wild type (A) or PARP1 knockout mice in 
the 129S background (B). 
 
 
Following LPS treatment, both cell lines expressed IL-10, IκBα, and COX-2 and the 
induction of these genes was independent of PAR formation (Figure 16A). We 
confirmed that PARP1 was expressed in wild type but not PARP1 knockout cells by 
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Western blot (Figure 16B), before we used customized microarrays (Figure 16C) to 
analyze NF-κB target gene expression after LPS treatment. 4 hours after LPS 
treatment, several genes were induced at least 2-fold (Figure 16D). Whereas some 
genes were expressed independent of PARP1, others showed impaired induction in 
PARP1 knockout cells. As in Raw264.7 cells, IL-6 was PARP1-independent, whereas 
Mpa2l, MIP-2 and IκBε were PARP1-dependent. Other PARP1-dependent genes 
include Vcam1, Icam1, COX-2 and Aif1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: PARP1 influences LPS-induced NF-κB target gene expression in peritoneal macrophages. 
(A) LPS induced gene expression 4 hours after treatment as revealed by conventional RT-PCR. (B) 
PARP1 protein levels in cells isolated from wild type or PARP1 knockout mice as revealed by Western 
blot. (C) Representative example of the customized microarray analysis to study NF-κB target gene 
expression. (D) Microarray results comparing wild type and PARP1 knockout cells. Genes with a more 
than 2-fold induction in wild type cells after LPS treatment are shown.  
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From the discussed analyses, the three genes Aif1, Mpa2l and IκΒε were robustly 
PARP1-dependent in two different cell culture systems. We confirmed PARP1-
dependency of these genes also in vivo, as all three genes were less induced in gastric 
epithelium isolated from PARP1 ko mice four weeks after infection with Helicobacter 
felis when compared to H. felis infected wild type mice (data not shown). Thus, from 
gene expression analyses of three different biological conditions (LPS treated 
Raw264.7 cells, LPS treated peritoneal macrophages, H. felis infected mice) the three 
genes Aif1, Mpa2l and the negative feedback regulator of NF-κΒ, IκΒε, were most 
robustly dependent on PARP1 for their expression. 
In an attempt to define what makes a gene PARP1-dependent, we used a 
bioinformatics approach to analyze PARP1-dependent versus PARP1-independent 
genes. When comparing PARP1-dependent with PARP1-independent genes as 
revealed by microarray analyses of LPS stimulated peritoneal macrophages, there was 
no difference in occurence of upstream cis elements or TATA box sequences (200 / 
1000 bp upstream and 1000 bp downstream of transcription start) (Figure 17A), no 
difference in chromosomal localization (chromosome number, distance to 
telomeres/centromere, +/- strand) and no difference in average gene length (Figure 
17B). Furthermore, there was no difference in the occurence of alternative splicing, 
gene overlaps or bidirectional promotors (data not shown) and no difference in the 
majority of pathways the genes are involved in (immunological disease, inflammatory 
disease, immune response, cancer, cellular movement, cell signaling). A significant 
difference was observed, however, in the involvement in cell death (8/9 vs. 4/11) and 
development and function of the reproductive system (5/9 vs. 1/11) (Figure 17C).  
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Figure 17: Global analysis of PARP1 dependent genes after LPS treatment of peritoneal macrophages. 
Based on the microarray analysis, PARP1 dependent versus PARP1 independent genes were analyzed 
in silico. PARP1 dependent genes did not show any obvious change in binding sites for DNA binding 
proteins (P-Match: http://www.gene-regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi.) 
(A), distance from telomeres, orientation, or gene length (B), nor in the pathways they are involved in 
(Ingenuity Pathways Analysis, Ingenuity® Systems, www.ingenuity.com) (C). 
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A slight difference was also observed at the positions 3, 8 and 10 of the NF-κΒ 
consensus binding sequence (κΒ-site) (Figure 18A) and in the predicted nucleosome 
formation potential specifically around the transcription start site (TSS) but not 
upstream or downstream of the TSS (Figure 18B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Global analysis of PARP1-dependent genes after LPS treatment of peritoneal macrophages. 
Based on the microarray analysis, PARP1-dependent versus PARP1-independent genes were analyzed 
in silico. PARP1-dependent genes showed a slight difference in the κB-site consensus sequence at 
positions 3, 8 and 10 (http://meme.sdsc.edu/meme/intro.html) (A) and in the nucleosome formation 
potential around the transcription start site (TSS) [154] (B). 
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PARP1 had recently been suggested to bind to S/MAR elements of certain genes 
[155, 156], but no difference was observed in S/MAR element-typical stress-induced 
duplex destabilization (SIDD) profiles between PARP1-independent and PARP1-
dependent genes (Figures 19A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: (A, B) Global analysis of PARP1 dependent genes after LPS treatment of peritoneal 
macrophages. Based on the microarray analysis, PARP1 dependent versus PARP1 independent genes 
were analyzed in silico. PARP1 dependent genes showed no difference in stress-induced duplex 
destabilization (SIDD) profiles [155, 156]. Probabilities p(x) and G(x) are depicted for genomic 
sequences from -1000 bp upstream of the TSS to the TSS.  http://www.genomecenter. 
ucdavis.edu/benham/sidd/ 
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Very recently, in a large scale screen for sequence-specific protein-DNA interactions, 
the PARP1-interacting protein XRCC1 was found to bind DNA in a sequence-specific 
manner [157]. Interestingly, we identified an XRCC1 consensus binding site just 450 
bp upstream of the TSS of IκΒε, one of the genes, whose expression most robustly 
depended on PARP1 (Figure 20). XRCC1 consensus binding sites or variations 
thereof were also found in the promotor regions of the PARP1-dependent genes 
Icam1, Ccr5, Casp4, Mpa2l, Ccl5, Vcam1 and Olr1, but not in the promotor regions 
of PARP1-independent genes (data not shown). Together, these analyses revealed 
variations in κΒ-sites, differences in nucleosome formation potential around the TSS 
and differences in XRCC1 binding sites in the promotor regions as possible 
characteristics to differentiate between PARP1-dependent and PARP1-independent 
genes. Especially the finding that PARP1-dependent genes contain XRCC1 binding 
motifs is intriguing and it will be interesting to investigate the putative role of the 
DNA damage repair protein XRCC1 for PARP1-dependent gene expression. 
 
 
 
 
 
 
 
 
 
 
Figure 20: An XRCC1 consensus binding motif is present 450 bp upstream of the TSS of IκBε. The 
genomic sequence from -1000 bp upstream of the TSS to the TSS of IκBε is shown. The XRCC1 
consensus sequence as previously described [157] is boxed and shown below as positional weight 
matrix (PWM).  
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2.4.4 PARP1 is activated by Helicobacter pylori 
In collaboration with Isabella Toller and Anne Müller (both IMCR, UZH) a possible 
role for PARP1 in Helicobacter pylori induced gastric inflammation was investigated 
(manuscript in preparation). We used the transformed gastric epithelial AGS cell line 
to study the potential interplay between PARP1 and Helicobacter pylori. PARP1 was 
expressed in this cell line as revealed by immunofluorescence (Figure 21A). In order 
to study PARP1 function, PARP1 was depleted from AGS cells by shRNA (Figure 
21B). PARP1 knockdown had no effect on the morphological changes typically 
observed after infection of AGS cells with H. pylori (Figure 21C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Helicobacter pylori induces morphological changes in AGS cells independent of PARP1. 
(A) PARP1 is expressed in AGS cells as revealed by immunofluorescence. (B) PARP1 was stably 
depleted from AGS cells by two different shRNAs and protein levels were determined by Western blot. 
(C) AGS cells were infected with Helicobacter pylori and morphological changes were recorded 22 
hours p.i. by light microscopy. 
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Unexpectedly, a protein at the size of about 55kDa was detected with a homemade 
anti-PARP1 antibody after H. pylori infection (Figure 22A). This protein was induced 
independent of the presence of PARP1. The protein was not observed in H. pylori 
lysates (data not shown) and therefore most likely was expressed by AGS cells and 
not by the bacteria. The protein was not analyzed any further nor identified by mass 
spectrometry. H. pylori infection did not alter total cell NF-κΒ protein levels (Figure 
22B).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Helicobacter pylori induces an unidentified protein of about 55kDa. (A) Western blot 
analysis of AGS whole cell extracts. (B) p65 protein levels are unchanged after Helicobacter pylori 
infection as revealed by Western blot. 
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Interestingly, infection of AGS cells with H. pylori resulted in the time-dependent 
synthesis of PAR (Figure 23A). PAR synthesis was blocked when cells were co-
treated with the PARP inhibitor PJ34 (Figure 23B). PAR formation after H. pylori 
infection was also observed in immortalized primary gastric epithelial cells (IMPGEs) 
and also in these cells PAR synthesis was blocked by PJ34 (Figure 23C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Helicobacter pylori induces PAR formation in gastric epithelial cells. (A) Helicobacter 
pylori induces time-dependent PAR formation in AGS cells as revealed by Western blot. (B) 
Helicobacter pylori induced PAR formation is abolished when AGS cells are treated with PARP 
inhibitor PJ34 (10µM) during infection. (C) Helicobacter pylori induces PAR formation 24 hours p.i. 
in IMPGE cells and PAR formation is abolished by PJ34 treatment. 
 
In order to test whether PARP1 was responsible for H. pylori-induced PAR 
formation, we depleted PARP1 in AGS cells by siRNA or shRNA (Figure 24A). 
Stable or transient knockdown of PARP1 greatly reduced PAR formation after H. 
pylori treatment, suggesting that indeed PARP1 is the main PARP family member 
responsible for H. pylori-induced PAR synthesis (Figures 24B and C). Remarkably, 
H. pylori mutants lacking the CagA effector protein did not induce PAR formation to 
the same extend as wild type bacteria (Figures 24C and D). H. pylori-induced PAR 
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formation is unlikely to be associated with apoptosis, as we were unable to detect 
cleaved PARP1 or cleaved caspase 3, two markers for apoptosis, in H. pylori infected 
cell extracts (Figure 24E). Together, these findings indicate that H. pylori infection of 
gastric epithelial cells results in PARP1 activation and PAR formation as a cellular 
response, which is not associated with cell death. Moreover, H. pylori CagA seems to 
be involved in PARP1 activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: PARP1 is mainly responsible for Helicobacter pylori induced PAR formation in AGS cells. 
(A) PARP1 or PARP2 were transiently depleted from AGS cells by siRNAs. PARP1 protein levels 
were analyzed by Western blot. (B) PAR formation 24 hours p.i. was analyzed by Western blot in cells 
stably (shRNA) or transiently (siRNA) depleted for PARP1 or PARP2. (C) PAR formation 24 hours 
p.i. with wild type (wt) or CagA mutant (mut) Helicobacter pylori was analyzed. (D) PAR formation 
24 hours p.i. with wild type (wt) or CagA mutant (PAI) Helicobacter pylori in the absence or preence 
of PJ34 was analyzed. (E) Helicobacter pylori does not induce significant levels of apoptosis in AGS 
cells 24 hours p.i. AGS cells were treated as indicated and two markers for apoptosis, cleaved PARP1 
and cleaved caspase 3, were analyzed by Western blot.  
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Since PARP1 is a co-activator for NF-κB target gene expression and H. pylori 
triggers a pro-inflammatory response in the gastric epithelium, we analyzed NF-κB 
target gene expression in H. pylori infected AGS cells. Known NF-κB targets such as 
IL-8, IL-1b and COX-2 were readily induced by H. pylori in PARP1-proficient cells 
(Figure 25). In cells depleted for PARP1, however, a reduced gene expression was 
observed. IL-8, IL-1b and COX-2 all showed a 50% reduced expression level in 
shPARP1 cells, while activation-induced deaminase (AID) was induced normally 
(Figure 25). Thus, PARP1 is involved in the efficient expression of NF-κB target 
genes after infection with H. pylori. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: A subset of Helicobacter pylori induced genes is PARP1 dependent. Gene expression in 
control cells and cells depleted for PARP1 was analyzed by quantitative RT-PCR. 
 
 
2.4.5 PARP1 is required for viral replication 
In collaboration with Daniel Mayer and Martin Schwemmle (Virology, University of 
Freiburg, Germany) the possible role of PARP1 for intracellular replication of RNA 
viruses was investigated. Mouse lung fibroblasts (MLFs) derived from wild type or 
PARP1 knockout animals (Figure 26A) were infected with a low MOI of semliki 
forest virus (SFV) or feline panleukopenia virus (FPV). At different time-points after 
infection, virus-containing cell supernatants were taken and virus titers were analyzed 
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by standard plaque assays. Interestingly, SFV titers were 10.000 fold lower in PARP1 
knockout MLFs as compared to wild type MLFs (Figure 26B). Importantly, the 
replication defect observed in PARP1 knockout MLFs could be completely rescued 
by re-introduction of PARP1, strongly indicating that SFV requires host cell PARP1 
for replication. FPV replication, on the other hand, did not require PARP1 (Figure 
26C). Together, these data suggest an important so far uncharacterized function for 
PARP1 in RNA virus replication, which is not observed when DNA viruses are tested 
(Daniel Mayer, unpublished data).   
 
 
 
 
 
 
 
 
 
 
 
Figure 26: PARP1 is required for SFV replication. (A) Mouse lung fibroblasts (MLFs) from wild type 
or PARP1 knockout mice were tested for the expression of PARP1, p65 and GAPDH by Western blot. 
(B) MLFs from wild type or PARP1 knockout mice or MLFs from PARP1 knockout mice, which had 
been complemented with human PARP1, were infected with SFV using an MOI of 0.1. Virus 
supernatants were collected at the indicated time-points. Virus titers were determined on confluent 
Vero cells using serial dilutions of virus supernatants (10-2 to 10-9) and standard plaque assays. (C) As 
in (B) with FPV. 
 
 
2.4.6 PARP1 expression in mouse spleen 
When PARP1 expression in mouse cecum was analyzed by immunofluorescence, we 
noted PARP1 expression mainly in the proliferative zone of the crypts (Altmeyer et 
al., submitted manuscript). In order to test whether PARP1 was also differentially 
expressed in other tissues, we analyzed PARP1 expression in mouse spleens. 
Interestingly, also in spleens only a subpopulation of cells expressed PARP1 as 
revealed by immunofluorescence (Figure 27). It remains to be tested whether PARP1 
expressing cells in the spleen show normal or higher levels of proliferation. 
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Figure 27: PARP1 is expressed in a subpopulation of mouse splenocytes. PARP1 was detected by 
immunofluorescence microscopy as described (Hapfelmeier et al., 2005) using cryosections stained 
with rabbit anti-PARP1 antibody H-250 (Santa Cruz), FITC-conjugated secondary antibody (Covance), 
and DAPI. Images were taken using an Olympus Mx51, NA 1.3 fluorescence microscope. 
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3 DISCUSSION 
 
3.1 Summary of the results 
We have investigated the molecular mechanism of PAR formation by PARP1 and the 
closely related PARP family members PARP2 and PARP3 [150]. PARP1 synthesized 
PAR more efficiently than PARP2. PARP3 on the other hand did not synthesize PAR, 
but showed mono-ADP-ribosylation activity. The generation of different chimera 
proteins revealed that the amino-terminal domains of PARP1, PARP2 and PARP3 
cooperate tightly with their corresponding catalytic domains. The DNA-dependent 
interaction between the amino-terminal DNA-binding domain and the catalytic 
domain of PARP1 increased Vmax and decreased the Km for NAD+. Furthermore, we 
found that glutamic acid residues in the auto-modification domain of PARP1 are not 
required for PAR formation. Instead, we identified individual lysine residues as 
acceptor sites for ADP-ribosylation. Two lysine residues within a nuclear localization 
signal were also identified in PARP2 as sites for auto-ADP-ribosylation [158, 159]. 
Interestingly, the acceptor sites for ADP-ribose in both PARP1 and PARP2 are also 
targets for acetylation by histone acetyltransferases (HATs), suggesting a functional 
cross-talk between ADP-ribosylation and acetylation [37, 158]. 
 The amino-terminal core histone tails are especially rich in the basic amino 
acids lysine and arginine. We found that PARP1 specifically modifies the histone tails 
of H2A, H2B, H3, and H4. By applying an extensive deletion and mutation strategy 
for each tail, we determined the region important for modification, and identified 
individual putative acceptor sites for ADP-ribose. The identified lysine residues are 
known targets for histone acetylation and/or methylation, again suggesting an 
interesting cross-talk between PARylation and other lysine modifications at histone 
tails. 
In collaboration with the group of Wolf-Dietrich Hardt (ETH Zurich), we 
investigated a possible role for PARP1 in Salmonella enterica serotype Typimurium-
induced colitis (manuscript submitted). We demonstrated that PARP1 is expressed in 
the proliferative zone of cecum crypts and is associated with a faster pro-
inflammatory host response to Salmonella infection. This accelerated response 
involved higher expression of pro-inflammatory genes and more severe inflammation 
with increased infiltration of immune cells. These findings link PARP1 to 
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Salmonella-induced pro-inflammatory gene expression and suggest an important role 
for PARP1 in controlling the host response to enteric Salmonella infection. 
In collaboration with Isabella Toller and Anne Müller (both IMCR, UZH 
Zurich), we investigated the possible role of PARP1 in Helicobacter pylori induced 
gastric inflammation (manuscript in preparation). PARP1 was required for the 
efficient expression of several pro-inflammatory genes induced by H. pylori in AGS 
cells. Moreover, PAR formation was observed in gastric epithelial cells after infection 
with H. pylori. Finally, treatment of mice with PARP inhibitor PJ34 severely reduced 
Helicobacter-induced gastric inflammation (Isabella Toller, unpublished results). 
These data link PARP1 to Helicobacter pylori induced gastritis and gastric cancer. 
PARP1 is a known transcriptional co-activator of NF-κΒ, a function, which 
may not require the enzymatic activity of PARP1 [108]. Using customized 
microarrays and quantitative RT-PCR, we identified a subset of NF-κΒ target genes, 
which was dependent on PARP1, but not on PARylation as tested with chemical 
PARP inhibitors, for efficient gene induction. PARP1 dependent genes have an 
altered nucleosome formation potential around the transcription start site. Moreover, 
at least some PARP1 dependent genes contain a recently identified consensus binding 
motif for the base excision repair protein and known PARP1 interactor XRCC1 in 
their promoter region. 
 Finally, in collaboration with the group of Martin Schwemmle (University of 
Freiburg, Germany), we investigated whether PARP1 was required for viral 
replication. Interestingly, semliki forest virus (SFV) was heavily dependent on 
PARP1 for successful replication in MLFs.  
 
3.2 Lysine residues as acceptors for ADP-ribose 
Biochemical studies in the 1980s had already aimed at identifying ADP-ribose 
acceptor sites in histones. Ogata et al. identified the glutamic acid residue at position 
2 within the amino terminal tail of H2B as acceptor site for ADP-ribose when they 
incubated chromatin from rat liver with radioactive NAD+ [151]. The same group also 
identified glutamic acid residues in the linker histone H1 as ADP-ribose acceptor sites 
[160]. Importantly, at that time no other PARP family member had been identified 
yet, and the tools to perform experiments in PARP1 negative systems, i.e. “loss-of-
function” studies, were not yet available. Furthermore, the identified sites had never 
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been confirmed by mutational analysis. Thus, it may well be that another PARP 
family member or even another PARP1-unrelated NAD+ consuming enzyme was 
responsible for the modification at the identified glutamates observed by Ogata and 
colleagues. In line with this notion, we observed no reduction in the modification of 
the H2B tail by recombinant purified PARP1 when we mutated the glutamate at 
position 2 of H2B to an alanine.  
In a very recent publication, Tao et al. identified ADP-ribose acceptor sites in 
the auto-modification domain of a catalytic PARP1 mutant by LC-MS/MS [161]. The 
acidic amino acids D387, E488, and E491 were within peptides that were modified by 
PARP1 E988Q and were proposed to be primary or secondary acceptor sites for ADP-
ribose. The use of relatively high concentrations of substrate NAD+ (500µM) together 
with the relatively long incubation time (2h at room temperature) may, however, have 
resulted in the unspecific and/or non-enzymatic modification of the identified sites. 
Another major drawback of this study is the lack of evidence for ADP-ribosylation of 
these three amino acids by wild type PARP1. The detected acidic residues may only 
function as acceptors in the context of the tested PARP1 E988Q mutant, and lysine 
residues may represent the primary acceptor sites for ADP-ribose in wild type 
PARP1. Obviously, only the identification of ADP-ribose acceptor sites in the context 
of full-length wild type auto-modified PARP1, though certainly challenging, will help 
to resolve this issue. 
The identification of lysine residues as acceptor sites for PARP1-mediated 
ADP-ribosylation has important implications for the reaction mechanism of 
PARylation. The initiation reaction, i.e. the attachment of the first ADP-ribose moiety 
onto an acceptor lysine, is not catalyzed by the amino acid E988 in PARP1, since an 
E988K mutant protein still possesses mono-ADP-ribosylation activity, while it is not 
able to catalyze PAR formation. Thus, E988 may be directly involved in chain 
elongation and possibly also branching, but not in the first step of PAR formation. A 
good candidate to catalyze the initiation reaction, however, is the amino acid K903, 
which is in very close distance to the substrate NAD+. This lysine may stabilize a 
transition state after the cleavage of NAD+ to nicotinamide and ADP-ribose and 
before the ADP-ribose is attached onto the acceptor lysine. Accordingly, a PARP1 
K903A mutant would be predicted to lose the ability to catalyze mono-ADP-
ribosylation. PARylation could consequently be mechanistically subdivided into the 
initiation reaction, which is catalyzed by K903 and transfers an ADP-ribose moiety 
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from NAD+ to an acceptor lysine, and the elongation/branching reaction, which in 
contrast is catalyzed by E988 and transfers ADP-ribose moieties onto hydroxyl 
groups of ribose molecules of the growing PAR chain. 
 
3.3 PARP1 and chromatin remodeling 
Chromatin remodeling mechanisms can be divided into (1) post-translational histone 
modifications, (2) ATP-dependent remodeling and (3) incorporation of histone 
variants [162]. PARP1 has now been implicated in all three of these processes: 
PARP1 covalently modifies core histone tails (own results), regulates the ATPase 
ALC1 [67, 68] and FACT-mediated H2AX incorporation [69]. Histones are modified 
by a range of post-translational modifications including acetylation, methylation, 
phosphorylation, ubiquitylation, and ribosylation [163]. Histone hyperacetylation 
mediated by histone acetyl transferases (HATs) generally correlates with 
transcriptionally active genes, while histone hypoacetylation mediated by histone 
deacetylases (HDACs) correlates with silenced genes. H3K9, H3K14, H3K16, H4K9 
and H4K16 are known target for acetylation [164]. Moreover, methylation of H3K9, 
H3K27 and H4K20 are generally associated with transcriptional silencing, whereas 
methylation of H3K4, H3K36 and H3K79 are associated with active chromatin [163]. 
Linker histone H1 stabilizes higher order chromatin structures and may function as 
global repressor of transcription. Interestingly, by using a ChIP-chip approach, the 
group of W.L. Kraus suggested that PARP1 and H1 bind reciprocally at chromatin 
and that PARP1 displaces H1 from the DNA [64]. 
We have identified in a first set of GST-histone tail deletion mutants the 
regions within the core histone tails that are targeted by PARP1 mediated PARylation. 
In a second set of GST histone tail mutants carrying single or multiple amino acid 
substitutions, we have identified the putative acceptor amino acids for ADP-ribose 
attachment. For histone H2A, the most prominent sites are lysines 13 and 15, two 
sites for which no other post-translational modification has been described before. For 
H2B, several lysine and/or arginine residues between lysine 27 and lysine 34 may be 
acceptors for ADP-ribose. Also for these residues, no other modification has been 
identified before. Lysines 23 and 27 were the most prominent ADP-ribose acceptor 
sites in H3, and for histone H4 we identified K16 and K20 as likely acceptor sites for 
PARylation. H3K23 is a target for ScSAS3 mediated acetylation, while H3K27 is a 
target for EZH2 mediated methylation in mammals, but not in budding and fission 
154
yeast [52]. Hypermethylation of H3K27 in higher eukaryotes is associated with a 
silent chromatin state and transcriptional repression. In line, H3K27 methylation is 
thought to be involved in the maintenance of the inactive X chromosome [52]. 
Acetylation of H3K23, on the other hand, is less well investigated but may be a mark 
of open chromatin. H4K16 is acetylated by Tip60 and by ScSAS2 (SpMST2), 
whereas H4K20 is also methylated by Pr-SET7/8, SUV4 20H1, SUV4 20H2 and 
SpSet9 [52]. The acetylation of H4K16 is a fairly well described histone modification. 
It prevents the formation of the 30nm chromatin fiber and the generation of higher 
order chromatin structures [165, 166]. Deacetylation at H4K16 is achieved by the 
fission yeast class III deacetylase Sir2 and by the human Sir family member SirT2 
[167]. SirT2 may thus have the ability to induce chromatin condensation in vivo by 
antagonizing H4K16 acetylation [52]. In contrast, methylation of H4K20 is strongly 
associated with silent heterochromatic regions and consequently with transcriptional 
repression. H4K20 methylation may be antagonized by the action of the JMJD2A 
lysine demethylase, which binds to H4K20me [168]. Interestingly, ionizing radiation 
induced DNA damage generates nuclear foci, which contain methylated H4K20 and 
p53BP1 to signal a G2/M arrest in order for the DNA to be repaired [169, 170]. As 
p53BP1 recruitment to these sites is dependent on H4K20 methylation, this 
modification has an important function in the DNA damage response apart from its 
role in transcription. 
It will be important to confirm the identified putative sites of PARP1 mediated 
histone ADP-ribosylation by mass spectrometry in vitro and eventually also in vivo, 
before the functional consequences of histone ADP-ribosylation can be addressed in a 
truly rational manner. It is, however, intriguing to already speculate about the 
potential cross-talks with other post-translational modifications at the same sites, at 
sites nearby, or even at sites further apart. PARylation and other histone modifications 
may be either mutually exclusive or coincide within certain chromatin domains. The 
tools to address this point and study global histone PARylation at specific amino acids 
are not yet available, but antibodies raised against single ADP-ribosylated residues 
within histone tails will hopefully allow for ChIP-chip analysis of histone 
PARylation. In parallel, the mechanistic analysis of the cross-talk between 
PARylation and histone acetylation by histone acetyltransferases or histone 
methylation by methyltransferases will provide important insights into the complex 
regulation of chromatin function by these modifications. Moreover, to investigate the 
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interplay between PARP1 and other chromatin-associated NAD+-consuming 
enzymes, such as the Sir family members, will most probably reveal fascinating links 
between chromatin modifications and cellular metabolism. Chromatin structure may 
be the platform to integrate the great variety of internal and external signals and 
translate them into an appropriate response in terms of DNA replication, repair or 
transcription, always in the light of cellular energy status. PARP1, with its important 
roles in transcription and repair, and as a cellular sensor of energy levels, may be a 
central component of this nuclear integration hub. It will be interesting to study how 
PARP1 and SirT2 cooperate to allow for H4K16 deacetylation and subsequent ADP-
ribosylation, for example, and how the same two enzymes may concurrently compete 
for the same substrate. 
Several post-translational histone modifications are recognized by specialized 
protein domains. Methylated lysines, for instance, are bound by chromo-like domains 
of the Royal family (chromo, tudor, MBT) and non-related PHD domains [52]. 
Acetylation marks, in contrast, are read by bromodomains, and phosphorylation is 
recognized by a domain within 14-3-3 proteins. PARP1 generated PAR was already 
described to be recognized by at least three different protein motifs, by a basic PAR 
binding motif, by PAR binding zinc fingers, and by macrodomains [62, 63, 72]. 
Whether proteins, which harbor these PAR sensing domains, would also recruit to 
PARylated histone tails has not been addressed experimentally yet. It is tempting to 
suggest, however, that macrodomain containing histone variants like H2A1.1, for 
example, would bind to PARylated core histone tails to mediate chromatin 
composition and function. Strikingly, all regions within the core histone tails, which 
are targeted by PARP1 mediated ADP-ribosylation, are close to the approximate sites 
where the tails exit the DNA superhelical gyres to the exterior of the nucleosome 
[152, 153]. This indicates, at least in principle, that histone tail PARylation and its 
recognition by PAR binding domains regulate nucleosome structure and/or the 
generation of higher order chromatin structures. From both charge and structure of 
PAR one would expect that histone tail PARylation can decompact heterochromatin 
and/or prevent free histones from being integrated into nucleosomes. Both processes 
may be especially important during replication, where heterochromatin needs to be 
dissolved and new nucleosomes have to be formed. 
Finally, most histone modifications are reversible and also PARylation is a 
transient and in general reversible process. As important as the analysis of PARP1 
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functions for chromatin structure modulation may thus be the analysis of PAR 
degrading enzymes, such as PARG and ADP-ribosyl protein lyase, and their 
contribution to the regulation of histone tail PARylation. Especially, the ADP-ribosyl 
protein lyase is only poorly described and it will be important to study whether 
histone tail PARylation is indeed fully reversible, or whether the histone proximal 
ADP-ribose unit remains attached to the tail as a stabile mark. A stabile histone tail 
mark, which could only be removed by replacing the affected histone with a non-
marked histone, could be part of a chromatin memory and function as an epigenetic 
mechanism.  
In summary, PARP1 mediated histone tail PARylation occurs as post-
translational modification at distinct lysine residues. The PARylation mark can be 
read by special PAR binding domains and probably has important cellular 
implications for processes such as histone dimerization or multimerization, histone 
shuttling, nucleosome formation or regulation of higher order chromatin structure. 
Since ADP-ribosylation of lysines not only neutralizes the positive charge of the 
amino acid side chain (as does lysine acetylation), but instead reverses it into a 
negative charge, the effects of lysine ADP-ribosylation can be assumed to be even 
more drastic than acetylation and may be especially required not only to prevent 
heterochromatin formation, but to unfold dense heterochromatic genomic regions. In 
contrast to mono-ADP-ribosylation of lysines, PARylation would even add a 
complex, bulky and highly anionic molecule to histone tail lysines. Accordingly, the 
effects of PARylation for unfolding heterochromatin can be expected to be much 
stronger than the attachment of a single ADP-ribose unit onto a histone tail lysine. 
 
3.4 PARP1 and NF-κΒ dependent transcription 
The role of PARP1 for NF-κΒ-dependent gene expression was analyzed in different 
systems. Interestingly, one of the genes, which was most robustly down-regulated 
after an inflammatory stimulus in cells and tissues lacking PARP1, was the inhibitor 
of NF-κΒ IκΒε. Messenger RNA levels of the IκΒε gene after LPS treatment were 
considerably lower in Raw264.7 macrophages depleted for PARP1 and in peritoneal 
macrophages isolated from PARP1 knockout mice as compared to PARP1 proficient 
control cells. IκΒε transcripts were also lower in the gastric epithelium of PARP1 
knockout mice after in vivo infection with Helicobacter felis than in tissue isolated 
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from infected wild type mice. IκΒε is one of several inhibitory proteins for NF-κΒ 
dependent transcription. Recently, it was suggested that IκΒε is especially important 
for a negative feedback loop that increases the cell-to-cell heterogeneity of the NF-κΒ 
response, which originates from intrinsic, stochastic transcriptional variability [171]. 
To determine the physiological importance of oscillatory gene expression and cell-to-
cell-heterogeneity in the inflammatory immune response is a challenge of future 
research and it will be interesting to elucidate the role of PARP1 in these still poorly 
understood phenomena. It seems obvious, however, that the misregulation of an NF-
κΒ feedback loop in cells lacking PARP1 may also indirectly influence the expression 
levels of other NF-κΒ target genes. 
From several customized microaray experiments, PARP1 and stimulus 
dependent genes can be summarized to mainly fall into four different categories: (1) 
genes upregulated after stimulation in wild type but not in PARP1 deficient cells (“co-
activator”), (2) genes downregulated after stimulation in wild type but not in PARP1 
deficient cells (“co-repressor”), (3) genes upregulated after stimulation in PARP1 
deficient but not in wild type cells (“co-repressor”), (4) genes downregulated after 
stimulation in PARP1 deficient but not in wild tpye cells (“co-activator”).  
It is more and more appreciated that transcription factors often work in concert 
with a multitude of co-factors, which regulate and fine-tune gene expression. 
Moreover, different transcription factors may cooperate on a gene promotor for 
complete activation of transcription. Indeed, many pro-inflammatory genes are 
responsive to NF-κΒ and the interferon responsive transcription factor STAT1 and 
contain binding sites for both transcription factors in their promoters [172]. NF-κΒ 
and STAT1 can thus have distinct as well as synergistic functions on gene expression. 
Of note, STAT1 transcript levels are regulated by NF-κΒ, as are other transcription 
factors involved in the immune response, for example IRFs and SRF [173]. 
 
3.5  Helicobacter pylori and DNA damage 
The host response to Helicobacter pylori is still largely undefined and a matter of 
current investigations. It has been noted, however, that Helicobacter pylori can cause 
DNA damage in gastric epithelial cells [174]. DNA fragmentation in AGS cells 
incubated with Helicobacter pylori extract correlated with increased levels of reactive 
oxygen species and reduced levels of glutathione. Moreover, also PAR formation was 
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observed [174]. Apart from this observation, the role of PARP1 for Helicobacter 
pylori induced host cell responses has not been studied extensively. Of note, 
Helicobacter pylori leads to the expression of NF-κΒ target genes via a mechanism 
involving the H. pylori virulence factor CagA and the host protein transforming 
growth factor-β-activated kinase 1 (TAK1), which activates IKK to phosphorylate 
IκΒa [175]. We observed that H. pylori induced NF-κΒ target genes in AGS cells and 
that some of these genes required PARP1 for efficient expression. Interestingly, H. 
pylori induced activation-induced deaminase (AID) independent of PARP1. AID was 
very recently described to induce DNA double strand breaks in non-Ig genes 
throughout the genome [176] and it is therefore tempting to suggest that H. pylori 
induced AID expression results in DNA double strand break formation in AGS cells, 
which in turn activate PARP1 and hence would be responsible for the observed 
PARP1-dependent PAR formation. Knockdown of AID in AGS cells would 
consequently be expected to reduce H. pylori induced DNA damage and PAR 
formation. 
 
3.6 A stochastic model for PARP1 dependent gene expression 
Transcription is a per se stochastic process and is preceded by multiple cellular events 
including chromatin decondensation, nucleosome remodeling, histone modifications, 
binding of transcriptional activators and co-activators to enhancers and promoters, 
and recruitment of the basal transcription machinery to the core promoter [177]. 
PARP1 is involved in transcription of genes under basal, unstimulated 
conditions but seems to be even more important for transcription of inducible genes 
after stimulation. PARP1 dependent inducible gene expression may predominantly be 
independent of PARP1 catalytic activity. Under certain conditions, however, gene 
expression may also depend on PAR formation. Furthermore, only subsets of genes 
analyzed in microarray studies show PARP1 dependency. PARP1 can enhance the 
expression of some (“co-activator”) and repress the expression of other genes (“co-
repressor”). Depending on the type of stimulus, stimulus strength, timescale, cell 
cycle stage and cell type or tissue, different subsets of genes may be PARP1 
dependent. Furthermore, up to now little is known about the possible roles of other 
PARP family members for transcription and it will be interesting to investigate a 
putative interplay between PARPs and PARP-like enzymes during gene expression. 
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Whereas the enzymatic activity of PARP1 may not be required for pro-inflammatory 
gene expression in the absence of DNA damage, activities of other PARP family 
members, e.g. the DNA-associated tankyrases, may well have a relevant function for 
gene expression under certain conditions. In line with this notion, it was recently 
shown that tankyrase inhibition suppresses β-catenin target gene expression [178]. 
This finding supports the idea, that PAR formation by tankyrases or other PARP 
family members may have so far undiscovered and undervalued functions for 
processes like transcription, replication or repair. 
PARP1 may be especially required for efficient gene expression under 
conditions where one or more component of the pre-initiation complex becomes 
limiting. These components may be inducible or non-inducible transcription factors, 
transcriptional co-activators or co-repressors, chromatin modifying or remodeling 
proteins or any other chromatin associated process that influences formation of the 
pre-initiation complex and the onset of transcription. Such limiting conditions may 
arise more likely under stimulated conditions, where gene expression is enhanced 
manifold, as compared to basal conditions with constitutive and moderate gene 
expression. Limiting conditions will not affect all genes, but instead will 
stochastically affect only certain loci on the genome and thus only a subset of genes. 
In other words, where, i.e. at which genomic locus, a limitation will occur, will 
largely have random character and differ from cell to cell. Especially in analyses of 
large cell populations in culture or in tissue, these limiting conditions at individual 
genomic loci in individual cells would generally disappear in the noise of the majority 
of cells which do not have a limitation at the same locus.  
The notion that PARP1 acts as a safeguard for efficient gene expression under 
conditions where one or more factors involved in transcription initiation become 
limiting, is consistent with a variety of experimental findings: (1) PARP1 is a highly 
abundant nuclear protein with high but sequence unspecific affinity for DNA and it 
has been estimated that one PARP1 molecule is present every 500 bases along the 3 
billion bases of the human genome. This high global abundance would allow PARP1 
to support the transcription machinery wherever limiting conditions arise; (2) up to 
now we have failed to clearly define the characteristics of PARP1 dependent or 
independent genes. We do not know exactly what makes a gene PARP1 dependent 
nor do we have a molecular understanding of why certain genes are PARP1 
dependent under one condition but are PARP1 independent under another condition. 
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A stochastic model for PARP1 dependent gene expression under limiting conditions 
would fully explain these observations; (3) PARP1 can both up-regulate some and 
down-regulate other genes. In fact, the regulation of PARP1 dependent genes is 
complex and probably includes all theoretically possible varieties. A stochastic model 
explains why PARP1 has both co-activator and co-repressor functions; (4) PARP1 
dependent gene expression in animal models is observed mostly under acute and 
strong stimulation, e.g. ischemia-reperfusion models or LPS-induced septic shock. 
Under physiological conditions, where limiting conditions are unlikely to occur in 
vivo, PARP1 may be nonessential and indeed PARP1 knockout mice show no obvious 
phenotype under normal conditions.  
Last, it may be worthwhile to speculate whether a stochastic model for PARP1 
dependent gene expression can also be applied to the role of PARP1 in the DNA 
damage response. Also here, PARP1 may be the safeguard that comes into play under 
limiting conditions. If a certain DNA damage response pathway is overloaded, 
PARP1 may be required to faithfully and efficiently launch the repair. Consistent with 
this notion, many publications have described PARP1 as being involved in most 
known DNA repair pathways; the true significance of PARP1 for the repair may, 
however, only show under conditions where a PARP1 independent repair pathway is 
already compromised. In line, a DNA safeguard function of PARP1 would explain the 
immense potential of PARP inhibitors in cancer treatment of tumors with defects in 
the DNA repair machinery. 
In conclusion, PARP1 may be regarded as safeguard for transcription and 
DNA repair under otherwise insufficient, limiting conditions. From an evolutionary 
perspective, such limiting conditions may have arisen once genomes became bigger 
and, in fact, the only eukaryotes, which do not encode a PARP1 homologue, are 
yeasts. These unicellular organisms have small genomes (in the order of 106-107 bp) 
as compared to other eukaryotes (generally >108 bp) and therefore may very rarely 
experience limiting conditions. 
 
3.7  Perspectives 
The identification of lysine residues instead of glutamates as acceptor sites for ADP-
ribose has challenged a dogma in the field of PARP research. Although technically 
challenging, it will be important to substantiate this finding by mass spectrometric 
analysis of ADP-ribosylated peptides in vitro. Eventually, the combined information 
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from mutational studies and mass spectrometry will hopefully yield a complete 
picture of the primary acceptor sites for covalent ADP-ribose attachment by PARP1. 
The identification of ADP-ribose acceptor sites will increase our understanding of 
both the auto-modification of PARP1 (and of other PARP family members) and the 
modification of acceptor proteins (e.g. histones). Moreover, it should be possible to 
generate specific antibodies against single ADP-ribosylated lysine residues, which 
will provide a great tool to study the many functions of PAR formation for chromatin 
remodeling, transcription and DNA repair in living cells and animal tissue. Certainly, 
this would reveal interesting and so far unforeseen insights into PARP1 functions. 
 We still do not have a completely comprehensive understanding of the role of 
PARP1 for transcription. Difficulties to address certain individual aspects of PARP1 
function may arise due to the many and in part overlapping functions PARP1 has in 
the context of chromatin. PARP1 changes chromosome composition and compaction, 
influences both basal and inducible gene expression, functions as co-activator and co-
repressor and may have different roles depending on cell type and condition. 
Moreover, some experimental approaches may suffer from the partial redundancy of 
PARP1 and PARP2 functions, and from the lack of truly specific PARP inhibitors.  
Importantly, PARP1 depletion or inhibition of PAR formation is beneficial in 
vivo in a variety of inflammation-associated diseases, such as Salmonella induced 
colitis (manuscript submitted) or Helicobacter pylori induced gastritis and gastric 
cancer (manuscript in preparation). Our understanding of the molecular mechanisms 
behind these beneficial effects, however, is only limited. Conditional knockout mice, 
in which both PARP1 and PARP2 can be simultaneously eliminated from a certain 
tissue, would provide a great tool to study the individual contribution of these two 
enzymes for different diseases. Also, better PARP inhibitors to target specifically 
PARP1, PARP2, or other PARP family members with negligible off-target effects 
would provide a means to dissect their individual functions. New technologies 
together with the careful investigation of observed putative PARP effects and how 
they are linked to PARP1, PARP2, other PARPs, mARTs or NAD+-consuming 
enzymes will further expand our understanding of this exciting family of enzymes and 
their contribution to health and disease. 
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4 ABBREVIATIONS 
 
53BP1  p53 binding protein 1 
AD  auto-modification domain  
ADP  adenosine diphosphate 
AID   activation-induced deaminase 
AIF  apoptosis inducing factor 
ALC1  amplified in liver cancer 1 
AP-1  activator protein 1 
ATM  ataxia telangiectasia mutated 
ATP  adenosine triphosphate 
Bp  base pair 
BRCA1 breast cancer type 1 susceptibility protein 
BRCT  BRCA1 C-terminus 
CAT  catalytic domain 
ChIP  chromatin immunoprecipitation 
CTCF  C2H2-type zinc fingers 
DBD  DNA binding domain 
DNA  desoxyribonucleic acid 
DNMT1 DNA methyltransferase 1 
FACT  facilitates chromatin transcription 
FOXO1 forkhead box O transcription factor 
FPV  feline panleukopenia virus 
GST  glutathione S-transferase 
HA  hemagglutinin 
HAT  histone acetyltransferase 
His  histidine 
HP1  heterochromatin protein 1 
IMPGEs immortalized primary gastric epithelial cells 
kDa  kilo dalton 
LC-MS liquid chromatography mass spectrometry 
mART  mono-ADP-ribosyltransferase 
MLF  mouse lung fibroblasts 
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MRE11 meiotic recombination 11 homolog 
mRNA  messenger ribonucleic acid 
NaCl  sodium chloride 
NAD  nicotinamide adenine dinucleotide 
NBS1  nijmegen breakage syndrome protein 1 
NF-κB  nuclear factor-kappaB 
NFAT  nuclear factor of activated T cells 
Ni  nickel 
NLS  nuclear localization signal 
NRF1  nuclear respiratory factor 1 
Oct-1  octamer-binding transcription factor 1 
PAR  poly(ADP-ribose) 
PARG  poly(ADP-ribose) glycohydrolase 
PARP  poly(ADP-ribose) polymerase 
PARylation poly(ADP-ribosyl)ation 
PTEN  phosphatase and tensin homolog 
RHD  Rel homology domain 
ROS  reactive oxygen species 
RT-PCR reverse transcription polymerase chain reaction 
SFV  semliki forest virus 
SIRT  Sir2-type 
TEF-1  transcription enhancer factor 1 
TopBP1 topoisomerase binding protein 1 
TSS  transcription start site 
WGR  tryptophane, glycine, arginine domain 
XRCC1 x-ray repair cross-complementing protein 1 
YY-1  ying-yang-1 
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